

منشور تعريفات رقم (8) لسنة 2017

السادة جمرك / مرسى باب الإدارة العامة للخلفوات

ت 8

تحية طيبة وبعد

نوجه النظر إلى انه يرد إلى الجمرك أصناف مواد صيدلانية ومكونات صيدلانية فعالة تدخل في إنتاج المنتجات الصيدلانية والأدوية وترد تحت مسمى "INN" international Nonproprietary Names وتعنى الأسماء الدولية غير المسجلة الملكية ، وهي عبارة عن نظام منسق للأسماء العامة للمواد الدوائية يستخدم لتسهيل تعريف المواد الصيدلانية والمكونات الصيدلانية الفعالة وكل "INN" هو اسم وحيد ، معروف على الصعيد العالمي وثابت دوليا ويعد من الممتلكات العامة .
ويدار هذا النظام تحت مظلة منظمة الصحة العالمية WHO بهدف المحافظة على الصحة والبيئة.

وحرصا من الإدارة العامة للتعريف في العمل على السرعة في إتخاذ القرارات في جميع المواقع الجمركية .
نتشرف أن نرفق طيه نسخة إلكترونية CD تحتوى على ملف EXCEL يضم قائمة تحتوى على عدد 3626 اسم "INN" وتبنيدها بنودها الخاصة في جدول التعريف المنسقة وفقا لقرارات لجان النظام المنسق HSC والتي تعد مرجع تصدره منظمة الجمارك العالمية WCO لأغراض تسهيل تبنيدها مثل هذه الأصناف .

ملاحظات هامة خاصة بملف EXCEL

- التظليل باللون الوردي يوضح أن اسم صنف "INN" تم تعديله بواسطة منظمة الصحة العالمية بعد اتخاذ قرار لجنة النظام المنسق منظمة الجمارك العالمية .
- بالنسبة للعمود (C) 2012 الأكواد المكونة من 6 أرقام والمظللة باللون الأخضر تشير إلى التبنيدها الحالي والمعمول به حاليا ، طالما أن جدول التعريف المنسقة إصدار 2012 ساري .
- بالنسبة للعمود (D) 2017 فان الأكواد المكونة من 6 أرقام والمظللة باللون الأخضر تشير إلى التبنيدها المستقبلي والذي سوف يعمل به بعد دخول جدول التعريف المنسقة 2017 في حيز النفاذ وذلك بعد اعتمادها وصدورها بقرار جمهوري .

رجاء التفضل بتنفيذ ما جاء به عاليه بكل دقه
مع التكرم بإذاعته على الإدارات الجمركية التابعة لسيادتكم
وتفضلوا سيادتكم بقبول فائق الاحترام و التقدير ...

رئيس الإدارة المركزية

للتعريف والقيمة والمنشأ



(مجدى سيد أحمد الأنصاري)

مدير عام

الإدارة العامة للتعريف



(سوزان فتح الله جوهر)

أُتيت صباح

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|---|----------------|------------|------------|---|---------|--------------|--------------|--------------|
| Note 1 : Lines appearing in pink colour indicate that the name of the product has been modified by the WHO after the decision taken by the Committee. | | | | | | | | |
| Note 2 (a) : The 6-digit codes in green cells referred to in column C ("Class 2012") are present classifications still into force, which will be replaced in 2017 by new codes already | | | | | | | | |
| Note 2 (b) : The 6-digit codes in green cells referred to in column D ("Class 2017") are future 2017 classifications already assigned by the HSC. | | | | | | | | |
| abacavir | abacavir | 2933.59 | | 42.100 Ann. O (V) | HSC/21 | 1998 | 76 | 136470-78-5 |
| abafungin | abafungine | 2941.90 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 129639-79-8 |
| abagovomab | abagovomab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 95 | 792921-10-9 |
| abaloparatide | abaloparatide | 2937.19 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 247062-33-5 |
| abametapir | abamétapir | 2933.39 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1762-34-1 |
| abaperidone | abapéridone | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 80 | 183849-43-6 |
| abarelix | abarélix | 2937.19 | | NC2116B1b Ann. R/7 | HSC/55 | 2015 | 78 | 183552-38-7 |
| abatacept | abatacept | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 91 | 332348-12-6 |
| abciximab | abciximab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 70 | 143653-53-6 |
| abecomotide | abécomotide | 3002.20 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 907596-50-3 |
| abediterol | abéditérol | 2933.79 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 915133-65-2 |
| abetimus | abétimus | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 81 | 167362-48-3 |
| abexinostat | abexinostat | 2932.99 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 783355-60-2 |
| abicipar pegol | abicipar pégol | 3907.20 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1327278-94-3 |
| abiraterone | abiratérone | 2937.29 | | NC2116B1b Ann. R/7 | HSC/55 | 2015 | 74 | 154229-19-3 |
| abitesartan | abitésartan | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 73 | 137882-98-5 |
| abituzumab | abituzumab | 3002.10 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 1105038-73-0 |
| abrilumab | abrilumab | 3002.10 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1342290-43-0 |
| abrineurin | abrineurine | 2937.19 | | NC0730B2 Ann. M/4 | HSC/31 | 2003 | 84 | 178535-93-8 |
| acalisib | acalisib | 2933.59 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 870281-34-8 |
| acarbose | acarbose | 2932.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 40 | 56180-94-0 |
| acemannan | acémannan | 3913.90 | | 38.100 Ann. Q (No. 118) | HSC/11 | 1993 | 64 | 110042-95-0 |
| acetorphine | acétorphine | 2939.19 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 17 | 25333-77-1 |
| acetylmethadol | acétylméthadol | 2922.19 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 5 | 509-74-0 |
| aciclovir | aciclovir | 2933.59 | | 38.100 Ann. Q (No. 119) | HSC/11 | 1993 | 42 | 59277-89-3 |
| acipimox | acipimox | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 33 | 51037-30-0 |
| acitazanolast | acitazanolast | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 72 | 114607-46-4 |
| acitretin | acitrétine | 2918.90 | | 38.100 Ann. Q (No. 121) | HSC/11 | 1993 | 56 | 55079-83-9 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|--------------------|----------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| aclantate | aclantate | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 27 | 39633-62-0 |
| aclerastide | aclérastide | 2933.29 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 227803-63-6 |
| aclidinium bromide | bromure d'aclidinium | 2934.99 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 320345-99-1 |
| acolbifene | acolbifène | 2934.99 | | NC0730B2 Ann. M/6 | HSC/31 | 2003 | 86 | 182167-02-8 |
| acotiamide | acotiamide | 2934.10 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 185106-16-5 |
| acrezast | acréozast | 2926.90 | | 42.100 Ann. O (VI) | HSC/21 | 1998 | 77 | 123548-56-1 |
| acrisorcin | acrisorcine | 2933.99 | | NC2116B1b Ann. R/6 | HSC/55 | 2015 | 13 | 7527-91-5 |
| acrivastine | acrivastine | 2933.39 | | 38.100 Ann. Q (No. 124) | HSC/11 | 1993 | 51 | 87848-99-5 |
| acrocinnonide | acrocinnonide | 2937.22 | | 38.100 Ann. Q (No. 125) | HSC/11 | 1993 | 27 | 28971-58-6 |
| acronine | acronine | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 22 | 7008-42-6 |
| actoxumab | actoxumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 107 | 1245634-25-6 |
| acumapimod | acumapimod | 2933.19 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 836683-15-9 |
| adalimumab | adalimumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 82 | 331731-18-1 |
| adaprolol | adaprolol | 2922.19 | | 40.260 Ann. L/2 (No. 38) | HSC/17 | 1996 | 63 | 101479-70-3 |
| adargileukin alfa | adargileukine alfa | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 89 | 250710-65-7 |
| adarotene | adarotène | 2918.29 | | NC1500B1b Ann. K/6 | HSC/44 | 2009 | 100 | 496868-77-0 |
| adatanserin | adatansérine | 2933.59 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 127266-56-2 |
| adecatumumab | adecatumumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 90 | 503605-66-1 |
| adefovir | adéfovir | 2933.59 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 106941-25-7 |
| adecalant | adékalant | 2933.39 | | NC0430B2 Ann. Q/1 (II) | HSC/27 | 2001 | 83 | 227940-00-3 |
| adelatinib | adélatinib | 2933.59 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 944842-54-0 |
| adelmidrol | adelmidrol | 2924.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 70 | 1675-66-7 |
| aderbasib | aderbasib | 2933.59 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 791828-58-5 |
| adibendan | adibendan | 2933.79 | | 38.100 Ann. Q (No. 126) | HSC/11 | 1993 | 57 | 100510-33-6 |
| adipiplon | adipiplon | 2933.59 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 840486-93-3 |
| adomiparin sodium | adomiparine sodique | 3001.90 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 9041-08-1 |
| adoprazine | adoprazine | 2934.99 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 222551-17-9 |
| adrogolide | adrogolide | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 82 | 171752-56-0 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-----------------------|-------------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| aducanumab | aducanumab | 3002.10 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1384260-65-4 |
| afacifenacin | afacifénacine | 2933.59 | | NC1604B1b Ann. N/5 | HSC/46 | 2010 | 101 | 877606-63-8 |
| afamelanotide | afamélanotide | 2937.19 | | NC1553B1b Ann. O/7 | HSC/45 | 2010 | 100 | 75921-69-6 |
| afatinib | afatinib | 2934.99 | | NC1604B1b Ann. N/6 | HSC/46 | 2010 | 102 | 850140-72-6 |
| afegostat | afégostat | 2933.39 | | NC1604B1b Ann. N/5 | HSC/46 | 2010 | 101 | 169105-89-9 |
| afelectan | afélétecan | 2939.99 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 215604-75-4 |
| afelimomab | afélimomab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 72 | 156227-98-4 |
| afimoxifene | afimoxifène | 2922.19 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 68392-35-8 |
| aflibercept | aflibercept | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 95 | 862111-32-8 |
| afovirsén | afovirsén | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 70 | 151356-08-0 |
| afoxolaner | afoxolaner | 2934.99 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1093861-60-9 |
| aftobétin | aftobétine | 2933.39 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 1208971-05-4 |
| afuresertib | afurésertib | 2934.99 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1047644-62-1 |
| afutuzumab | afutuzumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 99 | 949142-50-1 |
| agalsidase alfa | agalsidase alfa | 3507.90 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 104138-64-9 |
| agalsidase beta | agalsidase beta | 3507.90 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 104138-64-9 |
| aganépag | aganépag | 2934.99 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 910562-18-4 |
| aganirsén | aganirsén | 2934.99 | | NC1604B1b Ann. N/5 | HSC/46 | 2010 | 101 | 1146887-67-3 |
| agatolimod | agatolimod | 2934.99 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 207623-20-9 |
| aglepristone | aglèpristone | 2922.50 | | 42.100 Ann. O (VII) | HSC/21 | 1998 | 70 | 124478-60-0 |
| agomélatine | agomélatine | 2924.29 | | 42.100 Ann. O (IV) | HSC/21 | 1998 | 75 | 138112-76-2 |
| alacizumab pegol | alacizumab pégol | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 98 | 934216-54-3 |
| aladorian | aladorian | 2934.99 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 865433-00-7 |
| alagébrium chloride | chlorure d'alagébrium | 2934.10 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 341028-37-3 |
| alamifovir | alamifovir | 2933.59 | | NC0938B2b Ann. O/2 | HSC/35 | 2005 | 89 | 193681-12-8 |
| alatrofloxacin | alatrofloxacine | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 75 | 157182-32-6 |
| albaconazole | albaconazole | 2933.59 | | NC0845B2 Ann. M/1 (II) | HSC/33 | 2004 | 87 | 187949-02-6 |
| albenatide | albénatide | 3002.10 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1031700-39-6 |
| albiglutide | albiglutide | 2937.19 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 782500-75-8 |
| albinterferon alfa-2b | albinterféron alfa-2b | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 97 | 472960-22-8 |
| albitiazolium bromide | bromure d'albitiazolium | 2934.10 | | NC1604B1b Ann. N/5 | HSC/46 | 2010 | 101 | 321915-72-4 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-------------------------|-------------------------|------------|------------|---|---------|--------------|--------------|--------------|
| albutrepenonacog alfa | albutrèpènonacog alfa | 3002.10 | 3002.12 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 108 | 1357448-54-4 |
| alcaftadine | alcaftadine | 2933.39 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 147084-10-4 |
| alclofenac | alclofénac | 2918.90 | | 38.100 Ann. Q (No. 127) | HSC/11 | 1993 | 23 | 22131-79-9 |
| aldesleukin | aldesleukin | 3504.00 | | 38.100 Ann. Q (No. 128) | HSC/11 | 1993 | 63 | 110942-02-4 |
| aldoxorubicin | aldoxorubicine | 2941.90 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1361644-26-9 |
| alectinib | alectinib | 2934.99 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1256580-46-7 |
| alefacept | aléfacept | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 84 | 222535-22-0 |
| aleglitazar | aléglitazar | 2934.99 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 475479-34-6 |
| alemcinal | alemcinal | 2932.20 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 82 | 150785-53-8 |
| alemtuzumab | alemtuzumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 83 | 216503-57-0 |
| aleplasinin | aléplasinine | 2933.99 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 481629-87-2 |
| alfacalcidol | alfacalcidol | 2936.90 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 40 | 41294-56-8 |
| alfatradiol | alfatradiol | 2907.29 | | NC0730B2 Ann. M/4 | HSC/31 | 2003 | 84 | 57-91-0 |
| alfentanil | alfentanil | 2933.33 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 43 | 71195-58-9 |
| alferminogene tadenovec | alferminogène tadénovec | 3002.90 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 473553-86-5 |
| alfimeprase | alfiméprase | 3507.90 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 259074-76-5 |
| alglucosidase alfa | alglucosidase alfa | 3507.90 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 420784-05-0 |
| alicaforfen | alicaforfen | 2934.99 | | NC0730B2 Ann. M/4 (III) | HSC/31 | 2003 | 85 | 185229-68-9 |
| alicdamotide | alicdamotide | 3002.20 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 1201327-17-4 |
| alilusem | alilusem | 2933.49 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 144506-11-6 |
| alinastine | alinastine | 2933.39 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 154541-72-7 |
| alipogene tiparovec | alipogène tiparovec | 3002.90 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 929881-05-0 |
| alirocumab | alirocumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 107 | 1245916-14-6 |
| alisertib | alisertib | 2933.59 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 1028486-01-2 |
| aliskiren | aliskirène | 2924.29 | | NC0430B2 Ann. Q/1 (II) | HSC/27 | 2001 | 83 | 173334-57-1 |
| alispovir | alispovir | 2933.79 | | NC1553B1b Ann. O/7 | HSC/45 | 2010 | 100 | 254435-95-5 |
| alitreinoin | alitrétinoïne | 2936.21 | | NC0430B2 Ann. Q/1 (III) | HSC/27 | 2001 | 80 | 1241893 |
| allobarbital | allobarbital | 2933.53 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 1 | 52-43-7 |
| allopurinol | allopurinol | 2933.59 | | 38.100 Ann. Q (No. 131) | HSC/11 | 1993 | 14 | 315-30-0 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|--------------------|--------------------|------------|------------|---|---------|--------------|--------------|--------------|
| allylprodine | allylprodine | 2933.39 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 9 | 25384-17-2 |
| almagate | almagate | 2842.90 | | 38.100 Ann. Q (No. 132) | HSC/11 | 1993 | 41 | 66827-12-1 |
| almorexant | almorexant | 2933.49 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 871224-64-5 |
| almotriptan | almotriptan | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 76 | 154323-57-6 |
| almurtide | almurtide | 2932.99 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 61136-12-7 |
| alnespirone | alnespirone | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 70 | 138298-79-0 |
| alniditan | alniditan | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 72 | 152317-89-0 |
| alogliptin | alogliptine | 2933.59 | | NC1248B1b Ann. P/14 | HSC/40 | 2007 | 96 | 850649-61-5 |
| aloxistatin | aloxistatine | 2924.29 | | 38.100 Ann. Q (No. 133) | HSC/11 | 1993 | 57 | 88321-09-9 |
| alpelisib | alpelisib | 2934.10 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1217486-61-7 |
| alpertine | alpertine | 2933.59 | | 38.100 Ann. Q (No. 134) | HSC/11 | 1993 | 34 | 27076-46-6 |
| alphacetylmethadol | alphacétylméthadol | 2922.19 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 5 | 17199-58-5 |
| alphameprodine | alphaméprodine | 2933.39 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 1 | 468-51-9 |
| alphamethadol | alphaméthadol | 2922.19 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 5 | 17199-54-1 |
| alphaprodine | alphaprodine | 2933.39 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 1 | 77-20-3 |
| alprafenone | alprafénone | 2922.19 | | 40.260 Ann. L/2 (No. 39) | HSC/17 | 1996 | 62 | 124316-02-5 |
| alprazolam | alprazolam | 2933.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 30 | 28981-97-7 |
| alprenolol | alprénolol | 2922.19 | | 40.260 Ann. L/2 (No. 40) | HSC/17 | 1996 | 19 | 13655-52-2 |
| alsactide | alsactide | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 45 | 34765-96-3 |
| altapizone | altapizone | 2933.59 | | 38.100 Ann. Q (No. 135) | HSC/11 | 1993 | 55 | 93277-96-4 |
| altinicline | altinicline | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 82 | 179120-92-4 |
| altizide | altizide | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 13 | 5588-16-9 |
| altumomab | altumomab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 68 | 156586-92-4 |
| alvaneline | alvaneline | 2933.39 | | NC0090B2 Ann. M/1 (II) | HSC/23 | 1999 | 79 | 120241-31-8 |
| alvelestat | alvélestat | 2933.79 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 848141-11-7 |
| alvespimycin | alvespimycine | 2941.90 | | NC1553B1b Ann. O/1 | HSC/45 | 2010 | 96 | 467214-20-6 |
| alvimopan | alvimopan | 2933.39 | | NC0845B2 Ann. M/1 (II) | HSC/33 | 2004 | 87 | 156053-89-3 |
| alvocidib | alvocidib | 2934.99 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 146426-40-6 |
| amadinone | amadinone | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 25 | 30781-27-2 |
| amatuximab | amatuximab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 104 | 931402-35-6 |
| ambasilide | ambasilide | 2933.39 | | 38.100 Ann. Q (No. 137) | HSC/11 | 1993 | 59 | 83991-25-7 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|------------------------|--------------------------|------------|------------|--|---------|--------------|--------------|--------------|
| ambrisentan | ambrisentan | 2933.59 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 177036-94-1 |
| ambruticin | ambruticine | 2941.90 | | 38.100 Ann. Q (No. 138) | HSC/11 | 1993 | 39 | 58857-02-6 |
| amcinafal | amcinafal | 2937.22 | | 38.100 Ann. Q (No. 139) | HSC/11 | 1993 | 25 | 3924-70-7 |
| amcinafide | amcinafide | 2937.22 | | 38.100 Ann. Q (No. 140) | HSC/11 | 1993 | 25 | 7332-27-6 |
| amcinonide | amcinonide | 2937.22 | | 38.100 Ann. Q (No. 141) | HSC/11 | 1993 | 33 | 51022-69-6 |
| amdoxovir | amdoxovir | 2934.99 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 145514-04-1 |
| amebucort | amébucort | 2937.29 | | 38.100 Ann. Q (No. 142) | HSC/11 | 1993 | 54 | 83625-35-8 |
| amediplase | amédiplase | 3507.90 | | NC0090B2 Ann. M/1 (II) | HSC/23 | 1999 | 79 | 151912-11-7 |
| amelometasone | amélomé tasone | 2937.22 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 123013-22-9 |
| amelubant | amélubant | 2925.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 85 | 346735-24-8 |
| amenamévir | aménamévir | 2934.99 | | NC1500B1b Ann. K/6 | HSC/44 | 2009 | 100 | 841301-32-4 |
| amfepramone | amfépramone | 2922.31 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 13 | 90-84-6 |
| amfetamine | amfétamine | 2921.46 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 55 | 300-62-9 |
| amfomycin | amfomycine | 2941.90 | | 38.100 Ann. Q (No. 143) | HSC/11 | 1993 | 13 | 1402-82-0 |
| amibegron | amibégron | 2922.50 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 121524-08-1 |
| amifampridine | amifampridine | 2933.39 | | NC1310B1b Ann. N/10 | HSC/41 | 2008 | 96 | 54-96-6 |
| amiglumide | amiglumide | 2924.29 | | NC0430B2 Ann. Q/1 (I) | HSC/27 | 2001 | 82 | 119363-62-1 |
| amilintide | amilintide | 2937.19 | | NC1760B1b Ann. N/3 | HSC/49 | 2012 | 76 | 122384-88-7 |
| amilomotide | amilomotide | 3002.20 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 1238372-23-0 |
| amiloxate | amiloxate | 2918.90 | | NC0430B2 Ann. Q/1 (II) | HSC/27 | 2001 | 83 | 71617-10-2 |
| aminoethyl nitrate | nitrate d'aminoéthyle | 2922.50 | | 38.100 Ann. Q (No. 144) | HSC/11 | 1993 | 1 | 646-02-6 |
| aminorex | aminorex | 2934.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 14 | 2207-50-3 |
| amitifadine | amitifadine | 2933.99 | | NC1874B1b Ann. O/1 | HSC/51 | 2013 | 106 | 410074-73-6 |
| amitriptylinoxide | amitriptylinoxyde | 2929.90 | | 40.260 Ann. L/2 (No. 10) | HSC/17 | 1996 | 36 | 4317-14-0 |
| amlintide | amlintide | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 76 | 122384-88-7 |
| amobarbital | amobarbital | 2933.53 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 1 | 57-43-2 |
| amolmogène bepiplasmid | amolmogène bépiplasmide | 2934.99 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 870524-46-2 |
| amopyroquine | amopyroquine | 2933.49 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 8 | 550-81-2 |
| amotosalen | amotosalène | 2932.20 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 85 | 161262-29-9 |
| amoxydramine camsilate | camsilate d'amoxydramine | 2929.90 | | 40.260 Ann. L/2 (No. 11) | HSC/17 | 1996 | 15 | 15350-99-9 |
| amphenidone | amphénidone | 2933.79 | | 38.100 Ann. Q (No. 146) | HSC/11 | 1993 | 10 | 134-37-2 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|----------------------|----------------------|------------|------------|---|---------|--------------|--------------|--------------|
| amprenavir | amprénavir | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 79 | 161814-49-9 |
| amsilarotene | amsilarotène | 2931.00 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 125973-56-0 |
| amuvatinib | amuvatinib | 2934.99 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 850879-09-3 |
| amylmetacresol | amylmétacrésol | 2907.19 | | 38.100 Ann. Q (No. 147) | HSC/11 | 1993 | 55 | 1300-94-3 |
| anacetrapib | anacétrapib | 2934.99 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 875446-37-0 |
| anagestone | anagestone | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 16 | 2740-52-5 |
| anagliptin | anagliptine | 2933.59 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 739366-20-2 |
| anakinra | anakinra | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 70 | 143090-92-0 |
| anamorelin | anamoréline | 2933.39 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 249921-19-5 |
| anaritide | anaritide | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 57 | 95896-08-5 |
| anastrozole | anastrozole | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 72 | 120511-73-1 |
| anatibant | anatibant | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 88 | 209733-45-9 |
| anatumomab mafenatox | anatumomab mafénatox | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 79 | 0-00-0 |
| anaxirone | anaxirone | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 52 | 77658-97-0 |
| anzocine | anzocine | 2933.39 | | 38.100 Ann. Q (No. 151) | HSC/11 | 1993 | 30 | 15378-99-1 |
| ancestim | ancestim | 3002.10 | | NC0090B2 Ann. M/1 (II) | HSC/23 | 1999 | 79 | 163545-26-4 |
| ancriviroc | ancriviroc | 2933.39 | | NC1004B1b Ann. L/11 | HSC/36 | 2005 | 92 | 370893-06-4 |
| ancrod | ancrod | 3507.90 | | 38.100 Ann. Q (No. 152) | HSC/11 | 1993 | 23 | 9046-56-4 |
| andexanet alfa | andexanet alfa | 3002.10 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1262449-58-0 |
| anecortave | ané cortave | 2915.39 | | NC0430B2 Ann. Q/1 (III) | HSC/27 | 2001 | 80 | 7753-60-8 |
| anetumab ravtansine | anétumab ravtansine | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 109 | 1375258-01-7 |
| angiotensinamide | angiotensinamide | 2933.29 | | 38.100 Ann. Q (No. 153) | HSC/11 | 1993 | 12 | 53-73-6 |
| anidulafungin | anidulafungine | 2941.90 | | NC0430B2 Ann. Q/1 (III) | HSC/27 | 2001 | 81 | 166663-25-8 |
| anifrolumab | anifrolumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 109 | 1326232-46-5 |
| anileridine | aniléridine | 2933.33 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 5 | 144-14-9 |
| anispermus | anispermus | 2925.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 82 | 170368-04-4 |
| anistreplase | anistreplase | 3507.90 | | 38.100 Ann. Q (No. 154) | HSC/11 | 1993 | 59 | 81669-57-0 |
| anivamersen | anivamersen | 2934.99 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 959716-29-1 |
| anrukinzumab | anrukinzumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 98 | 910649-32-0 |
| anseculin | anséculine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 75 | 155773-59-4 |
| antazonite | antazonite | 2934.10 | | 38.100 Ann. Q (No. 155) | HSC/11 | 1993 | 15 | 25422-75-7 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|----------------------|-----------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| antithrombin alfa | antithrombine alfa | 3002.10 | 3002.12 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 93 | 84720-88-7 |
| antithrombin gamma | antithrombine gamma | 3002.10 | 3002.12 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 107 | 1311281-25-0 |
| apabetalone | apabétalone | 2933.59 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1044870-39-4 |
| apadenoson | apadénoson | 2934.99 | | NC1123B1b Ann. N/1 | HSC/38 | 2006 | 94 | 250386-15-3 |
| apadoline | apadoline | 2934.30 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 135003-30-4 |
| apaflurane | apaflurane | 2903.39 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 73 | 431-89-0 |
| apatorsen | apatorsen | 2934.99 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1002331-21-6 |
| apaxifylline | apaxifylline | 2939.59 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 71 | 151581-23-6 |
| apaziquone | apaziquone | 2933.99 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 114560-48-4 |
| apilimod | apilimod | 2934.99 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 541550-19-0 |
| apitolisib | apitolisib | 2934.99 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1032754-93-0 |
| apixaban | apixaban | 2933.79 | | NC1059B2b Ann. O/5 | HSC/37 | 2006 | 93 | 503612-47-3 |
| aplaviroc | aplaviroc | 2933.79 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 461443-59-4 |
| aplindore | aplindore | 2934.99 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 92 | 189681-70-7 |
| apolizumab | apolizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 87 | 267227-08-7 |
| apratostat | apratostat | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 93 | 287405-51-0 |
| apremilast | aprémilast | 2930.90 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 608141-41-9 |
| aprepitant | aprépitant | 2934.99 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 170729-80-3 |
| apricitabine | apricitabine | 2934.99 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 160707-69-7 |
| apricoxib | apricoxib | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 99 | 197904-84-0 |
| aprinocarsen | aprinocarsen | 2934.99 | | NC0938B2b Ann. O/2 | HSC/35 | 2005 | 89 | 151879-73-1 |
| aptazapine | aptazapine | 2933.59 | | 38.100 Ann. Q (No. 156) | HSC/11 | 1993 | 50 | 71576-40-4 |
| aptiganel | aptiganel | 2925.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 72 | 137159-92-3 |
| arasertaconazole | arasertaconazole | 2934.99 | | NC1059B2b Ann. O/5 | HSC/37 | 2006 | 93 | 583057-48-1 |
| arbaclofen | arbaclofène | 2922.49 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 69308-37-8 |
| arbaclofen placarbil | arbaclofène placarbil | 2924.29 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 847353-30-4 |
| arbakacin | arbékacine | 2941.90 | | 38.100 Ann. Q (No. 157) | HSC/11 | 1993 | 56 | 51025-85-5 |
| arcitumomab | arcitumomab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 74 | 154361-48-5 |
| ardenermin | ardénermine | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 88 | 305391-49-5 |
| ardeparin sodium | ardéparine sodique | 3001.90 | | NC1553B1b Ann. O/5 | HSC/45 | 2010 | 68 | 9041-08-1 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|---------------------|-----------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| arfalasin | arfalazine | 2933.29 | | 38.100 Ann. Q (No. 158) | HSC/11 | 1993 | 37 | 60173-73-1 |
| arformoterol | arformotérol | 2924.29 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 67346-49-0 |
| arginine | arginine | 2925.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 14 | 74-79-3 |
| argipressin | argipressine | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 13 | 113-79-1 |
| argiprestocin | argiprestocine | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 13 | 113-80-4 |
| arhalofenate | arhalofénate | 2924.29 | | NC1649B3b Ann. R/12 | HSC/47 | 2011 | 101 | 24136-23-0 |
| arimoclomol | arimoclomol | 2933.39 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 289893-25-0 |
| aripiprazole | aripiprazole | 2933.79 | | 42.100 Ann. O (IV) | HSC/21 | 1998 | 75 | 129722-12-9 |
| armodafinil | armodafinil | 2930.90 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 112111-43-0 |
| arnolol | arnolol | 2922.19 | | 38.100 Ann. Q (No. 160) | HSC/11 | 1993 | 56 | 87129-71-3 |
| arofylline | arofylline | 2939.59 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 75 | 136145-07-8 |
| arotinolol | arotinolol | 2934.10 | | 38.100 Ann. Q (No. 161) | HSC/11 | 1993 | 48 | 68377-92-4 |
| arprinocid | arprinocide | 2933.59 | | 38.100 Ann. Q (No. 162) | HSC/11 | 1993 | 38 | 55779-18-5 |
| artefenomel | artéfénomel | 2934.99 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 1029939-86-3 |
| arteflene | artéflène | 2932.99 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 123407-36-3 |
| artemisone | artémisone | 2934.99 | | NC1059B2b Ann. O/4 | HSC/37 | 2006 | 92 | 255730-18-8 |
| artemotil | artémotil | 2932.99 | | NC0090B2 Ann. M/5 | HSC/23 | 1999 | 80 | 75887-54-6 |
| artenimol | arténimol | 2932.99 | | NC0250B2 Ann. P/1 (II) | HSC/25 | 2000 | 81 | 81496-81-3 |
| arterolane | artérolane | 2932.99 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 664338-39-0 |
| arundic acid | acide arundique | 2915.90 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 185517-21-9 |
| arzoxifene | arzoxifène | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 80 | 182133-25-1 |
| asapiprant | asapiprant | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 109 | 932372-01-5 |
| ascorbyl gamolenate | gamolénate d'ascorbyl | 2932.20 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 79 | 109791-32-4 |
| aselizumab | asélizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 88 | 395639-53-9 |
| asenapine | asénapine | 2934.99 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 65576-45-6 |
| aseripide | aséripide | 2934.10 | | 42.100 Ann. O (VI) | HSC/21 | 1998 | 77 | 153242-02-5 |
| asfotase alfa | asfotase alfa | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 104 | 1174277-80-5 |
| asimadoline | asimadoline | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 74 | 153205-46-0 |
| asobamast | asobamast | 2934.10 | | 38.100 Ann. Q (No. 163) | HSC/11 | 1993 | 63 | 104777-03-9 |
| asoprisnil | asoprisnil | 2937.29 | | NC0938B2b Ann. O/1 | HSC/35 | 2005 | 86 | 199396-76-4 |
| asoprisnil ecamate | ecamate d'asoprisnil | 2937.29 | | NC0938B2b Ann. O/1 | HSC/35 | 2005 | 88 | 222732-94-7 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-----------------------|------------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| astemizole | astémizole | 2933.39 | | 38.100 Ann. Q (No. 164) | HSC/11 | 1993 | 42 | 68844-77-9 |
| astodrimer | astodrimère | 2924.29 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1379746-42-5 |
| asudemotide | asudémotide | 3002.20 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 1018833-53-8 |
| asunaprevir | asunaprèvir | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 105 | 630420-16-5 |
| asvasiran | asvasiran | 2934.99 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 870094-26-1 |
| atacipept | atacipept | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 95 | 845264-92-8 |
| ataciguat | ataciguat | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 88 | 254877-67-3 |
| atagabalin | atagabaline | 2922.49 | | NC1604B1b Ann. N/6 | HSC/46 | 2010 | 102 | 223445-75-8 |
| ataluren | ataluren | 2934.99 | | NC1604B1b Ann. N/5 | HSC/46 | 2010 | 101 | 775304-57-9 |
| atamestane | atamestane | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 54 | 96301-34-7 |
| ataquimast | ataquimast | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 82 | 182316-31-0 |
| atazanavir | atazanavir | 2933.39 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 198904-31-3 |
| atecegatran | atécégatran | 2933.99 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 917904-13-3 |
| atecegatran fexenetil | atécégatran fexénétill | 2933.99 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 433937-93-0 |
| atexakin alfa | atexakine alfa | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 72 | 143631-61-2 |
| atibeprone | atibéprone | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 72 | 153420-96-3 |
| atigliflozin | atigliflozine | 2940.00 | | NC1553B1b Ann. O/7 | HSC/45 | 2010 | 100 | 647834-15-9 |
| atilmotin | atilmotine | 2933.99 | | NC1059B2b Ann. O/4 | HSC/37 | 2006 | 92 | 533927-56-9 |
| atinumab | atinumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 104 | 1226761-65-4 |
| atiprimod | atiprimod | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 75 | 123018-47-3 |
| atiprosin | atiprosine | 2933.59 | | 38.100 Ann. Q (No. 166) | HSC/11 | 1993 | 54 | 89303-63-9 |
| atiratecan | atiratécane | 2939.99 | | NC1649B3b Ann. R/12 | HSC/47 | 2011 | 101 | 867063-97-6 |
| atizoram | atizoram | 2933.59 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 135637-46-6 |
| atliprofen | atliprofène | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 77 | 108912-17-0 |
| atocalcitol | atocalcitol | 2909.49 | | NC0938B2b Ann. O/1 | HSC/35 | 2005 | 88 | 302904-82-1 |
| atopaxar | atopaxar | 2934.99 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 751475-53-3 |
| atorolimumab | atorolimumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 80 | 202833-08-7 |
| atorvastatin | atorvastatine | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 71 | 134523-00-5 |
| atrasentan | atrasentan | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 83 | 195733-43-8 |
| atreleuton | atréleuton | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 78 | 154355-76-7 |
| atrimustine | atrimustine | 2922.49 | | 40.260 Ann. L/2 (No. 42) | HSC/17 | 1996 | 61 | 75219-46-4 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|----------------------|----------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| atromepine | atromépine | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 15 | 428-07-9 |
| auriclosene | auriclosène | 2929.90 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 846056-87-9 |
| avagacestat | avagacestat | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 104 | 1146699-66-2 |
| avanafil | avanafil | 2933.59 | | NC1004B1b Ann. L/11 | HSC/36 | 2005 | 92 | 330784-47-9 |
| avarofloxacin | avarofloxacine | 2933.49 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 878592-87-1 |
| avasimibe | avasimibe | 2929.90 | | NC0430B2 Ann. Q/1 (III) | HSC/27 | 2001 | 80 | 166518-60-1 |
| avatrombopag | avatrombopag | 2934.10 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 570406-98-3 |
| avibactam | avibactam | 2933.39 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 1192500-31-4 |
| aviptadil | aviptadil | 2933.29 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 40077-57-4 |
| aviscumine | aviscumine | 3002.90 | | NC0730B2 Ann. M/4 | HSC/31 | 2003 | 84 | 223577-45-5 |
| avitriptan | avitriptan | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 76 | 151140-96-4 |
| avorelin | avoréline | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 74 | 140703-49-7 |
| avosentan | avosentan | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 93 | 290815-26-8 |
| avotermin | avotermine | 2934.99 | | NC1649B3b Ann. R/10 | HSC/47 | 2011 | 77 | 182212-66-4 |
| axelopran | axélopran | 2933.39 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 949904-48-7 |
| axitinib | axitinib | 2933.39 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 319460-85-0 |
| axitirome | axitirome | 2924.29 | | NC0430B2 Ann. Q/1 (I) | HSC/27 | 2001 | 82 | 156740-57-7 |
| axomadol | axomadol | 2922.50 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 187219-95-0 |
| azabon | azabon | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 16 | 1150-20-5 |
| azalanstat | azalanstat | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 73 | 143393-27-5 |
| azatadine | azatadine | 2933.39 | | 38.100 Ann. Q (No. 170) | HSC/11 | 1993 | 18 | 3964-81-6 |
| azathioprine | azathioprine | 2933.59 | | 38.100 Ann. Q (No. 171) | HSC/11 | 1993 | 12 | 446-86-6 |
| azeliragon | azéliragon | 2933.29 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 603148-36-3 |
| azetirelin | azétiréline | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 60 | 95729-65-0 |
| azilsartan | azilsartan | 2934.99 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 147403-03-0 |
| azilsartan medoxomil | azilsartan médoxomil | 2934.99 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 863031-21-4 |
| azimilide | azimilide | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 72 | 149908-53-2 |
| azoximer bromide | bromure d'azoximère | 3911.90 | | NC1443B1b Ann. P/4 | HSC/43 | 2009 | 97 | 892497-01-7 |
| bacmecillinam | bacmécillinam | 2941.90 | | 42.100 Ann. O (II) | HSC/21 | 1998 | 38 | 50846-45-2 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|---------------|---------------|------------|------------|--|---------|--------------|--------------|--------------|
| bafetinib | bafétinib | 2933.59 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 859212-16-1 |
| balaglitazone | balaglitazone | 2934.10 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 199113-98-9 |
| balamapimod | balamapimod | 2933.49 | | NC1310B1b Ann. N/10 | HSC/41 | 2008 | 96 | 863029-99-6 |
| balapiravir | balapiravir | 2934.99 | | NC1500B1b Ann. K/6 | HSC/44 | 2009 | 100 | 690270-29-2 |
| balazipone | balazipone | 2926.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 71 | 137109-71-8 |
| balicatib | balicatib | 2933.59 | | NC1004B1b Ann. L/11 | HSC/36 | 2005 | 92 | 354813-19-7 |
| balofloxacin | balofloxacin | 2933.49 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 71 | 127294-70-6 |
| balugrastim | balugrastim | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 107 | 527698-09-5 |
| bamaquimast | bamaquimast | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 76 | 135779-82-7 |
| baminercept | baminercept | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 98 | 909110-25-4 |
| bamirastine | bamirastine | 2933.39 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 215529-47-8 |
| bamosiran | bamosiran | 2934.99 | | NC1874B1b Ann. O/1 | HSC/51 | 2013 | 106 | 1337968-84-9 |
| banoxantrone | banoxantrone | 2929.90 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 136470-65-0 |
| bapineuzumab | bapineuzumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 93 | 648895-38-9 |
| barasertib | barasertib | 2933.59 | | NC1649B3b Ann. R/13 | HSC/47 | 2011 | 102 | 722543-31-9 |
| barbital | barbital | 2933.53 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 4 | 57-44-3 |
| bardoxolone | bardoxolone | 2926.90 | | NC1649B3b Ann. R/12 | HSC/47 | 2011 | 101 | 218600-44-3 |
| baricitinib | baricitinib | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 107 | 1187594-09-7 |
| barixibat | barixibat | 2933.39 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 263562-28-3 |
| barusiban | barusiban | 2934.99 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 285571-64-4 |
| basifungin | basifungine | 2941.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 127785-64-2 |
| basiliximab | basiliximab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 76 | 179045-86-4 |
| basimglurant | basimglurant | 2933.39 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 802906-73-6 |
| basmisanil | basmisanil | 2934.99 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1159600-41-5 |
| batabulin | batabuline | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 90 | 195533-53-0 |
| batefenterol | batéfentérol | 2933.79 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 743461-65-6 |
| batimastat | batimastat | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 70 | 130370-60-4 |
| bavisant | bavisant | 2934.99 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 929622-08-2 |
| bavituximab | bavituximab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 95 | 648904-28-3 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|--------------------------|-----------------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| bazedoxifene | bazédoxifène | 2933.99 | | NC0730B2 Ann. M/6 | HSC/31 | 2003 | 86 | 198481-32-2 |
| becampanel | bécampanel | 2933.99 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 188696-80-2 |
| becaplermin | bécaplermine | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 74 | 165101-51-9 |
| becatecarin | becatecarine | 2941.90 | | NC1178B1c Ann. O/2 | HSC/39 | 2007 | 92 | 119673-08-4 |
| beclanorsen | béclanorsen | 2934.99 | | NC1604B1b Ann. N/5 | HSC/46 | 2010 | 101 | 1072859-54-1 |
| beclavubir | béclavubir | 2933.59 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 958002-33-0 |
| becocalcidiol | bécocalcidiol | 2906.19 | | NC1059B2b Ann. O/4 | HSC/37 | 2006 | 92 | 524067-21-8 |
| bectumomab | bectumomab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 75 | 158318-63-9 |
| bedaquiline | bédaquiline | 2933.49 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 843663-66-1 |
| bederocin | bédéroquine | 2934.99 | | NC1553B1b Ann. O/4 | HSC/45 | 2010 | 99 | 757942-43-1 |
| bedoradrine | bédoradrine | 2924.29 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 194785-19-8 |
| befetupitant | béfétupitant | 2934.99 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 290296-68-3 |
| befiradol | béfiradol | 2933.39 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 208110-64-9 |
| begacestat | bégacestat | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 97 | 769169-27-9 |
| begelomab | bégéломab | 3002.10 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1403744-56-8 |
| belaperidone | bélapéridone | 2933.59 | | 42.100 Ann. O (V) | HSC/21 | 1998 | 78 | 156862-51-0 |
| belatacept | belatacept | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 93 | 706808-37-9 |
| belinostat | bélinostat | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 97 | 414864-00-9 |
| belnacasan | belnacasan | 2934.99 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 273404-37-8 |
| beloranib | béloranib | 2922.19 | | NC1553B1b Ann. O/7 | HSC/45 | 2010 | 100 | 251111-30-5 |
| belotecan | bélotécan | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 91 | 256411-32-2 |
| beloxepin | béloxépine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 75 | 135928-30-2 |
| beminafil | béminafil | 2934.99 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 566906-50-1 |
| bemiparin sodium | bémiparine sodique | 3001.90 | | NC1553B1b Ann. O/5 | HSC/45 | 2010 | 75 | 9041-08-1 |
| bemotrizinol | bémotrizinol | 2933.69 | | NC1004B1b Ann. L/11 | HSC/36 | 2005 | 92 | 187393-00-6 |
| bempedoic acid | acide bempedoïque | 2918.19 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 738606-46-7 |
| benfurodil hemisuccinate | hémisuccinate de benfurodil | 2932.20 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 16 | 3447-95-8 |
| benolizime | bénolizime | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 45 | 61864-30-0 |
| benperidol | benpéridol | 2933.39 | | 38.100 Ann. Q (No. 175) | HSC/11 | 1993 | 14 | 2062-84-2 |
| benralizumab | benralizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 102 | 1044511-01-4 |
| bentamapimod | bentamapimod | 2934.20 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 848344-36-5 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|--------------------------|-----------------------------|------------|------------|---|---------|--------------|--------------|--------------|
| bentemazole | bentémazole | 2933.29 | | 38.100 Ann. Q (No. 176) | HSC/11 | 1993 | 40 | 63927-95-7 |
| benzalkonium chloride | chlorure de benzalkonium | 3402.12 | | 38.100 Ann. Q (No. 54) | HSC/11 | 1993 | 1 | 8001-54-5 |
| benzethidine | benzéthidine | 2933.39 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 9 | 3691-78-9 |
| benzfetamine | benzfétamine | 2921.46 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 55 | 156-08-1 |
| benzhydrocodone | benzhydrocodone | 2939.19 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1259440-61-3 |
| benzindopyrine | benzindopyrine | 2933.39 | | 38.100 Ann. Q (No. 177) | HSC/11 | 1993 | 13 | 16571-59-8 |
| benzonatate | benzonatate | 3402.13 | | 40.600 Ann. D par. 6 | HSC/18 | 1996 | 6 | 104-31-4 |
| benzopyrrolonium bromide | bromure de benzopyrrolonium | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 12 | 13696-15-6 |
| benzpiperylone | benzpipérylone | 2933.39 | | 38.100 Ann. Q (No. 55) | HSC/11 | 1993 | 13 | 53-89-4 |
| bepermingene perplasmid | béperminogène perplasmide | 2934.99 | | NC1310B1b Ann. N/7 | HSC/41 | 2008 | 95 | 627861-07-8 |
| bepotastine | bépotastine | 2933.39 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 125602-71-3 |
| berlafenone | berlafénone | 2922.19 | | 40.260 Ann. L/2 (No. 43) | HSC/17 | 1996 | 63 | 18965-97-4 |
| beroctocog alfa | béoctocog alfa | 3002.10 | 3002.12 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 95 | 9001-27-8 |
| berilimumab | berilimumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 88 | 375348-49-5 |
| berubicin | bérubicine | 2941.90 | | NC1553B1b Ann. O/3 | HSC/45 | 2010 | 98 | 677017-23-1 |
| berupipam | bérupipam | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 71 | 150490-85-0 |
| bervastatin | bervastatine | 2932.99 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 132017-01-7 |
| besifloxacin | bésifloxacine | 2933.49 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 141388-76-3 |
| besifovir | bésifovir | 2933.59 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 441785-25-7 |
| besilesomab | besilesomab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 92 | 537694-98-7 |
| besipirdine | bésipirdine | 2933.39 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 119257-34-0 |
| betacetylmethadol | bétacétylméthadol | 2922.19 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 5 | 17199-59-6 |
| betameprodine | bétaméprodine | 2933.39 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 1 | 468-50-8 |
| betamethadol | bétaméthadol | 2922.19 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 5 | 17199-55-2 |
| betamicin | bétamicine | 2941.90 | | 42.100 Ann. O (II) | HSC/21 | 1998 | 38 | 36889-15-3 |
| betaprodine | bétaprodine | 2933.39 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 5 | 468-59-7 |
| betasizofiran | bétasizofiran | 3913.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 39464-87-4 |
| betaxolol | bétaxolol | 2922.19 | | 40.260 Ann. L/2 (No. 44) | HSC/17 | 1996 | 40 | 63659-18-7 |
| betiatide | bétiatide | 2930.90 | | 38.100 Ann. Q (No. 179) | HSC/11 | 1993 | 58 | 103725-47-9 |
| betoxycaine | bétoxycaïne | 2922.50 | | 40.260 Ann. L/2 (No. 9) | HSC/17 | 1996 | 13 | 3818-62-0 |
| betrixaban | bétrixaban | 2933.39 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 330942-05-7 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|--------------|--------------|------------|------------|---|---------|--------------|--------------|--------------|
| bevacizumab | bevacizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 83 | 216974-75-3 |
| bevasiranib | bévasiranib | 2934.99 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 959961-96-7 |
| bevenopran | bévénopran | 2934.99 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 676500-67-7 |
| bevirimat | bévirimat | 2918.19 | | NC1310B1b Ann. N/10 | HSC/41 | 2008 | 96 | 174022-42-5 |
| bexarotene | bexarotène | 2916.39 | | NC0090B2 Ann. M/5 | HSC/23 | 1999 | 80 | 153559-49-0 |
| bexlosteride | bexlostéride | 2933.79 | | NC0250B2 Ann. P/1 (II) | HSC/25 | 2000 | 81 | 148905-78-6 |
| bezafibrate | bézafibrate | 2924.29 | | 38.100 Ann. Q (No. 180) | HSC/11 | 1993 | 35 | 41859-67-0 |
| bezitramide | bézitramide | 2933.33 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 15 | 15301-48-1 |
| bezlotoxumab | bezlotoxumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 107 | 1246264-45-8 |
| biapenem | biapénem | 2941.90 | | 39.600 Ann. D/1, par. 15 | HSC/16 | 1995 | 69 | 120410-24-4 |
| bibacitide | bibapcitide | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 78 | 153507-46-1 |
| bicalutamide | bicalutamide | 2930.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 90357-06-5 |
| bifarcept | bifarcept | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 86 | 163796-60-9 |
| bifeprunox | biféprunox | 2934.99 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 350992-10-8 |
| bilastine | bilastine | 2933.39 | | NC0430B2 Ann. Q/1 (I) | HSC/27 | 2001 | 82 | 202189-78-4 |
| bimagrumab | bimagrumab | 3002.13 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 108 | 1356922-05-8 |
| bimatoprost | bimatoprost | 2937.50 | | NC0730B2 Ann. M/4 (III) | HSC/31 | 2003 | 85 | 155206-00-1 |
| bimekizumab | bimékizumab | 3002.10 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1418205-77-2 |
| bimoclolmol | bimoclolmol | 2933.39 | | 42.100 Ann. O (V) | HSC/21 | 1998 | 76 | 130493-03-7 |
| bimosiamose | bimosiamose | 2940.00 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 187269-40-5 |
| binetrakin | binétrakine | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 82 | 207137-56-2 |
| binfloxacin | binfloxacine | 2933.49 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 60 | 108437-28-1 |
| binimetinib | binimétinib | 2933.99 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 606143-89-9 |
| binizolast | binizolast | 2933.59 | | 38.100 Ann. Q (No. 182) | HSC/11 | 1993 | 60 | 86662-54-6 |
| binodenoson | binodénoson | 2934.99 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 144348-08-3 |
| biricodar | biricodar | 2933.39 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 159997-94-1 |
| birinapant | birinapant | 2933.99 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 1260251-31-7 |
| biriperone | biripérone | 2933.59 | | 40.260 Ann. L/2 (No. 21) | HSC/17 | 1996 | 51 | 41510-23-0 |
| bisaramil | bisaramil | 2933.39 | | 38.100 Ann. Q (No. 183) | HSC/11 | 1993 | 60 | 89194-77-4 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|---------------------|----------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| bisegliptin | biséglipatine | 2933.99 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 862501-61-9 |
| bisnafide | bisnafide | 2925.19 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 73 | 144849-63-8 |
| bisoctrizole | bisoctrizole | 2933.99 | | NC1004B1b Ann. L/11 | HSC/36 | 2005 | 92 | 103597-45-1 |
| bisoprolol | bisoprolol | 2922.19 | | 40.260 Ann. L/2 (No. 45) | HSC/17 | 1996 | 48 | 66722-44-9 |
| bivalirudin | bivalirudine | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 72 | 128270-60-0 |
| bivatuzumab | bivatuzumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 83 | 214559-60-1 |
| bixalomer | bixalomère | 3911.90 | | NC1760B1b Ann. N/3 | HSC/49 | 2012 | 101 | 851373-13-2 |
| blinatumomab | blinatumomab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 100 | 853426-35-4 |
| blisibimod | blisibimod | 3002.13 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 107 | 1236126-45-6 |
| blonanserin | blonansérine | 2933.59 | | 42.100 Ann. O (V) | HSC/21 | 1998 | 76 | 132810-10-7 |
| blosozumab | blosozumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 105 | 1132758-87-2 |
| boceprevir | bocéprévir | 2933.99 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 394730-60-0 |
| bococizumab | bococizumab | 3002.10 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1407495-02-6 |
| bornaprolol | bornaprolol | 2922.19 | | 40.260 Ann. L/2 (No. 46) | HSC/17 | 1996 | 46 | 66451-06-7 |
| bortezomib | bortezomib | 2933.99 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 179324-69-7 |
| bosentan | bosentan | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 70 | 147536-97-8 |
| bosutinib | bosutinib | 2933.59 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 380843-75-4 |
| bradanicline | bradanicline | 2934.99 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 639489-84-2 |
| brasofensine | brasofensine | 2933.39 | | 42.100 Ann. O (V) | HSC/21 | 1998 | 76 | 171655-91-7 |
| brazergoline | brazergoline | 2939.69 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 37 | 60019-20-7 |
| brecanavir | brécanavir | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 94 | 313682-08-5 |
| bremazocine | brémazocine | 2933.39 | | 38.100 Ann. Q (No. 185) | HSC/11 | 1993 | 43 | 71990-00-6 |
| bremelanotide | brémélanotide | 2933.79 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 189691-06-3 |
| brentuximab vedotin | brentuximab védotine | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 103 | 914088-09-08 |
| brexpiprazole | brexpiprazole | 2934.99 | | NC1874B1b Ann. O/1 | HSC/51 | 2013 | 106 | 913611-97-9 |
| briakinumab | briakinumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 101 | 339308-60-0 |
| briciclib | briciclib | 2930.90 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 865783-99-9 |
| brifentanil | brifentanil | 2933.39 | | 38.100 Ann. Q (No. 186) | HSC/11 | 1993 | 63 | 101345-71-5 |
| brilacidin | brilacidine | 2933.59 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1224095-98-0 |
| brincidofovir | brincidofovir | 2933.59 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 444805-28-1 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|--------------------|--------------------|------------|------------|--|---------|--------------|--------------|--------------|
| brinzolamide | brinzolamide | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 76 | 138890-62-7 |
| briobacept | briobacept | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 98 | 869881-54-9 |
| brivanib alaninate | brivanib alaninate | 2933.99 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 649735-63-7 |
| brivaracetam | brivaracetam | 2933.79 | | NC1059B2b Ann. O/5 | HSC/37 | 2006 | 93 | 357336-20-0 |
| brobactam | brobactam | 2941.90 | | 42.100 Ann. O (II) | HSC/21 | 1998 | 53 | 26631-90-3 |
| brodalumab | brodalumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 105 | 1174395-19-7 |
| brofamfetamine | brofamfétamine | 2922.29 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 55 | 64638-07-9 |
| bromazepam | bromazépam | 2933.33 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 22 | 1812-30-2 |
| bromerguride | bromerguride | 2939.69 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 51 | 83455-48-5 |
| brometamine | brométénamine | 2933.69 | | 40.260 Ann. L/2 (No. 22) | HSC/17 | 1996 | 12 | 15585-71-4 |
| bromhexine | bromhexine | 2921.59 | | 38.100 Ann. Q (No. 188) | HSC/11 | 1993 | 20 | 3572-43-8 |
| bromindione | bromindione | 2914.70 | 2914.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 12 | 1146-98-1 |
| brontictuzumab | brontictuzumab | 3002.10 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1447814-75-6 |
| broperamole | bropéramole | 2933.39 | | 38.100 Ann. Q (No. 190) | HSC/11 | 1993 | 42 | 33144-79-5 |
| brostalicin | brostalicine | 2933.99 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 203258-60-0 |
| brotizolam | brotizolam | 2934.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 40 | 57801-81-7 |
| bucelipase alfa | bucélipase alfa | 3507.90 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 9026-00-0 |
| buciclovir | buciclovir | 2933.59 | | 38.100 Ann. Q (No. 191) | HSC/11 | 1993 | 52 | 86304-28-1 |
| budesonide | budésouide | 2937.29 | | 38.100 Ann. Q (No. 192) | HSC/11 | 1993 | 37 | 51333-22-3 |
| budiodarone | budiodarone | 2932.99 | | NC1604B1b Ann. N/5 | HSC/46 | 2010 | 101 | 335148-45-3 |
| budotitane | budotitane | 2914.40 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 56 | 85969-07-9 |
| bulaquine | bulaquine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 82 | 223661-25-4 |
| bumepidil | bumépidil | 2933.59 | | 38.100 Ann. Q (No. 194) | HSC/11 | 1993 | 44 | 62052-97-5 |
| bunaprolast | bunaprolast | 2915.39 | | 38.100 Ann. Q (No. 195) | HSC/11 | 1993 | 60 | 99107-52-5 |
| bunazosin | bunazosine | 2933.59 | | 38.100 Ann. Q (No. 196) | HSC/11 | 1993 | 50 | 80755-51-7 |
| bunolol | bunolol | 2922.19 | | 40.260 Ann. L/2 (No. 47) | HSC/17 | 1996 | 22 | 27591-01-1 |
| buparlisib | buparlisib | 2934.99 | | NC1874B1b Ann. O/1 | HSC/51 | 2013 | 106 | 944396-07-0 |
| bupranolol | bupranolol | 2922.19 | | 40.260 Ann. L/2 (No. 48) | HSC/17 | 1996 | 27 | 14556-46-8 |
| buprenorphine | buprénorphine | 2939.11 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 29 | 52485-79-7 |
| buquiterine | buquitérine | 2933.59 | | 38.100 Ann. Q (No. 197) | HSC/11 | 1993 | 53 | 76536-74-8 |
| burapitant | burapitant | 2934.99 | | NC1604B1b Ann. N/5 | HSC/46 | 2010 | 101 | 537034-22-3 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|--------------------|----------------------|------------|------------|--|---------|--------------|--------------|--------------|
| burixafor | burixafor | 2933.59 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 1191448-17-5 |
| burlulipase | burlulipase | 3507.90 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 1261982-91-5 |
| buserelin | buséreline | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 36 | 57982-77-1 |
| busulfan | busulfan | 2905.39 | | 42.100 Ann. O (I) | HSC/21 | 1998 | 6 | 55-98-1 |
| butalbital | butalbital | 2933.53 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 4 | 77-26-9 |
| butamirate | butamirate | 2922.19 | | 40.260 Ann. L/2 (No. 49) | HSC/17 | 1996 | 22 | 18109-80-3 |
| buthalital sodium | buthalital sodique | 2933.59 | | 38.100 Ann. Q (No. 199) | HSC/11 | 1993 | 8 | 510-90-7 |
| butixocort | butixocort | 2937.29 | | 38.100 Ann. Q (No. 200) | HSC/11 | 1993 | 63 | 120815-74-9 |
| butofilolol | butofilolol | 2922.19 | | 40.260 Ann. L/2 (No. 50) | HSC/17 | 1996 | 40 | 64552-17-6 |
| butorphanol | butorphanol | 2933.49 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 33 | 42408-82-2 |
| butropium bromide | bromure de butropium | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 30 | 29025-14-7 |
| butylphthalide | butylphthalide | 2932.20 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 6066-49-5 |
| cabazitaxel | cabazitaxel | 2932.99 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 183133-96-2 |
| cabiotraxetan | cabiotraxétan | 2934.99 | | NC1604B1b Ann. N/6 | HSC/46 | 2010 | 102 | 451478-45-8 |
| cabotegravir | cabotégravir | 2934.99 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1051375-10-0 |
| cabozantinib | cabozantinib | 2933.49 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 849217-68-1 |
| cadazolid | cadazolid | 2934.99 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 1025097-10-2 |
| cadrofloxacine | cadrofloxacine | 2933.59 | | NC0250B2 Ann. P/1 (II) | HSC/25 | 2000 | 81 | 153808-85-6 |
| calaspargase pegol | calaspargase pégol | 3507.90 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 941577-06-6 |
| calcium carbimide | carbimide calcique | 3102.90 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 10 | 156-62-7 |
| calcobutrol | calcobutrol | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 79 | 151878-23-8 |
| caldaret | caldaret | 2933.59 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 133804-44-1 |
| caloxetic acid | acide caloxétique | 2922.50 | | NC0250B2 Ann. P/1 (II) | HSC/25 | 2000 | 81 | 135306-78-4 |
| camazepam | camazépam | 2933.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 30 | 36104-80-0 |
| camicinal | camicinal | 2933.59 | | NC1874B1b Ann. O/1 | HSC/51 | 2013 | 106 | 923565-21-3 |
| camobucol | camobucol | 2930.90 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 216167-92-9 |
| canagliflozin | canagliflozine | 2934.99 | | NC1604B1b Ann. N/6 | HSC/46 | 2010 | 102 | 842133-18-0 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-----------------------|-------------------------|------------|------------|--------------------------|---------|--------------|--------------|---|
| canakinumab | canakinumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 97 | 402710-27-4 (light chain) 402710-25-2 (heavy chain) |
| candesartan | candésartan | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 71 | 139481-59-7 |
| candocuronium iodide | iodure de candocuronium | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 70 | 54278-85-2 |
| canertinib | canertinib | 2934.99 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 267243-28-7 |
| canfosfamide | canfosfamide | 2930.90 | | NC1059B2b Ann. O/4 | HSC/37 | 2006 | 92 | 158382-37-7 |
| cangrelor | cangrélor | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 82 | 163706-06-7 |
| canoctakin | canoctakine | 3002.10 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1019859-03-0 |
| canosimibe | canosimibe | 2933.79 | | NC1500B1b Ann. K/6 | HSC/44 | 2009 | 100 | 768394-99-6 |
| cantuzumab ravtansine | cantuzumab ravtansine | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 105 | 868747-45-9 |
| capadenoson | capadénoson | 2934.10 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 544417-40-5 |
| capecitabine | capécitabine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 72 | 154361-50-9 |
| capeserod | capésérod | 2934.99 | | NC1123B1b Ann. N/1 | HSC/38 | 2006 | 94 | 769901-96-4 |
| caplacizumab | caplacizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 106 | 915810-67-2 |
| capmatinib | capmatinib | 2933.49 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1029712-80-8 |
| capravirine | capravirine | 2933.39 | | NC0430B2 Ann. Q/1 (II) | HSC/27 | 2001 | 83 | 178979-85-6 |
| capromab | capromab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 70 | 151763-64-3 |
| capromorelin | capromoréline | 2933.99 | | NC1874B1b Ann. O/3 | HSC/51 | 2013 | 83 | 193273-66-4 |
| carabersat | carabersat | 2932.99 | | NC0090B2 Ann. M/5 | HSC/23 | 1999 | 80 | 184653-84-7 |
| carafiban | carafiban | 2933.29 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 177563-40-5 |
| carbaldrate | carbaldrate | 2842.90 | | 40.260 Ann. L/2 (No. 4) | HSC/17 | 1996 | 53 | 41342-54-5 |
| carbasalate calcium | carbasalate calcique | 2924.29 | | 38.100 Ann. Q (No. 202) | HSC/11 | 1993 | 27 | 5749-67-7 |
| carbazocine | carbazocine | 2933.49 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 16 | 15686-38-1 |
| carbetimer | carbétimère | 3911.90 | | 38.100 Ann. Q (No. 204) | HSC/11 | 1993 | 50 | 82230-03-3 |
| carboplatin | carboplatine | 2843.90 | | 38.100 Ann. Q (No. 205) | HSC/11 | 1993 | 48 | 41575-94-4 |
| carfenazine | carfénazine | 2934.30 | | 38.100 Ann. Q (No. 206) | HSC/11 | 1993 | 12 | 2622-30-2 |
| carfilzomib | carfilzomib | 2934.99 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 868540-17-4 |
| carglumic acid | acide carginique | 2924.19 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 1188-38-1 |
| caricotamide | caricotamide | 2933.39 | | NC1059B2b Ann. O/5 | HSC/37 | 2006 | 93 | 64881-21-6 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|------------------------|------------------------|------------|------------|--|---------|--------------|--------------|-------------|
| cariporide | cariporide | 2930.90 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 159138-80-4 |
| cariprazine | cariprazine | 2933.59 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 839712-12-8 |
| carisbamate | carisbamate | 2924.29 | | NC1310B1b Ann. N/10 | HSC/41 | 2008 | 96 | 194085-75-1 |
| carlumab | carlumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 104 | 915404-94-3 |
| carmegliptin | carmégliptine | 2933.79 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 813452-18-5 |
| carmofur | carmofur | 2933.59 | | 38.100 Ann. Q (No. 207) | HSC/11 | 1993 | 45 | 61422-45-5 |
| carmoterol | carmotérol | 2933.79 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 147568-66-9 |
| carotegrast | carotégrast | 2933.59 | | NC1604B1b Ann. N/6 | HSC/46 | 2010 | 102 | 401904-75-4 |
| cartasteine | cartastéine | 2934.10 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 149079-51-6 |
| carumonam | carumonam | 2941.90 | | 38.100 Ann. Q (No. 208) | HSC/11 | 1993 | 51 | 87638-04-8 |
| casopitant | casopitant | 2933.59 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 414910-27-3 |
| caspofungin | caspofungine | 2941.90 | | NC0250B2 Ann. P/1 (I) | HSC/25 | 2000 | 80 | 162808-62-0 |
| cathine | cathine | 2939.43 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 44 | 492-39-7 |
| cathinone | cathinone | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 44 | 71031-15-7 |
| catramilast | catramilast | 2933.29 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 183659-72-5 |
| catridecacog | catridécacog | 3002.10 | 3002.12 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 99 | 606138-08-3 |
| catumaxomab | catumaxomab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 93 | 509077-98-9 |
| cebranopadol | cébranopadol | 2934.99 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 863513-91-1 |
| cedelizumab | cédélizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 77 | 156586-90-2 |
| cediranib | cédiranib | 2933.59 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 288383-20-0 |
| cefilavancin | céfilavancine | 2941.90 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 722454-12-8 |
| cefluprenam | céfluprénam | 2941.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 71 | 116853-25-9 |
| cefmatilen | cefmatilène | 2941.90 | | NC0250B2 Ann. P/1 (II) | HSC/25 | 2000 | 81 | 140128-74-1 |
| cefoselis | céfosélis | 2941.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 71 | 122841-10-5 |
| cefovecin | céfovécine | 2941.90 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 234096-34-5 |
| cefquinome | cefquinome | 2941.90 | | 38.100 Ann. Q (No. 209) | HSC/11 | 1993 | 59 | 84957-30-2 |
| ceftaroline fosamil | ceftaroline fosamil | 2941.90 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 229016-73-3 |
| cefteram | ceftéram | 2941.90 | | 38.100 Ann. Q (No. 210) | HSC/11 | 1993 | 55 | 82547-58-8 |
| ceftizoxime alapivoxil | ceftizoxime alapivoxil | 2941.90 | | 42.100 Ann. O (VI) | HSC/21 | 1998 | 77 | 135821-54-4 |
| ceftobiprole | ceftobiprole | 2941.90 | | NC1004B1b Ann. L/11 | HSC/36 | 2005 | 92 | 209467-52-7 |
| ceftobiprole medocaril | ceftobiprole médocaril | 2941.90 | | NC1004B1b Ann. L/11 | HSC/36 | 2005 | 92 | 376653-43-9 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-------------------------|-------------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| ceftolozane | ceftolozane | 2941.90 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 689293-68-3 |
| cefuzonam | céfuzonam | 2941.90 | | 38.100 Ann. Q (No. 211) | HSC/11 | 1993 | 55 | 82219-78-1 |
| celecoxib | célécoxib | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 80 | 169590-42-5 |
| celgosivir | celgosivir | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 77 | 121104-96-9 |
| celivarone | célivarone | 2932.99 | | NC1123B1b Ann. N/1 | HSC/38 | 2006 | 94 | 401925-43-7 |
| cemadotin | cémadotine | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 75 | 159776-69-9 |
| cenderitide | cendéritide | 2937.19 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 507289-11-4 |
| cenersen | cénersen | 2934.99 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 872847-66-0 |
| cenicriviroc | cénicriviroc | 2933.29 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 497223-25-3 |
| cenisertib | cénisertib | 2933.59 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 871357-89-0 |
| censavudine | censavudine | 2934.99 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 634907-30-5 |
| cepeginterferon alfa-2b | cépeginterféron alfa-2b | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 105 | 1192706-52-7 |
| ceralifimod | céralifimod | 2933.99 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 891859-12-4 |
| cerdulatinib | cerdulatinib | 2935.00 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1198300-79-6 |
| ceritinib | céritinib | 2933.59 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 1032900-25-6 |
| cerivastatin | cérivastatine | 2933.39 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 145599-86-6 |
| cerlapirdine | cerlapirdine | 2933.99 | | NC1874B1b Ann. O/1 | HSC/51 | 2013 | 106 | 925448-93-7 |
| cerliponase alfa | cerliponase alfa | 3507.90 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 151662-36-1 |
| certolizumab pegol | certolizumab pegol | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 90 | 428863-50-7 |
| certoparin sodium | certoparine sodique | 3001.90 | | NC1553B1b Ann. O/5 | HSC/45 | 2010 | 70 | 0-00-0 |
| ceruletide | cérulétide | 2933.79 | | 40.260 Ann. L/2 (No. 23) | HSC/17 | 1996 | 34 | 17650-98-5 |
| cetermin | cétermine | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 74 | 157238-32-9 |
| cethromycin | céthromycine | 2941.90 | | NC0845B2 Ann. M/1 (II) | HSC/33 | 2004 | 87 | 205110-48-1 |
| cetilistat | cétilistat | 2934.99 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 282526-98-1 |
| cetrimide | cétrimide | 3808.94 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 46 | 505-86-2 |
| cetuximab | cétuximab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 82 | 205923-56-4 |
| cevimeline | céviméline | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 76 | 107233-08-9 |
| cevipabulin | cévipabulin | 2933.59 | | NC1310B1b Ann. N/10 | HSC/41 | 2008 | 96 | 849550-05-6 |
| cevoglitazar | cévoglitazar | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 94 | 839673-52-8 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-------------------------|---------------------------|------------|------------|--|---------|--------------|--------------|--------------|
| chloralodol | chloralodol | 2911.00 | | 42.100 Ann. O (I) | HSC/21 | 1998 | 12 | 3563-58-4 |
| chlordiazepoxide | chlordiazépoxyde | 2933.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 11 | 58-25-3 |
| chlorotrianisene | chlorotrianiséne | 2909.30 | | 38.100 Ann. Q (No. 212) | HSC/11 | 1993 | 6 | 569-57-3 |
| choline fenofibrate | fénofibrate de choline | 2923.10 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 856676-23-8 |
| choriagonadotropin alfa | choriagonadotropine alfa | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 75 | 177073-44-8 |
| ciaftalan zinc | ciaftalane zinc | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 74 | 14320-04-8 |
| ciclesonide | ciclésouide | 2937.29 | | 38.100 Ann. Q (No. 213) | HSC/11 | 1993 | 74 | 141845-82-1 |
| cicloprolol | cicloprolol | 2922.19 | | 40.260 Ann. L/2 (No. 51) | HSC/17 | 1996 | 48 | 63659-12-1 |
| ciclosporin | ciclosporine | 2941.90 | | 40.260 Ann. L/2 (No. 24) | HSC/17 | 1996 | 47 | 59865-13-3 |
| cidofovir | cidofovir | 2933.59 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 113852-37-2 |
| cilengitide | cilengitide | 2933.79 | | NC0250B2 Ann. P/1 (II) | HSC/25 | 2000 | 81 | 188968-51-6 |
| cilmostim | cilmostim | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 71 | 148637-05-2 |
| cilobradine | cilobradine | 2933.79 | | 38.100 Ann. Q (No. 214) | HSC/11 | 1993 | 66 | 109859-78-1 |
| cilofungin | cilofungine | 2941.90 | | 38.100 Ann. Q (No. 215) | HSC/11 | 1993 | 60 | 79404-91-4 |
| cilomilast | cilomilast | 2926.90 | | NC0430B2 Ann. Q/1 (I) | HSC/27 | 2001 | 82 | 153259-65-5 |
| ciluprevir | ciluprévir | 2934.10 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 300832-84-2 |
| cimaglermin alfa | cimaglermine alfa | 2934.99 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1350717-96-2 |
| cinacalcet | cinacalcet | 2921.49 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 226256-56-0 |
| cinaciguat | cinaciguat | 2922.50 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 329773-35-5 |
| cinalukast | cinalukast | 2934.10 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 128312-51-6 |
| cinamolol | cinamolol | 2922.19 | | 40.260 Ann. L/2 (No. 52) | HSC/17 | 1996 | 44 | 39099-98-4 |
| cindunistat | cindunistat | 2930.90 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 364067-22-1 |
| cintredekin besudotox | cintrédékine bésudotox | 3002.90 | | NC1178B1c Ann. O/2 | HSC/39 | 2007 | 92 | 372075-36-0 |
| cipamfylline | cipamfylline | 2939.59 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 71 | 132210-43-6 |
| cipargamin | cipargamine | 2933.79 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1193314-23-6 |
| cipemastat | cipémastat | 2933.39 | | NC0250B2 Ann. P/1 (II) | HSC/25 | 2000 | 81 | 190648-49-8 |
| cipralisant | cipralisant | 2933.29 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 213027-19-1 |
| cisatracurium besilate | bésilate de cisatracurium | 2933.49 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 73 | 96946-42-8 |
| cismadinone | cismadinone | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 12 | 54063-31-9 |
| citatumumab bogatox | citatumumab bogatox | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 99 | 945228-49-9 |
| cixutumumab | cixutumumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 100 | 947687-12-9 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-----------------------|-----------------------|------------|------------|---|---------|--------------|--------------|--------------|
| cizolirtine | cizolirtine | 2933.19 | | 42.100 Ann. O (V) | HSC/21 | 1998 | 76 | 142155-43-9 |
| clamikalant | clamikalant | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 81 | 158751-64-5 |
| clazakizumab | clazakizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 107 | 1236278-28-6 |
| clazosentan | clazosentan | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 90 | 180384-56-9 |
| clenoliximab | clénoliximab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 77 | 182912-58-9 |
| clevidipine | clévidipine | 2933.39 | | 42.100 Ann. O (IV) | HSC/21 | 1998 | 75 | 167221-71-8 |
| clevudine | clévudine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 78 | 163252-36-6 |
| cliropamine | cliropamine | 2922.50 | | 38.100 Ann. Q (No. 217) | HSC/11 | 1993 | 59 | 109525-44-2 |
| clobazam | clobazam | 2933.72 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 25 | 22316-47-8 |
| clofarabine | clofarabine | 2934.99 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 123318-82-1 |
| clofenoxycide | clofénoxyde | 2914.70 | 2914.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 14 | 3030-53-3 |
| clomifénoxide | clomifénoxide | 2929.90 | | 40.260 Ann. L/2 (No. 12) | HSC/17 | 1996 | 54 | 97642-74-5 |
| clonazepam | clonazépam | 2933.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 22 | 1622-61-3 |
| clonitazene | clonitazène | 2933.99 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 11 | 3861-76-5 |
| cloprednol | cloprednol | 2937.22 | | 42.100 Ann. O (I) | HSC/21 | 1998 | 31 | 5251-34-3 |
| cloranolol | cloranolol | 2922.19 | | 40.260 Ann. L/2 (No. 53) | HSC/17 | 1996 | 41 | 39563-28-5 |
| clotiazepam | clotiazépam | 2934.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 30 | 33671-46-4 |
| cloxazolam | cloxazolam | 2934.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 29 | 24166-13-0 |
| cloxestradiol | cloxestradiol | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 12 | 54063-33-1 |
| cobicistat | cobicistat | 2934.10 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 1004316-88-4 |
| cobimetinib | cobimétinib | 2933.39 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 934660-93-2 |
| cobiprostone | cobiprostone | 2937.50 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 333963-42-1 |
| codactide | codactide | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 24 | 22572-04-9 |
| codoxime | codoxime | 2939.19 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 15 | 7125-76-0 |
| codrituzumab | codrituzumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 109 | 1365267-33-9 |
| coleneuramide | coléneuramide | 2932.99 | | NC1553B1b Ann. O/7 | HSC/45 | 2010 | 100 | 204200-47-5 |
| colesevelam | colésévélam | 3911.90 | | 42.100 Ann. O (VI) | HSC/21 | 1998 | 77 | 182815-43-6 |
| colestilan | colestilan | 3911.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 74 | 95522-45-5 |
| colimecycline | colimécycline | 2941.30 | | 40.260 Ann. L/2 (No. 5) | HSC/17 | 1996 | 33 | 58298-92-3 |
| coltuximab ravtansine | coltuximab ravtansine | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 109 | 1269764-99-9 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-----------------------|-----------------------|------------|------------|--|---------|--------------|--------------|--------------|
| coluracetam | coluracétam | 2934.99 | | NC0730B2 Ann. M/6 | HSC/31 | 2003 | 86 | 135463-81-9 |
| conatumumab | conatumumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 99 | 896731-82-1 |
| conbercept | conbercept | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 105 | 1227158-72-6 |
| concizumab | concizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 108 | 1312299-39-0 |
| condoliase | condoliase | 3507.90 | | NC1604B1b Ann. N/6 | HSC/46 | 2010 | 102 | 9024-13-9 |
| conestat alfa | conestat alfa | 3002.10 | 3002.12 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 98 | 80295-38-1 |
| conivaptan | conivaptan | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 82 | 210101-16-9 |
| contusugene ladenovec | contusugène ladénovec | 3002.90 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 600735-73-7 |
| copanlisib | copanlisib | 2934.99 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1032568-63-0 |
| corifollitropin alfa | corifollitropine alfa | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 80 | 195962-23-3 |
| cortodoxone | cortodoxone | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 15 | 152-58-9 |
| cositecan | cositécan | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 100 | 203923-89-1 |
| crenezumab | crénezumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 105 | 1095207-05-8 |
| crenolanib | créolanib | 2934.99 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 670220-88-9 |
| cridanimod | cridanimod | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 83 | 38609-97-1 |
| crilvastatin | crilvastatine | 2933.79 | | 38.100 Ann. Q (No. 221) | HSC/11 | 1993 | 63 | 120551-59-9 |
| crisantaspase | crisantaspase | 3507.90 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 1349719-22-7 |
| crisnatol | crisnatol | 2922.19 | | 38.100 Ann. Q (No. 222) | HSC/11 | 1993 | 58 | 96389-68-3 |
| crizotinib | crizotinib | 2933.39 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 877399-52-5 |
| crobenetine | crobénetine | 2933.39 | | NC0430B2 Ann. Q/1 (I) | HSC/27 | 2001 | 82 | 221019-25-6 |
| crolibulin | crolibuline | 2932.99 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 1000852-17-4 |
| cromakalim | cromakalim | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 58 | 94470-67-4 |
| cromoglicate lisetil | cromoglicate lisétil | 2932.99 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 110816-79-0 |
| crotoniazide | crotoniazide | 2933.39 | | 38.100 Ann. Q (No. 224) | HSC/11 | 1993 | 11 | 7007-96-7 |
| custirsén | custirsén | 2934.99 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 903916-27-8 |
| cutamesine | cutamésine | 2933.59 | | NC1500B1b Ann. K/6 | HSC/44 | 2009 | 100 | 165377-43-5 |
| cyclobarbitol | cyclobarbitol | 2933.53 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 1 | 52-31-3 |
| cyclopentolate | cyclopentolate | 2922.19 | | 40.260 Ann. L/2 (No. 54) | HSC/17 | 1996 | 39 | 512-15-2 |
| cystine | cystine | 2930.90 | | NC0430B2 Ann. Q/1 (I) | HSC/27 | 2001 | 82 | 56-89-3 |
| dabelotine | dabélotine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 74 | 118976-38-8 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-----------------------|-----------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| dabigatran | dabigatran | 2933.39 | | NC0430B2 Ann. Q/1 (II) | HSC/27 | 2001 | 83 | 211914-51-1 |
| dabigatran etexilate | dabigatran éxexilate | 2933.39 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 211915-06-9 |
| dabrafenib | dabrafénib | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 105 | 1195765-45-7 |
| dacetuzumab | dacétuzumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 98 | 880486-59-9 |
| daclatasvir | daclatasvir | 2933.29 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 1099119-64-5 |
| daclizumab | daclizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 78 | 152923-56-3 |
| dacomitinib | dacomitinib | 2933.59 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 1110813-31-4 |
| dactolisib | dactolisib | 2933.49 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 915019-65-7 |
| daglutril | daglutril | 2933.79 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 182821-27-8 |
| dagrocorat | dagrocorat | 2933.39 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1044535-52-5 |
| dalantercept | dalantercept | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 105 | 1186210-24-1 |
| dalatazide | dalatazide | 3002.90 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1081110-69-1 |
| dalbavancin | dalbavancine | 2941.90 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 171500-79-1 |
| dalbraminol | dalbraminol | 2933.19 | | 38.100 Ann. Q (No. 225) | HSC/11 | 1993 | 58 | 81528-80-5 |
| dalcetrapib | dalcétrapib | 2930.90 | | NC1310B1b Ann. N/10 | HSC/41 | 2008 | 96 | 211513-37-0 |
| dalcotidine | dalcotidine | 2933.39 | | 42.100 Ann. O (V) | HSC/21 | 1998 | 76 | 120958-90-9 |
| dalotuzumab | dalotuzumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 102 | 1005389-60-5 |
| dalteparin sodium | daltéparine sodique | 3001.90 | | NC1553B1b Ann. O/5 | HSC/45 | 2010 | 64 | 9041-08-1 |
| damoctocog alfa pegol | damoctocog alfa pégol | 3002.10 | 3002.12 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 109 | 1363853-26-2 |
| danaparoid sodium | danaparoïde sodique | 3913.90 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 83513-48-8 |
| danegaptide | danégaptide | 2933.99 | | NC1604B1b Ann. N/5 | HSC/46 | 2010 | 101 | 943134-39-2 |
| daniplestim | daniplestim | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 76 | 161753-30-6 |
| daniquidone | daniquidone | 2933.79 | | 38.100 Ann. Q (No. 226) | HSC/11 | 1993 | 62 | 67199-66-0 |
| danirixin | danirixine | 2933.39 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 954126-98-8 |
| danoprevir | danoprévir | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 102 | 916881-67-9 |
| danusertib | danusertib | 2933.59 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 827318-97-8 |
| dapabutan | dapabutan | 2922.49 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 6582-31-6 |
| dapaconazole | dapaconazole | 2933.29 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1269726-67-1 |
| dapagliflozin | dapagliflozine | 2932.99 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 461432-26-8 |
| dapiclermin | dapiclermine | 2933.29 | | NC1059B2b Ann. O/5 | HSC/37 | 2006 | 93 | 444069-80-1 |
| dapirolizumab pegol | dapirolizumab pégol | 3002.10 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1416147-64-2 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-----------------------|--------------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| dapitant | dapitant | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 74 | 153438-49-4 |
| dapivirine | dapivirine | 2933.59 | | NC0730B2 Ann. M/6 | HSC/31 | 2003 | 86 | 244767-67-7 |
| daporinad | daporinad | 2933.39 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 201034-75-5 |
| darapladib | darapladib | 2933.59 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 356057-34-6 |
| daratumumab | daratumumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 101 | 945721-28-8 |
| darbepoetin alfa | darbépoéatine alfa | 3002.10 | 3002.12 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 85 | 209810-58-2 |
| darbufelone | darbufélonge | 2934.10 | | NC0250B2 Ann. P/1 (I) | HSC/25 | 2000 | 80 | 139226-28-1 |
| darexaban | darexaban | 2933.99 | | NC1604B1b Ann. N/5 | HSC/46 | 2010 | 104 | 365462-23-3 |
| darglitazone | darglitazone | 2934.10 | | 39.600 Ann. D/1, par. 15 | HSC/16 | 1995 | 69 | 141200-24-0 |
| darifenacin | darifénacine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 70 | 133099-04-4 |
| darinaparsin | darinaparsine | 2930.90 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 69819-86-9 |
| darotropium bromide | bromure de darotropium | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 99 | 850607-58-8 |
| darsidormine | darsidomine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 74 | 137500-42-6 |
| darunavir | darunavir | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 88 | 206361-99-1 |
| darusentan | darusentan | 2933.59 | | NC0430B2 Ann. Q/1 (I) | HSC/27 | 2001 | 82 | 171714-84-4 |
| dasabuvir | dasabuvir | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 109 | 1132935-63-7 |
| dasantafil | dasantafil | 2933.59 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 569351-91-3 |
| dasatinib | dasatinib | 2934.10 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 302962-49-8 |
| dasolampanel | dasolampanel | 2933.49 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 503294-13-1 |
| dasotraline | dasotraline | 2921.49 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 675126-05-3 |
| datelliptium chloride | chlorure de datelliptium | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 57 | 105118-14-7 |
| davalintide | davalintide | 2937.19 | | NC1649B3b Ann. R/12 | HSC/47 | 2011 | 101 | 863919-85-1 |
| davasaicin | davasaïcine | 2924.29 | | NC1178B1c Ann. O/2 | HSC/39 | 2007 | 92 | 147497-64-1 |
| davunetide | davunétide | 2933.99 | | NC1553B1b Ann. O/7 | HSC/45 | 2010 | 100 | 211439-12-2 |
| daxalipram | daxalipram | 2934.99 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 189940-24-7 |
| decitropine | décitropine | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 18 | 1242-69-9 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|--------------------|----------------------|------------|------------|--|---------|--------------|--------------|--------------|
| declenperone | déclenpérone | 2933.39 | | 38.100 Ann. Q (No. 228) | HSC/11 | 1993 | 42 | 63388-37-4 |
| declopramide | déclopramide | 2924.29 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 891-60-1 |
| decoglutrant | décoglutrant | 2933.59 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 911115-16-7 |
| decominol | décominol | 2922.19 | | 40.260 Ann. L/2 (No. 55) | HSC/17 | 1996 | 45 | 60812-35-3 |
| defactinib | défactinib | 2935.00 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1073154-85-4 |
| deferasirox | déférasirox | 2933.99 | | NC0730B2 Ann. M/6 | HSC/31 | 2003 | 86 | 201530-41-8 |
| deferitazole | déféritazole | 2934.10 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 945635-15-4 |
| deferitrin | déféritrine | 2934.10 | | NC1004B1b Ann. L/11 | HSC/36 | 2005 | 92 | 239101-33-8 |
| deflazacort | déflazacort | 2937.29 | | 38.100 Ann. Q (No. 229) | HSC/11 | 1993 | 39 | 14484-47-0 |
| defoslimod | défoslimod | 2932.99 | | NC0430B2 Ann. Q/1 (III) | HSC/27 | 2001 | 79 | 171092-39-0 |
| degarelix | dégarélix | 2937.19 | | NC0730B2 Ann. M/6 | HSC/31 | 2003 | 86 | 214766-78-6 |
| delafloxacin | délafloxicine | 2933.49 | | NC1553B1b Ann. O/7 | HSC/45 | 2010 | 100 | 189279-58-1 |
| delamanid | délamanid | 2934.99 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 681492-22-8 |
| delanzomib | délanzomib | 2933.39 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 847499-27-8 |
| delavirdine | délavirdine | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 71 | 136817-59-9 |
| delcasertib | delcasertib | 2934.99 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 949100-39-4 |
| deleobuvir | déléobuvir | 2933.59 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 863884-77-9 |
| delequamine | déléquamine | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 73 | 119905-05-4 |
| deligoparin sodium | déligoparine sodique | 3001.90 | | NC1553B1b Ann. O/5 | HSC/45 | 2010 | 89 | 9041-08-1 |
| delimotecan | délimotécan | 2939.99 | | NC1443B1b Ann. P/4 | HSC/43 | 2009 | 97 | 187852-63-7 |
| delmitide | delmitide | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 92 | 287096-87-1 |
| delorazepam | délorazépam | 2933.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 40 | 2894-67-9 |
| deloxolone | déloxolone | 2918.19 | | 38.100 Ann. Q (No. 230) | HSC/11 | 1993 | 51 | 68635-50-7 |
| delparantag | delparantag | 2924.29 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 872454-31-4 |
| deltibant | deltibant | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 75 | 140661-97-8 |
| delucemine | délucémine | 2921.49 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 186495-49-8 |
| demcizumab | demcizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 107 | 1243262-17-0 |
| demegestone | démégestone | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 24 | 10116-22-0 |
| demitraz | demitraz | 2933.29 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 944263-65-4 |
| denagliptin | dénagliptine | 2933.99 | | NC1123B1b Ann. N/1 | HSC/38 | 2006 | 94 | 483369-58-0 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-------------------------|-------------------------|------------|------------|---|---------|--------------|--------------|--------------|
| denaverine | dénavérine | 2922.19 | | 40.260 Ann. L/2 (No. 56) | HSC/17 | 1996 | 25 | 3579-62-2 |
| denbufylline | denbufylline | 2939.59 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 55 | 57076-71-8 |
| denenicokin | dénénicokine | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 99 | 716840-32-3 |
| denibulin | dénibuline | 2933.99 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 284019-34-7 |
| denileukin diffitox | dénileukine diffitox | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 78 | 173146-27-5 |
| denintuzumab mafodotine | dénintuzumab mafodotine | 3002.10 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1399672-02-6 |
| denosumab | dénosumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 94 | 615258-40-7 |
| denotivir | dénotivir | 2934.10 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 51287-57-1 |
| denufosol | dénufosol | 2934.99 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 211448-85-0 |
| deoxycholic acid | acide désoxycholique | 2918.19 | | NC1874B1B Ann. O/1 | HSC/51 | 2013 | 106 | 83-44-3 |
| depelestat | dépélestat | 2934.99 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 506433-25-6 |
| depreotide | dépréotide | 2933.79 | | NC0250B2 Ann. P/1 (I) | HSC/25 | 2000 | 80 | 161982-62-3 |
| depropine | depropine | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 12 | 604-51-3 |
| deracoxib | déracoxib | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 80 | 169590-41-4 |
| derenofylline | dérénofylline | 2933.59 | | NC1604B1b Ann. N/6 | HSC/46 | 2010 | 102 | 251945-92-3 |
| derpanicate | derpanicate | 2933.39 | | 38.100 Ann. Q (No. 233) | HSC/11 | 1993 | 58 | 99518-29-3 |
| derquantel | derquantel | 2934.99 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 187865-22-1 |
| dersalazine | dersalazine | 2933.39 | | NC0730B2 Ann. M/6 | HSC/31 | 2003 | 86 | 188913-58-8 |
| desaspidin | désaspidine | 2914.50 | | 42.100 Ann. O (I) | HSC/21 | 1998 | 15 | 114-43-2 |
| desciclovir | desciclovir | 2933.59 | | 38.100 Ann. Q (No. 234) | HSC/11 | 1993 | 55 | 84408-37-7 |
| descinolone | descinolone | 2937.22 | | 38.100 Ann. Q (No. 235) | HSC/11 | 1993 | 17 | 595-52-8 |
| desirudin | désirudine | 3001.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 120993-53-5 |
| deslanoside | deslanoside | 2938.90 | | 38.100 Ann. Q (No. 236) | HSC/11 | 1993 | 14 | 17598-65-1 |
| desloratadine | desloratadine | 2933.39 | | NC0090B2 Ann. M/5 | HSC/23 | 1999 | 80 | 100643-71-8 |
| desmeninol | désméninol | 2930.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 583-91-5 |
| desmopressin | desmopressine | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 33 | 16679-58-6 |
| desmoteplase | desmoteplase | 3507.90 | | NC0250B2 Ann. P/1 (I) | HSC/25 | 2000 | 80 | 145137-38-8 |
| desomorphine | désomorphine | 2939.19 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 5 | 427-00-9 |
| desoximetasone | désoximétasone | 2937.22 | | 38.100 Ann. Q (No. 238) | HSC/11 | 1993 | 20 | 382-67-2 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|---------------------------|-----------------------------|------------|------------|---|---------|--------------|--------------|-------------|
| detanosal | détanosal | 2922.19 | | 40.260 Ann. L/2 (No. 57) | HSC/17 | 1996 | 23 | 23573-66-2 |
| detivaciclovir | détivaciclovir | 2933.59 | | NC0730B2 Ann. M/6 | HSC/31 | 2003 | 86 | 220984-26-9 |
| detumomab | détumomab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 70 | 145832-33-3 |
| deutolperisone | deutolpérisone | 2845.90 | | NC1059B2b Ann. O/4 | HSC/37 | 2006 | 92 | 474641-19-5 |
| dexamethasone cipeccilate | cipécilate de dexaméthasone | 2937.22 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 132245-57-9 |
| dexamfetamine | dexamfétamine | 2921.46 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 55 | 51-64-9 |
| dexbudesonide | dexbudésonide | 2932.99 | | NC0250B2 Ann. P/1 (I) | HSC/25 | 2000 | 80 | 51372-29-3 |
| dexecadotril | dexécadotril | 2930.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 73 | 112573-72-5 |
| dexefaroxan | dexéfarrowan | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 76 | 143249-88-1 |
| dexelvucitabine | dexelvucitabine | 2934.99 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 134379-77-4 |
| dexketoprofen | dexkétoprofène | 2918.30 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 22161-81-5 |
| dexlansoprazole | dexlansoprazole | 2933.39 | | NC1059B2b Ann. O/5 | HSC/37 | 2006 | 93 | 138530-94-6 |
| dexmecamylamine | dexmécamylamine | 2921.30 | | NC1874B1b Ann. O/1 | HSC/51 | 2013 | 106 | 107538-05-6 |
| dexmethylphenidate | dexméthylphénidate | 2933.39 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 40431-64-9 |
| dexneбиволol | dexnébivolol | 2932.99 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 118457-15-1 |
| dexpemedolac | dexpémédolac | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 71 | 114030-44-3 |
| dexpramipexole | dexpramipexole | 2934.20 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 104632-28-2 |
| dexpropranolol | dexpropranolol | 2922.19 | | 40.260 Ann. L/2 (No. 58) | HSC/17 | 1996 | 21 | 5051-22-9 |
| dexsotalol | dexsotalol | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 74 | 30236-32-9 |
| dextiopronin | dextiopronine | 2930.90 | | NC0090B2 Ann. M/1 (II) | HSC/23 | 1999 | 79 | 29335-92-0 |
| dextofisopam | dextofisopam | 2933.99 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 82059-50-5 |
| dextromethorphan | dextrométhorphan | 2933.49 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 1 | 125-71-3 |
| dextromoramide | dextromoramide | 2934.91 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 6 | 357-56-2 |
| dextropropoxyphene | dextropropoxyphène | 2922.14 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 7 | 469-62-5 |
| dextrorphan | dextrorphan | 2933.49 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 1 | 125-73-5 |
| dezaguanine | dézaguanine | 2933.79 | | 38.100 Ann. Q (No. 241) | HSC/11 | 1993 | 51 | 41729-52-6 |
| diampromide | diampromide | 2924.29 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 10 | 552-25-0 |
| dianhydrogalactitol | dianhydrogalactitol | 2910.90 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 23261-20-3 |
| dianicline | dianicline | 2934.99 | | NC1059B2b Ann. O/5 | HSC/37 | 2006 | 93 | 292634-27-6 |
| diaplasinin | diaplasinine | 2933.99 | | NC1123B1b Ann. N/1 | HSC/38 | 2006 | 94 | 481631-45-2 |
| diazepam | diazépan | 2933.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 12 | 439-14-5 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|----------------------------|-------------------------------|------------|------------|---|---------|--------------|--------------|--------------|
| diboterminalfa | dibotermine alfa | 2933.29 | | NC0938B2b Ann. O/2 | HSC/35 | 2005 | 89 | 246539-15-1 |
| dibunate | dibunate | 2904.10 | | 38.100 Ann. Q (No. 69) | HSC/11 | 1993 | 48 | no mention |
| dichlorisone | dichlorisone | 2937.22 | | 38.100 Ann. Q (No. 242) | HSC/11 | 1993 | 10 | 7008-26-6 |
| diciferron | diciferron | 2931.00 | | 38.100 Ann. Q (No. 243) | HSC/11 | 1993 | 44 | 65606-61-3 |
| dicirenone | dicirénone | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 50 | 41020-79-5 |
| diclofenac etalhyaluronate | étalhyaluronate de diclofénac | 3913.90 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1608089-20-8 |
| dicobalt edetate | édétate dicobaltique | 2922.49 | | 38.100 Ann. Q (No. 245) | HSC/11 | 1993 | 45 | 36499-65-7 |
| dienestrol | diènestrol | 2907.29 | | 38.100 Ann. Q (No. 246) | HSC/11 | 1993 | 1 | 84-17-3 |
| dienogest | diénogest | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 49 | 65928-58-7 |
| diethylstilbestrol | diéthylstilbestrol | 2907.29 | | 38.100 Ann. Q (No. 248) | HSC/11 | 1993 | 4 | 56-53-1 |
| diethylthiambutene | diéthylthiambutène | 2934.99 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 3 | 86-14-6 |
| dietifen | diétifène | 2922.19 | | 40.260 Ann. L/2 (No. 59) | HSC/17 | 1996 | 22 | 3686-78-0 |
| difemerine | difémérine | 2922.19 | | 40.260 Ann. L/2 (No. 60) | HSC/17 | 1996 | 17 | 80387-96-8 |
| difenoximide | difénoximide | 2933.39 | | 38.100 Ann. Q (No. 249) | HSC/11 | 1993 | 32 | 47806-92-8 |
| difenoxin | difénoxine | 2933.33 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 25 | 28782-42-5 |
| difeterol | difétérol | 2922.19 | | 40.260 Ann. L/2 (No. 61) | HSC/17 | 1996 | 36 | 14587-50-9 |
| diflomotecan | diflomotécan | 2939.99 | | NC0730B2 Ann. M/4 | HSC/31 | 2003 | 84 | 220997-97-7 |
| difluprednate | difluprednate | 2937.22 | | 38.100 Ann. Q (No. 250) | HSC/11 | 1993 | 21 | 23674-86-4 |
| dihydrocodeine | dihydrocodéine | 2939.11 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 8 | 125-28-0 |
| dilmapimod | dilmapimod | 2933.79 | | NC1649B3b Ann. R/13 | HSC/47 | 2011 | 102 | 444606-18-2 |
| dilopetine | dilopétine | 2934.99 | | NC1123B1b Ann. N/1 | HSC/38 | 2006 | 94 | 247046-52-2 |
| diltiazem | diltiazem | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 30 | 42399-41-7 |
| dimabefylline | dimabéfylline | 2939.59 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 19 | 1703-48-6 |
| dimadectin | dimadectine | 2941.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 73 | 156131-91-8 |
| dimelazine | dimélazine | 2934.30 | | 38.100 Ann. Q (No. 253) | HSC/11 | 1993 | 14 | 15302-12-2 |
| dimenoxadol | diménoxadol | 2922.19 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 7 | 509-78-4 |
| dimepheptanol | dimépheptanol | 2922.19 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 5 | 545-90-4 |
| dimesone | dimésone | 2937.22 | | 38.100 Ann. Q (No. 254) | HSC/11 | 1993 | 23 | 25092-07-3 |
| dimethylthiambutene | diméthylthiambutène | 2934.99 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 3 | 524-84-5 |
| dinaciclib | dinaciclib | 2933.59 | | NC1649B3b Ann. R/13 | HSC/47 | 2011 | 102 | 779353-01-4 |
| dinutuximab | dinutuximab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 109 | 1363687-32-4 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|------------------------|---------------------------|------------|------------|---|---------|--------------|--------------|--------------|
| dioxaphetyl butyrate | butyrate de dioxaphétyl | 2934.99 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 5 | 467-86-7 |
| diphenoxylate | diphénoxyllate | 2933.33 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 10 | 915-30-0 |
| dipipanone | dipipanone | 2933.33 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 5 | 467-83-4 |
| diprafenone | diprafénone | 2922.19 | | 40.260 Ann. L/2 (No. 63) | HSC/17 | 1996 | 48 | 81447-80-5 |
| dipraglurant | dipraglurant | 2933.39 | | NC1604B1b Ann. N/6 | HSC/46 | 2010 | 102 | 872363-17-2 |
| diprogulic acid | acide diprogulique | 2932.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 35 | 18467-77-1 |
| diridavumab | diridavumab | 3002.10 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1393659-46-5 |
| dirithromycin | dirithromycine | 2941.50 | | 38.100 Ann. Q (No. 256) | HSC/11 | 1993 | 53 | 62013-04-1 |
| dirlotapide | dirlotapide | 2933.99 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 481658-94-0 |
| dirucotide | dirucotide | 2933.29 | | NC1553B1b Ann. O/7 | HSC/45 | 2010 | 100 | 152074-97-0 |
| disitertide | disitertide | 2933.99 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 272105-42-7 |
| disogluside | disogluside | 2938.90 | | 38.100 Ann. Q (No. 257) | HSC/11 | 1993 | 47 | 14144-06-0 |
| disomotide | disomotide | 3002.20 | | NC1248E1b Ann. F/11 par. 8 | HSC/40 | 2007 | 94 | 181477-43-0 |
| disufenton sodium | disufenton sodique | 2929.90 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 168021-79-2 |
| disulergine | disulergine | 2939.69 | | 42.100 Ann. O (I) | HSC/21 | 1998 | 45 | 59032-40-5 |
| disulfiram | disulfirame | 2930.30 | | 38.100 Ann. Q (No. 258) | HSC/11 | 1993 | 1 | 97-77-8 |
| disuprazole | disuprazole | 2933.39 | | 38.100 Ann. Q (No. 259) | HSC/11 | 1993 | 56 | 99499-40-8 |
| ditekiren | ditékirène | 2933.39 | | 38.100 Ann. Q (No. 260) | HSC/11 | 1993 | 84 | 103336-05-6 |
| ditercalinium chloride | chlorure de ditercalinium | 2933.39 | | 38.100 Ann. Q (No. 261) | HSC/11 | 1993 | 49 | 74517-42-3 |
| dithranol | dithranol | 2914.50 | | 38.100 Ann. Q (No. 262) | HSC/11 | 1993 | 4 | 480-22-8 |
| divaplon | divaplone | 2933.59 | | 38.100 Ann. Q (No. 263) | HSC/11 | 1993 | 61 | 90808-12-1 |
| dizocilpine | dizocilpine | 2933.49 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 60 | 77086-21-6 |
| docetaxel | docétaxel | 2932.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 71 | 114977-28-5 |
| dofequidar | doféquidar | 2933.59 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 129716-58-1 |
| dolutegravir | dolutégravir | 2934.99 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 1051375-16-6 |
| domitroban | domitroban | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 73 | 112966-96-8 |
| domoprednate | domoprednate | 2937.29 | | 38.100 Ann. Q (No. 266) | HSC/11 | 1993 | 47 | 66877-67-6 |
| domperidone | dompéridone | 2933.39 | | 38.100 Ann. Q (No. 267) | HSC/11 | 1993 | 36 | 57808-66-9 |
| donepezil | donépézil | 2933.39 | | 42.100 Ann. O (IV) | HSC/21 | 1998 | 75 | 120014-06-4 |
| donitriptan | donitriptan | 2933.59 | | NC0430B2 Ann. Q/1 (I) | HSC/27 | 2001 | 82 | 170912-52-4 |
| doqualast | doqualast | 2933.59 | | 38.100 Ann. Q (No. 268) | HSC/11 | 1993 | 48 | 64019-03-0 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|------------------------------|----------------------------|------------|------------|---|---------|--------------|--------------|--------------|
| doramapimod | doramapimod | 2934.99 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 285983-48-4 |
| doramectin | doramectine | 2941.90 | | 38.100 Ann. Q (No. 269) | HSC/11 | 1993 | 65 | 117704-25-3 |
| doranidazole | doranidazole | 2933.29 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 149838-23-3 |
| dorastine | dorastine | 2933.39 | | 38.100 Ann. Q (No. 270) | HSC/11 | 1993 | 23 | 21228-13-7 |
| doravirine | doravirine | 2933.79 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 1338225-97-0 |
| doripenem | doripénem | 2941.90 | | NC0590B2 Ann. L/10 | HSC/29 | 2002 | 83 | 148016-81-3 |
| dornase alfa | dornase alfa | 3507.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 143831-71-4 |
| dosergoside | dosergoside | 2939.69 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 54 | 87178-42-5 |
| dovitinib | dovitinib | 2933.79 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 405169-16-6 |
| doxercalciferol | doxercalciférol | 2936.29 | | NC0430B2 Ann. Q/1 (I) | HSC/27 | 2001 | 82 | 54573-75-0 |
| draquinolol | draquinolol | 2933.79 | | 38.100 Ann. Q (No. 272) | HSC/11 | 1993 | 54 | 67793-71-9 |
| drinabant | drinabant | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 99 | 358970-97-5 |
| drisapersen | drisapersen | 2934.99 | | NC1874B1b Ann. O/1 | HSC/51 | 2013 | 106 | 1251830-50-8 |
| droloxifene | droloxifène | 2922.19 | | 40.260 Ann. L/2 (No. 64) | HSC/17 | 1996 | 53 | 82413-20-5 |
| dronedarone | dronédarone | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 75 | 141626-36-0 |
| drosiprenone | drosipirénone | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 63 | 67392-87-4 |
| drotebanol | drotébanol | 2933.49 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 24 | 3176-03-2 |
| drotrecogin alfa (activated) | drotrécogine alfa (activé) | 3002.10 | 3002.12 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 86 | 98530-76-8 |
| droxinavir | droxinavir | 2924.21 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 159910-86-8 |
| drozitumab | drozitumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 103 | 912628-39-8 |
| dulaglutide | dulaglutide | 2937.19 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 923950-08-7 |
| dulanermin | dulanermine | 2933.29 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 867153-61-5 |
| duligotumab | duligotumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 107 | 1314238-96-4 |
| dupilumab | dupilumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 108 | 1190264-60-8 |
| dusigitumab | dusigitumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 108 | 1204390-13-5 |
| dutacatib | dutacatib | 2933.59 | | NC1123B1b Ann. N/1 | HSC/38 | 2006 | 94 | 501000-36-8 |
| dutasteride | dutastéride | 2937.29 | | NC2116B1b Ann. R/7 | HSC/55 | 2015 | 78 | 164656-23-9 |
| duteplase | dutéplase | 3507.90 | | 38.100 Ann. Q (No. 275) | HSC/11 | 1993 | 62 | 120608-46-0 |
| dutogliptin | dutogliptine | 2933.99 | | NC1500B1b Ann. K/6 | HSC/44 | 2009 | 100 | 852329-66-9 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|---------------|----------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| duvelisib | duvélisib | 2933.79 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1201438-56-3 |
| duvoglustat | duvoglustat | 2933.39 | | NC1604B1b Ann. N/6 | HSC/46 | 2010 | 102 | 19130-96-2 |
| ebalzotan | ébalzotan | 2932.99 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 149494-37-1 |
| ecalcidene | ecalcidene | 2933.39 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 150337-94-3 |
| ecallantide | ecallantide | 2934.99 | | NC1059B2b Ann. O/5 | HSC/37 | 2006 | 93 | 460738-38-9 |
| ecamsule | écamsule | 2914.70 | 2914.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 75 | 92761-26-7 |
| ecenofloxacin | écénofloxacine | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 78 | 162301-05-5 |
| ecipramidil | écipramidil | 2922.19 | | 40.260 Ann. L/2 (No. 65) | HSC/17 | 1996 | 40 | 64552-16-5 |
| ecogramostim | écogramostim | 3504.00 | | 38.100 Ann. Q (No. 276) | HSC/11 | 1993 | 62 | 123120-99-0 |
| ecomustine | écomustine | 2932.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 61 | 98383-18-7 |
| ecopipam | ecopipam | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 80 | 112108-01-7 |
| ecopladib | ecopladib | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 90 | 381683-92-7 |
| ecraprost | ecraprost | 2937.50 | | NC2116B1b Ann. R/7 | HSC/55 | 2015 | 83 | 136892-64-3 |
| ecromeximab | écromeximab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 87 | 292819-64-8 |
| eculizumab | eculizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 87 | 219685-50-4 |
| edaglitazone | edaglitazone | 2934.10 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 213411-83-7 |
| edaravone | édaravone | 2933.19 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 89-25-8 |
| edelfosine | édelfosine | 2923.90 | | 38.100 Ann. Q (No. 278) | HSC/11 | 1993 | 59 | 70641-51-9 |
| edifolone | édifolone | 2932.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 56 | 90733-40-7 |
| edivoxetine | édivoxétine | 2934.99 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 1194508-25-2 |
| edodekin alfa | édodékine alfa | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 79 | 187348-17-0 |
| edonentan | edonentan | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 86 | 210891-04-6 |
| edotecarin | édotécarine | 2934.99 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 174402-32-5 |
| edotreotide | édotréotide | 2934.99 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 204318-14-9 |
| edoxaban | édoxaban | 2934.99 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 480449-70-5 |
| edratide | edratide | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 89 | 433922-67-9 |
| edrecolomab | édrecolomab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 74 | 156586-89-9 |
| edronocaine | édronocaïne | 2922.19 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 190258-12-9 |
| efalizumab | éfalizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 85 | 214745-43-4 |
| efaproxiral | éfaproxiral | 2924.29 | | NC0730B2 Ann. M/6 | HSC/31 | 2003 | 86 | 131179-95-8 |
| efavirenz | éfavirenz | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 78 | 154598-52-4 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-------------------|-------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| efegatran | éfégatran | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 71 | 105806-65-3 |
| efepristin | éfépristine | 2941.90 | | 42.100 Ann. O (IV) | HSC/21 | 1998 | 75 | 57206-54-9 |
| efinaconazole | éfinaconazole | 2933.39 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 164650-44-6 |
| efipladib | efipladib | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 92 | 381683-94-9 |
| eflapégastrim | éflapégastrim | 3002.10 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1384099-30-2 |
| efletirizine | éflétirizine | 2933.59 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 71 | 150756-35-7 |
| eflucimibe | éflucimibe | 2930.90 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 202340-45-2 |
| efmoroctocog alfa | efmoroctocog alfa | 3002.10 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1270012-79-7 |
| eftrenonacog alfa | eftrénonacog alfa | 3002.10 | 3002.12 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 109 | 1270012-74-2 |
| efungumab | éfungumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 95 | 762260-74-2 |
| eganoprost | eganoprost | 2937.50 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 63266-93-3 |
| egaptivon pegol | egaptivon pégol | 3907.20 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 934868-74-3 |
| eglumetad | églumétad | 2922.49 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 90 | 176199-48-7 |
| elacridar | élacridar | 2933.49 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 76 | 143664-11-3 |
| elacytarabine | élacytarabine | 2934.99 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 188181-42-2 |
| elagolix | élagolix | 2937.90 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 834153-87-6 |
| elarofiban | elarofiban | 2933.39 | | NC0430B2 Ann. Q/1 (II) | HSC/27 | 2001 | 83 | 198958-88-2 |
| elbasvir | elbasvir | 2934.99 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1370468-36-2 |
| elbimilast | elbimilast | 2933.39 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 107 | 418794-42-0 |
| eldacimibe | eldacimibe | 2922.50 | | 42.100 Ann. O (V) | HSC/21 | 1998 | 76 | 141993-70-6 |
| eldecalcitol | eldécalcitol | 2936.29 | | NC1443B1b Ann. P/3 | HSC/43 | 2009 | 97 | 104121-92-8 |
| eldelumab | eldélumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 109 | 946414-98-8 |
| eledoisin | élédoïsine | 2933.79 | | 40.260 Ann. L/2 (No. 25) | HSC/17 | 1996 | 28 | 69-25-0 |
| elesclomol | élesclomol | 2930.90 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 488832-69-5 |
| eletriptan | élétriptan | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 74 | 143322-58-1 |
| eliglustat | éliglustat | 2934.99 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 491833-29-5 |
| elinafide | élinafide | 2925.19 | | 42.100 Ann. O (IV) | HSC/21 | 1998 | 75 | 162706-37-8 |
| elinogrel | élinogrel | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 101 | 936500-94-6 |
| elisartan | élisartan | 2933.29 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 158682-68-9 |
| elisidepsin | élisidepsine | 2934.99 | | NC1649B3b Ann. R/12 | HSC/47 | 2011 | 101 | 681272-30-0 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|---------------------|-----------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| elliptinium acetate | acétate d'elliptinium | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 43 | 58337-35-2 |
| elobixibat | élobixibat | 2934.99 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 439087-18-0 |
| elocalcitol | élocalcitol | 2906.19 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 199798-84-0 |
| elomotecan | élototécan | 2939.99 | | NC1059B2b Ann. O/4 | HSC/37 | 2006 | 92 | 220998-10-7 |
| elopiprazole | élopiprazole | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 70 | 115464-77-2 |
| elosulfase alfa | élosulfase alfa | 3507.90 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 9025-60-9 |
| elotuzumab | elotuzumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 100 | 915296-00-3 |
| elpamotide | elpamotide | 3002.20 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 673478-49-4 |
| elpetrigine | elpétrigine | 2933.99 | | NC1604B1b Ann. N/5 | HSC/46 | 2010 | 101 | 212778-82-0 |
| elsamitrucin | elsamitrucine | 2941.90 | | 38.100 Ann. Q (No. 281) | HSC/11 | 1993 | 62 | 97068-30-9 |
| elsibucol | elsibucol | 2930.90 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 216167-95-2 |
| elsiglutide | elsiglutide | 2937.19 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 914009-84-0 |
| eltrombopag | eltrombopag | 2933.19 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 496775-61-2 |
| elubrixin | élubrixine | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 107 | 688763-64-6 |
| eluxadoline | eluxadoline | 2933.29 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 864821-90-9 |
| elvitegravir | elvitégravir | 2933.49 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 697761-98-1 |
| elzasonan | elzasonan | 2934.99 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 361343-19-3 |
| emactuzumab | emactuzumab | 3002.10 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1448221-67-7 |
| emapticap pegol | émapticap pégol | 3907.20 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1390630-22-4 |
| emapunil | émapunil | 2933.59 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 226954-04-7 |
| embeconazole | embéconazole | 2934.99 | | NC1059B2b Ann. O/4 | HSC/37 | 2006 | 92 | 329744-44-7 |
| embusartan | embusartan | 2933.79 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 156001-18-2 |
| emfilermin | emfilermine | 2933.29 | | NC0430B2 Ann. Q/1 (I) | HSC/27 | 2001 | 82 | 159075-60-2 |
| emibetuzumab | émibetuzumab | 3002.10 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1365287-97-3 |
| emicerfont | emicerfont | 2933.29 | | NC1649B3b Ann. R/13 | HSC/47 | 2011 | 102 | 786701-13-1 |
| emideltide | émideltide | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 70 | 62568-57-4 |
| emivirine | émivirine | 2933.59 | | NC0430B2 Ann. Q/1 (I) | HSC/27 | 2001 | 82 | 149950-60-7 |
| emixustat | émixustat | 2922.50 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1141777-14-1 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|--------------------|---------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| emoctakin | émoctakine | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 74 | 142298-00-8 |
| emodepside | emodepside | 2934.99 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 155030-63-0 |
| empagliflozin | empagliflozin | 2932.19 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 864070-44-0 |
| empegfilgrastim | empegfilgrastim | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 107 | 1192706-53-8 |
| emricasan | emricasan | 2924.29 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 254750-02-2 |
| emtricitabine | emtricitabine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 80 | 143491-57-0 |
| enadenotcirev | énadénotcirev | 3002.90 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1402042-02-7 |
| enavatuzumab | énavatuzumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 104 | 62149-33-0 |
| encaleret | encaléret | 2922.19 | | NC1874B1b Ann. O/4 | HSC/51 | 2013 | 105 | 787583-71-5 |
| encenicline | encénicline | 2934.99 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 550999-75-2 |
| encorafenib | encorafénib | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 109 | 1269440-17-6 |
| endixaprine | endixaprine | 2933.39 | | 38.100 Ann. Q (No. 282) | HSC/11 | 1993 | 60 | 93181-85-2 |
| enecadin | énécadine | 2933.59 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 259525-01-4 |
| enestebol | énestébol | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 22 | 2320-86-7 |
| enfortumab vedotin | enfortumab vedotin | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 109 | 1346452-25-2 |
| enfuvirtide | enfuvirtide | 2933.29 | | NC0730B2 Ann. M/4 (III) | HSC/31 | 2003 | 85 | 159519-65-0 |
| eniluracil | eniluracil | 2933.59 | | 42.100 Ann. O (VI) | HSC/21 | 1998 | 77 | 59989-18-3 |
| eniporide | éniporide | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 79 | 176644-21-6 |
| enisamium iodide | iodure d'énisamium | 2933.39 | | NC1604B1b Ann. N/5 | HSC/46 | 2010 | 101 | 201349-37-3 |
| enlimomab | enlimomab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 70 | 142864-19-5 |
| enlimomab pegol | enlimomab pégol | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 77 | 169802-84-0 |
| enobosarm | enobosarm | 2926.90 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 841205-47-8 |
| enocitabine | énocitabine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 46 | 55726-47-1 |
| enokizumab | énokizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 104 | 909875-08-7 |
| enoticumab | énoticumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 107 | 1192578-27-0 |
| enoxacin | énoxacine | 2933.59 | | 38.100 Ann. Q (No. 285) | HSC/11 | 1993 | 49 | 74011-58-8 |
| enoxaparin sodium | énoxaparine sodique | 3001.90 | | NC1553B1b Ann. O/5 | HSC/45 | 2010 | 65 | 9041-08-1 |
| enoximone | énoximone | 2933.29 | | 38.100 Ann. Q (No. 287) | HSC/11 | 1993 | 52 | 77671-31-9 |
| enprofylline | enprofylline | 2939.59 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 44 | 41078-02-8 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-----------------|------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| enrasentan | enrasentan | 2932.99 | | NC0090B2 Ann. M/5 | HSC/23 | 1999 | 80 | 167256-08-8 |
| ensereptide | ensérepride | 2934.99 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 254433-51-7 |
| ensituximab | ensituximab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 103 | 1092658-06-4 |
| ensulizole | ensulizole | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 83 | 27503-81-7 |
| entasobulin | entasobuline | 2933.49 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 501921-61-5 |
| entecavir | entécavir | 2933.59 | | NC0430B2 Ann. Q/1 (I) | HSC/27 | 2001 | 82 | 142217-69-4 |
| entinostat | entinostat | 2933.39 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 209783-80-2 |
| entolimod | entolimod | 3002.10 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 951628-22-1 |
| entospletinib | entosplétinib | 2934.99 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1229208-44-9 |
| enzacamene | enzacamène | 2914.39 | | NC0430B2 Ann. Q/1 (II) | HSC/27 | 2001 | 83 | 36861-47-9 |
| enzalutamide | enzalutamide | 2933.29 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 915087-33-1 |
| enzastaurin | enzastaurine | 2933.39 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 170364-57-5 |
| epafipase | epafipase | 3507.90 | | NC0730B2 Ann. M/4 (III) | HSC/31 | 2003 | 85 | 208576-22-1 |
| epelsiban | épelsiban | 2934.99 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 872599-83-2 |
| eperezolid | épérezolide | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 76 | 165800-04-4 |
| epervudine | épervudine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 61 | 60136-25-6 |
| epetirimod | épétirimod | 2933.99 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 227318-71-0 |
| epicriptine | épicriptine | 2939.69 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 58 | 88660-47-3 |
| epiestriol | épiestriol | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 12 | 547-81-9 |
| epimestrol | épimestrol | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 22 | 7004-98-0 |
| epipropidine | épipropidine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 12 | 5696-17-3 |
| epirubicin | épirubicine | 2941.90 | | 38.100 Ann. Q (No. 294) | HSC/11 | 1993 | 48 | 56420-45-2 |
| epitizide | épitizide | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 91 | 1764-85-8 |
| epitumomab | epitumomab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 82 | 263547-71-3 |
| eplerenone | éplérénone | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 77 | 107724-20-9 |
| eplivanserin | éplivansérine | 2928.00 | | NC0090B2 Ann. M/5 | HSC/23 | 1999 | 80 | 130579-75-8 |
| epoetin alfa | époétine alfa | 3002.10 | | NC1310B1b Ann. N/6 | HSC/41 | 2008 | 66 | 113427-24-0 |
| epoetin beta | époétine bêta | 3002.10 | | NC1310B1b Ann. N/6 | HSC/41 | 2008 | 62 | 122312-54-3 |
| epoetin delta | époétine delta | 3002.10 | | NC0730B2 Ann. M/4 (III) | HSC/31 | 2003 | 85 | 261356-80-3 |
| epoetin epsilon | époétine epsilon | 3002.10 | | NC0090B2 Ann. M/1 (III) | HSC/23 | 1999 | 72 | 154725-65-2 |
| epoetin gamma | époétine gamma | 3002.10 | | NC1310B1b Ann. N/6 | HSC/41 | 2008 | 67 | 130455-76-4 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|--------------------------------|-----------------------------|------------|------------|---|---------|--------------|--------------|--------------|
| epoetin kappa | époéine kappa | 3002.10 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 879555-13-2 |
| epoetin omega | époéine oméga | 3002.10 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 73 | 148363-16-0 |
| epoetin theta | époéine thêta | 3002.10 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 762263-14-9 |
| epoetin zeta | époéine zéta | 3002.10 | | NC1178B1c Ann. O/2 | HSC/39 | 2007 | 92 | 604802-70-2 |
| epratuzumab | épratuzumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 82 | 205923-57-5 |
| eprinomectin | éprinomectine | 2941.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 73 | 123997-26-2 |
| eprodisate | éprodisate | 2904.10 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 21668-77-9 |
| eprosartan | éprosartan | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 71 | 133040-01-4 |
| eprotrirome | éprotrirome | 2924.29 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 355129-15-6 |
| epsiprantel | epsiprantel | 2933.59 | | 38.100 Ann. Q (No. 296) | HSC/11 | 1993 | 57 | 98123-83-2 |
| eptacog alfa (activated) | eptacog alfa (activé) | 3002.10 | 3002.12 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 72 | 102786-61-8 |
| eptacog alfa pegol (activated) | eptacog alfa pégol (activé) | 3002.10 | 3002.12 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 101 | 944130-77-2 |
| eptapirone | eptapirone | 2933.69 | | NC0430B2 Ann. Q/1 (I) | HSC/27 | 2001 | 82 | 179756-85-5 |
| eptaplatin | eptaplatine | 2843.90 | | NC0430B2 Ann. Q/1 (II) | HSC/27 | 2001 | 83 | 146665-77-2 |
| eptifibatide | eptifibatide | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 78 | 148031-34-9 |
| eptotermin alfa | eptotermine alfa | 2933.29 | | NC0938B2b Ann. O/2 | HSC/35 | 2005 | 89 | 129805-33-0 |
| eravacycline | éravacycline | 2941.30 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1207283-85-9 |
| ergometrine | ergométrine | 2939.61 | | E.N. Chap. 29 - List I-III (Precursors) | HSC/21 | 1998 | 4 | 60-79-7 |
| ergotamine | ergotamine | 2939.62 | | E.N. Chap. 29 - List I-III (Precursors) | HSC/21 | 1998 | 4 | 113-15-5 |
| eribaxaban | éribaxaban | 2933.79 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 536748-46-6 |
| eribulin | éribuline | 2932.19 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 253128-41-5 |
| ericolol | éricolol | 2922.19 | | 40.260 Ann. L/2 (No. 66) | HSC/17 | 1996 | 50 | 85320-67-8 |
| erismodegib | érismodégib | 2934.99 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 956697-53-3 |
| eritoran | eritoran | 2932.99 | | NC1178B1c Ann. O/2 | HSC/39 | 2007 | 92 | 185955-34-4 |
| eritrityl tetranitrate | tétranitrate d'étrityle | 2920.90 | | 38.100 Ann. Q (No. 298) | HSC/11 | 1993 | 13 | 7297-25-8 |
| erlizumab | erlizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 84 | 211323-03-4 |
| erlotinib | erlotinib | 2933.59 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 183321-74-6 |
| ersentilide | ersentilide | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 72 | 125279-79-0 |
| ertapenem | ertapénem | 2941.90 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 153832-46-3 |
| erteberel | ertébérel | 2932.99 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 533884-09-2 |
| ertiprotafib | ertiprotafib | 2934.99 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 251303-04-5 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|------------------------|------------------------|------------|------------|---|---------|--------------|--------------|--------------|
| ertugliflozin | ertugliflozine | 2932.99 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 1210344-57-2 |
| ertumaxomab | ertumaxomab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 93 | 509077-99-0 |
| esatenolol | ésaténolol | 2924.29 | | 42.100 Ann. O (V) | HSC/21 | 1998 | 76 | 93379-54-5 |
| escitalopram | escitalopram | 2932.99 | | NC0430B2 Ann. Q/1 (I) | HSC/27 | 2001 | 82 | 128196-01-0 |
| esketamine | eskétamine | 2922.39 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 81 | 33643-46-8 |
| eslicarbazepine | eslicarbazépine | 2933.99 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 104746-04-5 |
| esmirtazapine | esmirtazapine | 2933.59 | | NC1059B2b Ann. O/5 | HSC/37 | 2006 | 93 | 61337-87-9 |
| esmolol | esmolol | 2922.19 | | 40.260 Ann. L/2 (No. 67) | HSC/17 | 1996 | 50 | 103598-03-4 |
| esomeprazole | ésoméprazole | 2933.39 | | NC0090B2 Ann. M/1 (II) | HSC/23 | 1999 | 79 | 119141-88-7 |
| esonarimod | ésonarimod | 2930.90 | | NC0090B2 Ann. M/1 (II) | HSC/23 | 1999 | 79 | 101973-77-7 |
| esorubicin | ésorubicine | 2941.90 | | 38.100 Ann. Q (No. 299) | HSC/11 | 1993 | 47 | 63521-85-7 |
| esoxybutynin | ésoxybutynine | 2922.19 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 119618-22-3 |
| esreboxetine | esréboxétine | 2934.99 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 98819-76-2 |
| estazolam | estazolam | 2933.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 31 | 29975-16-4 |
| eszopiclone | eszopiclone | 2933.79 | | NC0845B2 Ann. M/1 (II) | HSC/33 | 2004 | 87 | 138729-47-2 |
| etafedrine | étafédrine | 2939.49 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 14 | 7681-79-0 |
| etafenone | étafénone | 2922.19 | | 40.260 Ann. L/2 (No. 68) | HSC/17 | 1996 | 19 | 90-54-0 |
| etalocib | étalocib | 2918.90 | | NC1059B2b Ann. O/4 | HSC/37 | 2006 | 92 | 161172-51-6 |
| etamicastat | étamicastat | 2934.99 | | NC1604B1b Ann. N/5 | HSC/46 | 2010 | 101 | 760173-05-5 |
| etanercept | étanercept | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 81 | 185243-69-0 |
| etaracizumab | étaracizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 99 | 892553-42-3 |
| eteplirsén | étéplirsén | 2934.99 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 1173755-55-9 |
| ethchlorvynol | éthchlorvynol | 2905.51 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 38 | 113-18-8 |
| ethinamate | éthinamate | 2924.24 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 6 | 126-52-3 |
| ethyl loflazepate | loflazébate d'éthyle | 2933.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 43 | 29177-84-2 |
| ethylcellulose | éthylcellulose | 3912.39 | | NC0090B2 Ann. M/5 | HSC/23 | 1999 | 80 | 9004-57-3 |
| ethylestrenol | éthylestrénol | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 13 | 965-90-2 |
| ethylmethylthiambutene | éthylméthylthiambutène | 2934.99 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 3 | 441-61-2 |
| ethynerone | éthynérone | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 17 | 3124-93-4 |
| ethypicone | éthypicone | 2933.79 | | 38.100 Ann. Q (No. 302) | HSC/11 | 1993 | 6 | 467-90-3 |
| eticyclidine | éticyclidine | 2921.49 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 44 | 2201-15-2 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-------------------------|---------------------------|------------|------------|---|---------|--------------|--------------|--------------|
| etiguanfacine | étiguanfacine | 2925.29 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1346686-31-4 |
| etilamfetamine | étilamfétamine | 2921.46 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 40 | 457-87-4 |
| etilevodopa | étilévodopa | 2922.50 | | NC0090B2 Ann. M/5 | HSC/23 | 1999 | 80 | 37178-37-3 |
| etiprednol dicloacetate | dicloacétate d'étiprednol | 2937.22 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 199331-40-3 |
| etirinotecan pegol | étirinotecan pégol | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 107 | 848779-32-8 |
| etisomicin | étisomicine | 2941.90 | | 42.100 Ann. O (II) | HSC/21 | 1998 | 47 | 70639-48-4 |
| etisulergine | étisulergine | 2939.69 | | 42.100 Ann. O (I) | HSC/21 | 1998 | 47 | 64795-23-9 |
| etofenamate | étofénamate | 2922.49 | | 40.260 Ann. L/2 (No. 69) | HSC/17 | 1996 | 29 | 30544-47-9 |
| etofylline | étofylline | 2939.59 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 14 | 519-37-9 |
| etofylline clofibrate | clofibrate d'étofylline | 2939.59 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 38 | 54504-70-0 |
| etonitazene | étonitazène | 2933.99 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 11 | 911-65-9 |
| etoposide | étoposide | 2938.90 | | 38.100 Ann. Q (No. 305) | HSC/11 | 1993 | 34 | 33419-42-0 |
| etoricoxib | étoricoxib | 2933.39 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 202409-33-4 |
| etorphine | étorphine | 2939.11 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 17 | 14521-96-1 |
| etoxeridine | étoxéridine | 2933.39 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 6 | 469-82-9 |
| etoxybamide | étoxybamide | 2924.19 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 66857-17-8 |
| etrabamine | étrabamine | 2934.20 | | 38.100 Ann. Q (No. 306) | HSC/11 | 1993 | 59 | 70590-58-8 |
| etravirine | etravirine | 2933.59 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 269055-15-4 |
| etriciguat | etriciguat | 2933.59 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 402595-29-3 |
| etrolizumab | étrolizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 104 | 1044758-60-2 |
| eufausease | eufausérase | 3507.90 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 0-00-0 |
| evacetrapib | évacétrapib | 2933.99 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 1186486-62-3 |
| evandamine | évandamine | 2934.20 | | 38.100 Ann. Q (No. 307) | HSC/11 | 1993 | 56 | 100035-75-4 |
| evatanepag | évatanépag | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 101 | 223488-57-1 |
| evernimicin | evernimicine | 2941.90 | | NC0590B2 Ann. L/10 | HSC/29 | 2002 | 82 | 109545-84-8 |
| everolimus | évérolimus | 2934.99 | | NC1874B1b Ann. O/5 | HSC/51 | 2013 | 82 | 159351-69-6 |
| evodenoson | évodénoson | 2934.99 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 844873-47-8 |
| evofosfamide | évofosfamide | 2933.29 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 918633-87-1 |
| evogliptin | évogliptin | 2933.59 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 1222102-29-5 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|------------------------|---------------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| evolocumab | évolocumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 108 | 1256937-27-5 |
| exametazime | examétazime | 2928.00 | | 38.100 Ann. Q (No. 308) | HSC/11 | 1993 | 57 | 105613-48-7 |
| examorelin | examoréline | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 72 | 140703-51-1 |
| exaprolol | exaprolol | 2922.19 | | 40.260 Ann. L/2 (No. 70) | HSC/17 | 1996 | 32 | 55837-19-9 |
| exatecan | exatécan | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 81 | 171335-80-1 |
| exatecan alideximer | exatécan alideximer | 2939.99 | | NC1059B2b Ann. O/3 | HSC/37 | 2006 | 89 | 0-00-0 |
| exbivirumab | exbivirumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 91 | 569658-80-6 |
| exenatide | exenatide | 2937.19 | | NC1760B1b Ann. N/3 | HSC/49 | 2012 | 89 | 141758-74-9 |
| exeporfinium chloride | chlorure d'exéporfinium | 2933.99 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 718638-68-7 |
| exisulind | exisulind | 2930.90 | | NC0090B2 Ann. M/5 | HSC/23 | 1999 | 80 | 59973-80-7 |
| ezatiostat | ézatiostat | 2930.90 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 168682-53-9 |
| ezetimibe | ézétimibe | 2933.79 | | NC0430B2 Ann. Q/1 (II) | HSC/27 | 2001 | 83 | 163222-33-1 |
| ezlopitant | ezlopitant | 2933.39 | | NC0430B2 Ann. Q/1 (I) | HSC/27 | 2001 | 82 | 147116-64-1 |
| fabesetron | fabésétron | 2933.79 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 129300-27-2 |
| facinicline | facinicline | 2933.39 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 677306-35-3 |
| fadolmidine | fadolmidine | 2933.29 | | NC0430B2 Ann. Q/1 (I) | HSC/27 | 2001 | 86 | 189353-31-9 |
| faldaprevir | faldaprévir | 2934.10 | | NC1874B1b Ann. O/1 | HSC/51 | 2013 | 106 | 801283-95-4 |
| falnidamol | falnidamol | 2933.59 | | NC0250B2 Ann. P/1 (II) | HSC/25 | 2000 | 81 | 196612-93-8 |
| famciclovir | famciclovir | 2933.59 | | 38.100 Ann. Q (No. 309) | HSC/11 | 1993 | 61 | 104227-87-4 |
| famiraprinium chloride | chlorure de famiraprinium | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 58 | 108894-41-3 |
| fampridine | fampridine | 2933.39 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 504-24-5 |
| famprnil | fampronil | 2933.29 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 134183-95-2 |
| fanapanel | fanapanel | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 80 | 161605-73-8 |
| fandofloxacin | fandofloxacine | 2933.59 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 164150-99-6 |
| fandosentan | fandosentan | 2934.99 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 221241-63-0 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|---------------------|------------------------|------------|------------|---|---------|--------------|--------------|--------------|
| faralimomab | faralimomab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 76 | 167816-91-3 |
| farampator | farampator | 2934.99 | | NC1059B2b Ann. O/4 | HSC/37 | 2006 | 92 | 211735-76-1 |
| farglitazar | farglitazar | 2934.99 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 196808-45-4 |
| farletuzumab | farletuzumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 100 | 896723-44-7 |
| fasidotril | fasidotril | 2932.99 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 135038-57-2 |
| fasiglifam | fasiglifam | 2932.99 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 1000413-72-8 |
| fasinumab | fasinumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 107 | 1190239-42-9 |
| fasitibant chloride | chlorure de fasitibant | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 103 | 1157852-02-2 |
| fasobegron | fasobégron | 2922.50 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 643094-49-9 |
| fasoracetam | fasoracétam | 2933.79 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 110958-19-5 |
| favipiravir | favipiravir | 2933.99 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 259793-96-9 |
| faxeladol | faxéladol | 2922.29 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 433265-65-7 |
| fazarabine | fazarabine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 56 | 65886-71-7 |
| febuxostat | febuxostat | 2934.10 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 144060-53-7 |
| fedotozine | fédotozine | 2922.19 | | 40.260 Ann. L/2 (No. 71) | HSC/17 | 1996 | 62 | 123618-00-8 |
| fedovapagon | fédovapagon | 2933.99 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 347887-36-9 |
| fedratinib | fédratinib | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 108 | 936091-26-8 |
| felbinac | felbinac | 2916.39 | | 38.100 Ann. Q (No. 312) | HSC/11 | 1993 | 54 | 5728-52-9 |
| feloprentan | féloprentan | 2933.59 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 204267-33-4 |
| felvizumab | felvizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 77 | 167747-20-8 |
| fenalcomine | fénalcomine | 2922.19 | | 40.260 Ann. L/2 (No. 72) | HSC/17 | 1996 | 29 | 34616-39-2 |
| fencamfamin | fencamfamime | 2921.46 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 12 | 1209-98-9 |
| fenetylline | fénétylline | 2939.51 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 16 | 3736-08-1 |
| fenfluthrin | fenfluthrine | 2916.20 | | 38.100 Ann. Q (No. 314) | HSC/11 | 1993 | 54 | 75867-00-4 |
| fenleuton | fenleuton | 2928.00 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 141579-54-6 |
| fenproporex | fenproporex | 2926.30 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 17 | 15686-61-0 |
| fentanyl | fentanyl | 2933.33 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 14 | 437-38-7 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|---------------------------------|---------------------------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| fentonium bromide | bromure de fentonium | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 29 | 5868-06-4 |
| fermagate | fermagate | 2842.90 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 119175-48-3 |
| ferric (59Fe) citrate injection | soluté injec.de citrate ferrique (59F | 2844.40 | | 38.100 Ann. Q (No. 315) | HSC/11 | 1993 | 24 | 54063-42-2 |
| ferric carboxymaltose | carboxymaltose ferrique | 2940.00 | | NC1553B1b Ann. O/2 | HSC/45 | 2010 | 97 | 9007-72-1 |
| ferric derisomaltose | dérisomaltose ferrique | 2940.00 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1345510-43-1 |
| ferric maltol | maltol ferrique | 2932.99 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 33725-54-1 |
| ferroquine | ferroquine | 2933.49 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 185055-67-8 |
| ferrotrenine | ferroténine | 2925.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 15 | 15339-50-1 |
| fesoterodine | fésotérodine | 2922.50 | | NC0730B2 Ann. M/4 | HSC/31 | 2003 | 84 | 286930-03-8 |
| fevipirant | févipirant | 2933.99 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 872365-14-5 |
| fexofenadine | fexofénadine | 2933.39 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 83799-24-0 |
| fezakinumab | fézakinumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 101 | 1007106-86-6 |
| fiacitabine | fiacitabine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 59 | 69123-90-6 |
| fiboflapon | fiboflapon | 2933.39 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 936350-00-4 |
| ficlatuzumab | ficlatuzumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 105 | 1174900-84-5 |
| fidarestat | fidarestat | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 78 | 136087-85-9 |
| fidaxomicin | fidaxomicine | 2941.90 | | NC1553B1b Ann. O/7 | HSC/45 | 2010 | 100 | 873857-62-6 |
| fidexaban | fidexaban | 2933.39 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 183305-24-0 |
| fiduxosin | fiduxosine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 82 | 208993-54-8 |
| figitumumab | figitumumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 100 | 943453-46-1 |
| figopitant | figopitant | 2933.59 | | NC0430B2 Ann. Q/1 (I) | HSC/27 | 2001 | 82 | 502422-74-4 |
| filaminast | filaminast | 2928.00 | | 42.100 Ann. O (IV) | HSC/21 | 1998 | 75 | 141184-34-1 |
| filanesib | filanésib | 2934.99 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 885060-09-3 |
| filgotinib | filgotinib | 2934.99 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1206161-97-8 |
| filibuvir | filibuvir | 2934.99 | | NC1604B1b Ann. N/5 | HSC/46 | 2010 | 101 | 877130-28-4 |
| filociclovir | filociclovir | 2933.59 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 632325-71-4 |
| filorexant | filorexant | 2933.59 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1088991-73-4 |
| fimaporfin | fimaporfine | 2933.99 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1443547-43-0 |
| fimasartan | fimasartan | 2933.59 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 247257-48-3 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|---------------------------|-----------------------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| finafloxacin | finafloxacine | 2934.99 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 209342-40-5 |
| finerenone | finérénone | 2933.99 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1050477-31-0 |
| fingolimod | fingolimod | 2922.19 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 162359-55-9 |
| finrozole | finrozole | 2933.90 | | NC0250B2 Ann. P/1 (II) | HSC/25 | 2000 | 81 | 160146-17-8 |
| finrozole | finrozole | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 81 | 160146-17-8 |
| fipamezole | fipamézole | 2933.29 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 150586-58-6 |
| firategrast | firatégrast | 2924.29 | | NC1310B1b Ann. N/10 | HSC/41 | 2008 | 96 | 402567-16-2 |
| firivumab | firivumab | 3002.10 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1443004-15-6 |
| firtecan peglumer | firtécan péglumère | 2933.99 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1204768-03-5 |
| firtecan pegol | firtécan pégol | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 107 | 946062-05-1 |
| fispemifene | fispémifène | 2909.49 | | NC0938B2b Ann. O/2 | HSC/35 | 2005 | 89 | 341524-89-8 |
| flanvotumab | flanvotumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 106 | 1188277-05-5 |
| flestolol | flestolol | 2924.21 | | 38.100 Ann. Q (No. 317) | HSC/11 | 1993 | 53 | 87721-62-8 |
| fletikumab | f létikumab | 3002.10 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1357158-22-5 |
| flibanserin | flibansérine | 2933.59 | | 42.100 Ann. O (IV) | HSC/21 | 1998 | 75 | 167933-07-5 |
| flindokalner | flindokalner | 2933.79 | | NC0730B2 Ann. M/6 | HSC/31 | 2003 | 86 | 187523-35-9 |
| flomoxef | flomoxef | 2941.90 | | 38.100 Ann. Q (No. 318) | HSC/11 | 1993 | 55 | 99665-00-6 |
| flopristin | flopristine | 2941.90 | | NC1553B1b Ann. O/3 | HSC/45 | 2010 | 98 | 318498-76-9 |
| florbenazine (18F) | florbénazine (18F) | 2844.40 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 956903-29-0 |
| florbetaben (18F) | florbétabène (18F) | 2844.40 | | NC1604B1b Ann. N/6 | HSC/46 | 2010 | 102 | 902143-01-5 |
| florbetapir (18F) | florbétapir (18F) | 2844.40 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 956103-76-7 |
| florfenicol | florfénicol | 2941.40 | | 40.260 Ann. L/2 (No. 1) | HSC/17 | 1996 | 54 | 76639-94-6 |
| florilglutamic acid (18F) | acide florilglutamique (18F) | 2844.40 | | NC1874B1b Ann. O/1 | HSC/51 | 2013 | 106 | 1196963-74-2 |
| flortanidazole (18F) | flortanidazole (¹⁸ F) | 2844.40 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 70878-86-2 |
| flotegatide (18F) | flotégatide (¹⁸ F) | 2844.40 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1010702-75-6 |
| flovagatran | flovagatran | 2933.99 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 871576-03-3 |
| fluciclatide (18F) | fluciclatide (18F) | 2844.40 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 879894-01-6 |
| fluciclovine (18F) | fluciclovine (18F) | 2844.40 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 222727-39-1 |
| fludalanine | fludalanine | 2845.90 | | 38.100 Ann. Q (No. 319) | HSC/11 | 1993 | 38 | 35523-45-6 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-----------------------|------------------------------------|------------|------------|--|---------|--------------|--------------|--------------|
| fludeoxyglucose (18F) | fludésoxyglucose (18F) | 2844.40 | | 38.100 Ann. Q (No. 320) | HSC/11 | 1993 | 61 | 105851-17-0 |
| fludiazepam | fludiazépam | 2933.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 36 | 3900-31-0 |
| flugestone | flugestone | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 16 | 337-03-1 |
| fluindarol | fluindarol | 2914.70 | 2914.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 16 | 6723-40-6 |
| fluindione | fluindione | 2914.70 | 2914.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 40 | 957-56-2 |
| flumazenil | flumazénil | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 55 | 78755-81-4 |
| flumoxonide | flumoxonide | 2937.22 | | 40.260 Ann. L/2 (No. 29) | HSC/17 | 1996 | 38 | 60135-22-0 |
| flunitrazepam | flunitrazépam | 2933.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 24 | 1622-62-4 |
| fluocortin | fluocortine | 2937.22 | | 42.100 Ann. O (I) | HSC/21 | 1998 | 31 | 33124-50-4 |
| fluorfenidine (18F) | fluorfénidine (¹⁸ F) | 2844.40 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 917894-12-3 |
| fluralaner | fluralaner | 2934.99 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 864731-61-3 |
| flurazepam | flurazépam | 2933.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 20 | 17617-23-1 |
| flurpiridaz (18F) | flurpiridaz (18F) | 2844.40 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 863887-89-2 |
| flusoxolol | flusoxolol | 2922.19 | | 40.260 Ann. L/2 (No. 73) | HSC/17 | 1996 | 50 | 84057-96-5 |
| fluspirilene | fluspirilène | 2933.39 | | 40.260 Ann. L/2 (No. 26) | HSC/17 | 1996 | 15 | 1841-19-6 |
| flutemetamol (18F) | flutémétamol (18F) | 2844.40 | | NC1604B1b Ann. N/5 | HSC/46 | 2010 | 101 | 765922-62-1 |
| fluticasone furoate | furoate de fluticasone | 2937.22 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 397864-44-7 |
| flutriciclamide (18F) | flutriciclamide (¹⁸ F) | 2844.40 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1274863-98-7 |
| fluvastatin | fluvastatine | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 62 | 93957-54-1 |
| fodipir | fodipir | 2933.39 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 118248-91-2 |
| folitixorin | folitixorine | 2933.59 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 3432-99-3 |
| follitropin alfa | follitropine alfa | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 71 | 9002-68-0 |
| follitropin beta | follitropine bêta | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 75 | 150490-84-9 |
| follitropin gamma | follitropine gamma | 2937.19 | | NC1874B1b Ann. O/1 | HSC/51 | 2013 | 106 | 1219693-73-8 |
| fomidacillin | fomidacilline | 2941.10 | | 38.100 Ann. Q (No. 325) | HSC/11 | 1993 | 55 | 98048-07-8 |
| fomivirsén | fomivirsén | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 75 | 144245-52-3 |
| fondaparinux sodium | fondaparinux sodique | 2932.99 | | NC0590B2 Ann. L/10 | HSC/29 | 2002 | 83 | 114870-03-0 |
| fontolizumab | fontolizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 87 | 326859-36-3 |
| fonturacetam | fonturacétam | 2933.79 | | NC1604B1b Ann. N/5 | HSC/46 | 2010 | 101 | 77472-70-9 |
| foralumab | foralumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 103 | 946415-64-1 |
| forasartan | forasartan | 2933.39 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 145216-43-9 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|----------------------|----------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| foravirumab | foravirumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 99 | 944548-38-3 |
| foretinib | forétinib | 2934.99 | | NC1604B1b Ann. N/6 | HSC/46 | 2010 | 102 | 849217-64-7 |
| forigerimod | forigérimod | 2933.29 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 497156-60-2 |
| formebolone | formébolone | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 31 | 2454-11-7 |
| forodesine | forodesine | 2933.59 | | NC1059B2b Ann. O/4 | HSC/37 | 2006 | 92 | 209799-67-7 |
| foropafant | foropafant | 2934.10 | | 42.100 Ann. O (IV) | HSC/21 | 1998 | 75 | 136468-36-5 |
| fosalvudine tidoxil | fosalvudine tidoxil | 2934.99 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 763903-67-9 |
| fosamprenavir | fosamprénavir | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 83 | 226700-79-4 |
| fosaprepitant | fosaprépitant | 2934.99 | | NC1123B1b Ann. N/1 | HSC/38 | 2006 | 94 | 172673-20-0 |
| fosbretabulin | fosbrétabuline | 2919.90 | | NC1500B1b Ann. K/6 | HSC/44 | 2009 | 100 | 222030-63-9 |
| fosdagrocorat | fosdagrocorat | 2933.39 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1044535-58-1 |
| fosdevirine | fosdévirine | 2933.99 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 1018450-26-4 |
| fosfluconazole | fosfluconazole | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 83 | 194798-83-9 |
| fosfluridine tidoxil | fosfluridine tidoxil | 2934.99 | | NC1059B2b Ann. O/5 | HSC/37 | 2006 | 93 | 174638-15-4 |
| fosfructose | fosfructose | 2940.00 | | NC0250B2 Ann. P/1 (II) | HSC/25 | 2000 | 81 | 488-69-7 |
| fosopamine | fosopamine | 2922.29 | | 40.260 Ann. L/2 (No. 74) | HSC/17 | 1996 | 69 | 103878-96-2 |
| fospropofol | fospropofol | 2919.90 | | NC1123B1b Ann. N/1 | HSC/38 | 2006 | 94 | 258516-89-1 |
| fosquidone | fosquidone | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 64 | 114517-02-1 |
| fosravuconazole | fosravuconazole | 2934.10 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 351227-64-0 |
| fostamatinib | fostamatinib | 2934.99 | | NC1500B1b Ann. K/6 | HSC/44 | 2009 | 100 | 901119-35-5 |
| fostriecin | fostriécine | 2932.20 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 55 | 87810-56-8 |
| fosveset | fosvéset | 2922.50 | | NC0430B2 Ann. Q/1 (II) | HSC/27 | 2001 | 83 | 193901-91-6 |
| fozivudine tidoxil | fozivudine tidoxil | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 73 | 141790-23-0 |
| fradafiban | fradafiban | 2933.79 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 148396-36-5 |
| frakefamide | frakéfamide | 2924.29 | | NC0250B2 Ann. P/1 (II) | HSC/25 | 2000 | 81 | 188196-22-7 |
| fresolimumab | frésolimumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 101 | 948564-73-6 |
| frovatriptan | frovatriptan | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 78 | 158747-02-5 |
| fudosteine | fudostéine | 2930.90 | | 42.100 Ann. O (VI) | HSC/21 | 1998 | 77 | 13189-98-5 |
| fuladectin | fuladectine | 3003.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 71 | 0-00-0 |
| fulranumab | fulranumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 104 | 902141-80-4 |
| fulvestrant | fulvestrant | 2937.23 | | NC2116B1b Ann. R/7 | HSC/55 | 2015 | 78 | 129453-61-8 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|----------------------|-----------------------|------------|------------|---|---------|--------------|--------------|--------------|
| funapide | funapide | 2934.99 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1259933-16-8 |
| furaprevir | furaprévir | 2935.00 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1435923-88-8 |
| furethidine | furéthidine | 2934.99 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 9 | 2385-81-1 |
| furomine | furomine | 2932.19 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 142996-66-5 |
| futuximab | futuximab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 107 | 1310460-85-5 |
| gabapentin enacarbil | gabapentine énacarbil | 2924.29 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 478296-72-9 |
| gacyclidine | gacyclidine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 76 | 68134-81-6 |
| gadocoletic acid | acide gadocolétique | 2846.90 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 280776-87-6 |
| gadodenterate | gadodentérate | 2846.90 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 544697-52-1 |
| gadodiamide | gadodiamide | 2846.90 | | 38.100 Ann. Q (No. 329) | HSC/11 | 1993 | 70 | 131410-48-5 |
| gadofosveset | gadofosvésset | 2846.90 | | NC0430B2 Ann. Q/1 (II) | HSC/27 | 2001 | 83 | 193901-90-5 |
| gadomelitol | gadométilol | 2846.90 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 227622-74-4 |
| gadopenamide | gadopénamide | 2846.90 | | 38.100 Ann. Q (No. 330) | HSC/11 | 1993 | 60 | 117827-80-2 |
| gadopentetic acid | acide gadopentétique | 2846.90 | | 38.100 Ann. Q (No. 331) | HSC/11 | 1993 | 50 | 80529-93-7 |
| gadoteric acid | acide gadotérique | 2846.90 | | 38.100 Ann. Q (No. 332) | HSC/11 | 1993 | 59 | 72573-82-1 |
| gadoversetamide | gadoversétamide | 2846.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 71 | 131069-91-5 |
| gadoxetic acid | acide gadoxétique | 2846.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 71 | 135326-11-3 |
| galantamine | galantamine | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 79 | 357-70-0 |
| galarubicin | galarubicine | 2941.90 | | NC0090B2 Ann. M/5 | HSC/23 | 1999 | 80 | 140637-86-1 |
| galdansetron | galdansétron | 2933.29 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 116684-92-5 |
| galeterone | galétérone | 2937.29 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 851983-85-2 |
| galsulfase | galsulfase | 3507.90 | | NC1004B1b Ann. L/11 | HSC/36 | 2005 | 92 | 552858-79-4 |
| galunisertib | galunisertib | 2933.49 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 700874-72-2 |
| gamithromycin | gamithromycine | 2941.90 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 145435-72-9 |
| ganaxolone | ganaxolone | 2914.40 | | 42.100 Ann. O (V) | HSC/21 | 1998 | 76 | 38398-32-2 |
| ganciclovir | ganciclovir | 2933.59 | | 38.100 Ann. Q (No. 334) | HSC/11 | 1993 | 56 | 82410-32-0 |
| gandotinib | gandotinib | 2934.99 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1229236-86-5 |
| ganetespib | ganétespib | 2933.99 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 888216-25-9 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|----------------------|-------------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| ganglefene | ganglefène | 2922.19 | | 40.260 Ann. L/2 (No. 75) | HSC/17 | 1996 | 12 | 299-61-6 |
| ganitumab | ganitumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 103 | 905703-97-1 |
| ganstigmine | ganstigmine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 81 | 457075-21-7 |
| gantacurium chloride | chlorure de gantacurium | 2933.49 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 213998-46-0 |
| gantenerumab | ganténérumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 97 | 89957-37-9 |
| gantofiban | gantofiban | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 80 | 183547-57-1 |
| garenoxacin | garénoxacine | 2933.49 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 194804-75-6 |
| garnocestim | garnocestim | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 85 | 246861-96-1 |
| gataparsen | gataparsen | 2934.99 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 1065019-70-6 |
| gatifloxacin | gatifloxacine | 2933.59 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 160738-57-8 |
| gavestinel | gavestinel | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 77 | 153436-22-7 |
| gavilimomab | gavilimomab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 84 | 244096-20-6 |
| gaxilose | gaxilose | 2940.00 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 14087-31-1 |
| geclosporin | géclosporine | 2933.79 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 74436-00-3 |
| gedatolisib | gedatolisib | 2934.99 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1197160-78-3 |
| gefitinib | gefitinib | 2934.99 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 184475-35-2 |
| gemcabene | gemcabène | 2918.90 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 183293-82-5 |
| gemcitabine | gemcitabine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 62 | 95058-81-4 |
| gemcitabine elaidate | élaïdate de gemcitabine | 2934.99 | | NC1874B1b Ann. O/1 | HSC/51 | 2013 | 106 | 210829-30-4 |
| gemifloxacin | gémifloxacine | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 81 | 204519-64-2 |
| gemigliptin | gémigliptine | 2933.79 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 911637-19-9 |
| gemilukast | gémilukast | 2933.99 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1232861-58-3 |
| gemopatrilat | gémopatrilate | 2933.79 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 160135-92-2 |
| gemtuzumab | gemtuzumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 83 | 220578-59-6 |
| gevokizumab | gévoquizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 104 | 1129435-60-4 |
| gimatecan | gimatécan | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 86 | 292618-32-7 |
| gimeracil | giméracil | 2933.39 | | NC0090B2 Ann. M/5 | HSC/23 | 1999 | 80 | 103766-25-2 |
| giminabant | giminabant | 2933.59 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 890033-57-5 |
| giractide | giractide | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 29 | 24870-04-0 |
| girentuximab | girentuximab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 101 | 916138-87-9 |
| giripladib | giripladib | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 96 | 865200-20-0 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|---------------------------|----------------------------|------------|------------|--|---------|--------------|--------------|--------------|
| gisadenafil | gisadénafil | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 101 | 334826-98-1 |
| givinostat | givinostat | 2928.00 | | NC1649B3b Ann. R/12 | HSC/47 | 2011 | 101 | 497833-27-9 |
| glasdegib | glasdégib | 2933.39 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1095173-27-5 |
| glaspimod | glaspimod | 2933.79 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 134143-28-5 |
| glaziovine | glaziovine | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 34 | 17127-48-9 |
| glembatumumab | glembatumumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 102 | 1020264-78-1 |
| glenvastatin | glenvastatine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 70 | 122254-45-9 |
| gleptoferron | gleptoferron | 3913.90 | | 38.100 Ann. Q (No. 336) | HSC/11 | 1993 | 36 | 57680-55-4 |
| gloximonam | gloximonam | 2941.90 | | 38.100 Ann. Q (No. 337) | HSC/11 | 1993 | 54 | 90850-05-8 |
| glucalox | glucalox | 3003.90 | | 42.100 Ann. O (II) | HSC/21 | 1998 | 13 | 12182-48-8 |
| glucarpidase | glucarpidase | 3507.90 | | NC1004B1b Ann. L/11 | HSC/36 | 2005 | 92 | 9074-87-7 |
| glufosfamide | glufosfamide | 2940.00 | | 42.100 Ann. O (VI) | HSC/21 | 1998 | 77 | 132682-98-5 |
| glusoferron | glusoferron | 3911.90 | | 38.100 Ann. Q (No. 338) | HSC/11 | 1993 | 37 | 56959-18-3 |
| glutethimide | glutéthimide | 2925.12 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 6 | 77-21-4 |
| glycerol phenylbutyrate | phénylbutyrate de glycérol | 2916.39 | | NC1874B1b Ann. O/1 | HSC/51 | 2013 | 106 | 611168-24-2 |
| golimumab | golimumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 91 | 476181-74-5 |
| golnerminogene pradenovec | golnerminogène pradénovec | 3002.90 | | NC1649B3b Ann. R/12 | HSC/47 | 2011 | 101 | 957472-14-9 |
| golotimod | golotimod | 2933.99 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 229305-39-9 |
| golvatinib | golvatinib | 2933.59 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 928037-13-2 |
| goralatide | goralatide | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 72 | 120081-14-3 |
| goserelin | goséréline | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 55 | 65807-02-5 |
| gosogliptin | gosogliptin | 2933.59 | | NC1649B3b Ann. R/12 | HSC/47 | 2011 | 101 | 869490-23-3 |
| goxalapladi | goxalapladi | 2933.39 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 412950-27-7 |
| granotapide | granotapide | 2924.29 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 594842-13-4 |
| grapiprant | grapiprant | 2935.00 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 415903-37-6 |
| grazoprevir | grazoprévir | 2935.00 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1350514-68-9 |
| guafecainol | guafécainol | 2922.19 | | 40.260 Ann. L/2 (No. 76) | HSC/17 | 1996 | 38 | 36199-78-7 |
| guaïactamine | guaïactamine | 2922.19 | | 40.260 Ann. L/2 (No. 77) | HSC/17 | 1996 | 16 | 15687-23-7 |
| guaraprolose | guaraprolose | 1302.32 | | NC1649B3b Ann. R/13 | HSC/47 | 2011 | 102 | 39421-75-5 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|---------------------------------|----------------------------------|------------|------------|---|---------|--------------|--------------|--------------|
| guselkumab | guselkumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 109 | 1350289-85-8 |
| halazepam | halazépam | 2933.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 29 | 23092-17-3 |
| halopredone | haloprédone | 2937.22 | | 38.100 Ann. Q (No. 341) | HSC/11 | 1993 | 36 | 57781-15-4 |
| haloxazolam | haloxazolam | 2934.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 38 | 59128-97-1 |
| hemoglobin crosfumaril | hémoglobine crosfumaril | 3002.10 | 3002.12 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 76 | 142261-03-8 |
| hemoglobin crosfumaril (bovine) | hémoglobine crosfumaril (bovine) | 3002.10 | 3002.12 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 108 | 1360741-07-6 |
| hemoglobin glutamer | hémoglobine glutamère | 3002.10 | 3002.12 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 80 | 0-00-0 |
| hemoglobin raffimer | raffimère d'hémoglobine | 3002.10 | 3002.12 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 89 | 197462-97-8 |
| hexobendine | hexobendine | 2922.19 | | 40.260 Ann. L/2 (No. 78) | HSC/17 | 1996 | 15 | 54-03-5 |
| histrelin | histréline | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 53 | 76712-82-8 |
| homidium bromide | bromure d'homidium | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 36 | 1239-45-8 |
| hydrocodone | hydrocodone | 2939.11 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 1 | 125-29-1 |
| hydroflumethiazide | hydrofluméthiazide | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 10 | 135-09-1 |
| hydromorphinol | hydromorphinol | 2939.19 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 11 | 2183-56-4 |
| hydromorphone | hydromorphone | 2939.11 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 1 | 466-99-9 |
| hydroxycarbamide | hydroxycarbamide | 2928.00 | | 38.100 Ann. Q (No. 342) | HSC/11 | 1993 | 16 | 127-07-1 |
| hydroxypethidine | hydroxypéthidine | 2933.39 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 5 | 468-56-4 |
| hyetellose | hyétellose | 3912.39 | | NC0090B2 Ann. M/5 | HSC/23 | 1999 | 80 | 9004-62-0 |
| hymetellose | hymétellose | 3912.39 | | NC0090B2 Ann. M/5 | HSC/23 | 1999 | 80 | 9032-42-2 |
| hypolose | hypolose | 3912.39 | | NC0090B2 Ann. M/5 | HSC/23 | 1999 | 80 | 9004-64-2 |
| hypromellose | hypromellose | 3912.39 | | 38.100 Ann. Q (No. 343) | HSC/11 | 1993 | 80 | 9004-65-3 |
| ibacitabine | ibacitabine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 57 | 611-53-0 |
| ibafloxacin | ibafloxacin | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 60 | 91618-36-9 |
| ibalizumab | ibalizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 97 | 680188-33-4 |
| ibandronic acid | acide ibandronique | 2931.00 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 71 | 114084-78-5 |
| ibazocine | ibazocine | 2933.39 | | 40.260 Ann. L/2 (No. 16) | HSC/17 | 1996 | 36 | 57653-28-8 |
| ibipinabant | ibipinabant | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 99 | 464213-10-3 |
| iboctadekin | iboctadékin | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 92 | 479198-61-3 |
| ibodutant | ibodutant | 2934.99 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 522664-63-7 |
| ibritumomab tiuxetan | ibritumomab tiuxétan | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 81 | 206181-63-7 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-----------------------|------------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| ibrolipim | ibrolipim | 2931.00 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 133208-93-2 |
| ibrutinib | ibrutinib | 2933.59 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 936563-96-1 |
| ibudilast | ibudilast | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 58 | 50847-11-5 |
| ibutamoren | ibutamoren | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 78 | 159634-47-6 |
| icaridin | icaridine | 2933.39 | | NC0730B2 Ann. M/6 | HSC/31 | 2003 | 86 | 119515-38-7 |
| iclaprim | iclaprim | 2934.99 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 192314-93-5 |
| icometasone enbutate | icométasone enbutate | 2937.22 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 103466-73-5 |
| icomucret | icomucret | 2918.19 | | NC1059B2b Ann. O/4 | HSC/37 | 2006 | 92 | 54845-95-3 |
| icopezil | icopézil | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 75 | 145508-78-7 |
| icosabutate | icosabutate | 2918.99 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1253909-57-7 |
| icospiramide | icospiramide | 2933.39 | | 40.260 Ann. L/2 (No. 27) | HSC/17 | 1996 | 68 | 79449-99-3 |
| icrucumab | icrucumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 104 | 1024603-92-6 |
| idalopirdine | idalopirdine | 2933.99 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 467459-31-0 |
| idarubicin | idarubicine | 2941.90 | | 38.100 Ann. Q (No. 347) | HSC/11 | 1993 | 47 | 58957-92-9 |
| idarucizumab | idarucizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 109 | 1362509-93-0 |
| idasanutlin | idasanutline | 2933.99 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1229705-06-9 |
| idelalisib | idéllalisib | 2933.59 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 870281-82-6 |
| idrabioparinix sodium | idrabioparinix sodique | 2934.99 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 405159-59-3 |
| idramantone | idramantone | 2914.40 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 71 | 20098-14-0 |
| idraparinix sodium | idraparinix sodique | 2932.99 | | NC0430B2 Ann. Q/1 (II) | HSC/27 | 2001 | 83 | 149920-56-9 |
| idremcinal | idremcinal | 2941.50 | | NC0250B2 Ann. P/1 (II) | HSC/25 | 2000 | 81 | 110480-13-2 |
| idronoxil | idronoxil | 2932.99 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 81267-65-4 |
| idropranolol | idropranolol | 2922.19 | | 40.260 Ann. L/2 (No. 79) | HSC/17 | 1996 | 31 | 27581-02-8 |
| idursulfase | idursulfase | 3507.90 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 90 | 50936-59-9 |
| idursulfase beta | idursulfase bêta | 3507.90 | | NC1874B1b Ann. O/1 | HSC/51 | 2013 | 106 | 1271734-34-9 |
| iferanserin | iféransérine | 2933.39 | | NC0938B2b Ann. O/2 | HSC/35 | 2005 | 89 | 58754-46-4 |
| ifetroban | iféetroban | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 71 | 143443-90-7 |
| iganidipine | iganidipine | 2933.59 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 119687-33-1 |
| igovomab | igovomab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 74 | 171656-50-1 |
| iguratimod | iguratimod | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 86 | 123663-49-0 |
| ilaprazole | ilaprazole | 2933.39 | | NC0730B2 Ann. M/6 | HSC/31 | 2003 | 86 | 172152-36-2 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|----------------------|----------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| ilepatril | ilépatril | 2933.79 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 473289-62-2 |
| ilepcimide | ilepcimide | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 70 | 82857-82-7 |
| ilodecakin | ilodécakine | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 81 | 149824-15-7 |
| ilomastat | ilomastat | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 73 | 142880-36-2 |
| ilonidap | ilonidap | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 70 | 135202-79-8 |
| iloprost | iloprost | 2918.19 | | 38.100 Ann. Q (No. 351) | HSC/11 | 1993 | 48 | 73873-87-7 |
| ilorasertib | ilorasertib | 2934.99 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1227939-82-3 |
| imagabalin | imagabaline | 2922.49 | | NC1604B1b Ann. N/5 | HSC/46 | 2010 | 101 | 610300-07-7 |
| imalumab | imalumab | 3002.10 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1430205-07-4 |
| imatinib | imatinib | 2933.59 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 152459-95-5 |
| imazodan | imazodan | 2933.29 | | 38.100 Ann. Q (No. 352) | HSC/11 | 1993 | 55 | 84243-58-3 |
| imeglimin | iméglimine | 2933.69 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 775351-65-0 |
| imepitoin | imépitoïne | 2934.99 | | NC1310B1b Ann. N/10 | HSC/41 | 2008 | 96 | 188116-07-6 |
| imetelstat | imételstat | 2934.99 | | NC1604B1b Ann. N/5 | HSC/46 | 2010 | 101 | 868169-64-6 |
| imgatuzumab | imgatuzumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 107 | 959963-46-3 |
| imidafenacin | imidafénacine | 2933.29 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 170105-16-5 |
| imidaprilat | imidaprilate | 2933.29 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 71 | 89371-44-8 |
| imiglitazar | imiglitazar | 2934.99 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 250601-04-8 |
| imiglucerase | imiglucérase | 3507.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 154248-97-2 |
| imirestat | imirestat | 2933.21 | | 38.100 Ann. Q (No. 353) | HSC/11 | 1993 | 59 | 89391-50-4 |
| imisopasem manganese | imisopasem manganèse | 2933.39 | | NC1310B1b Ann. N/3 | HSC/41 | 2008 | 95 | 218791-21-0 |
| imitrodast | imitrodast | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 70 | 114686-12-3 |
| implitapide | implitapide | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 82 | 177469-96-4 |
| inakalant | inakalant | 2934.99 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 335619-18-6 |
| incadronic acid | acide incadronique | 2931.00 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 124351-85-5 |
| inlacumab | inlacumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 106 | 1256258-86-2 |
| incyclinide | incyclinide | 2924.29 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 15866-90-7 |
| indacaterol | indacaterol | 2933.79 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 312753-06-3 |
| indalpine | indalpine | 2933.39 | | 38.100 Ann. Q (No. 354) | HSC/11 | 1993 | 41 | 63758-79-2 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|------------------------|------------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| indanidine | indanidine | 2933.29 | | 38.100 Ann. Q (No. 355) | HSC/11 | 1993 | 50 | 85392-79-6 |
| indantadol | indantadol | 2924.29 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 202844-10-8 |
| indatuximab ravtansine | indatuximab ravtansine | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 105 | 1238517-16-2 |
| indeglitazar | indéglitazar | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 100 | 835619-41-5 |
| indenolol | indénolol | 2922.19 | | 40.260 Ann. L/2 (No. 80) | HSC/17 | 1996 | 37 | 60607-68-3 |
| indibulin | indibuline | 2933.39 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 204205-90-3 |
| indinavir | indinavir | 2933.59 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 150378-17-9 |
| indiplon | indiplon | 2934.99 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 325715-02-4 |
| indisetron | indisétron | 2933.59 | | 42.100 Ann. O (V) | HSC/21 | 1998 | 76 | 141549-75-9 |
| indisulam | indisulam | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 86 | 165668-41-7 |
| indolidan | indolidan | 2933.79 | | 38.100 Ann. Q (No. 356) | HSC/11 | 1993 | 57 | 100643-96-7 |
| indoprofen | indoprofène | 2933.79 | | 38.100 Ann. Q (No. 357) | HSC/11 | 1993 | 32 | 31842-01-0 |
| indoramin | indoramine | 2933.39 | | 38.100 Ann. Q (No. 358) | HSC/11 | 1993 | 25 | 26844-12-2 |
| indoximod | indoximod | 2933.99 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 110117-83-4 |
| inecalcitol | inécalcitol | 2906.19 | | NC0938B2b Ann. O/1 | HSC/35 | 2005 | 87 | 163217-09-2 |
| infliximab | infliximab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 77 | 170277-31-3 |
| ingenol mebutate | mébutate d'ingénol | 2916.19 | | NC1553B1b Ann. O/7 | HSC/45 | 2010 | 100 | 75567-37-2 |
| ingliforib | ingliforib | 2933.99 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 186392-65-4 |
| iniparib | iniparib | 2924.29 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 160003-66-7 |
| inocoterone | inocotérone | 2937.90 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 54 | 83646-97-3 |
| inogatran | inogatran | 2933.39 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 155415-08-0 |
| inolimomab | inolimomab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 71 | 152981-31-2 |
| inolitazone | inolitazone | 2934.10 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 223132-37-4 |
| inotuzumab ozogamicin | inotuzumab ozogamicine | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 92 | 635715-01-4 |
| insulin argine | insuline argine | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 58 | 68859-20-1 |
| insulin aspart | insuline aspartate | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 76 | 116094-23-6 |
| insulin degludec | insuline dégludec | 2937.19 | | NC1649B3b Ann. R/12 | HSC/47 | 2011 | 101 | 844439-96-9 |
| insulin detemir | insuline detemir | 2937.19 | | NC2116B1b Ann. R/7 | HSC/55 | 2015 | 80 | 169148-63-4 |
| insulin glargine | insuline glargine | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 76 | 160337-95-1 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|----------------------------|----------------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| insulin glulisine | insuline glulisine | 2937.19 | | NC0730B2 Ann. M/4 | HSC/31 | 2003 | 84 | 207748-29-6 |
| insulin lispro | insuline lispro | 2937.19 | | NC2116B1b Ann. R/7 | HSC/55 | 2015 | 72 | 133107-64-9 |
| insulin peglispro | insulin péglispro | 2937.19 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 1200440-65-8 |
| insulin tregopil | insuline trégopil | 2937.19 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 874442-57-6 |
| intedanib | intédanib | 2933.79 | | NC1649B3b Ann. R/13 | HSC/47 | 2011 | 102 | 656247-17-5 |
| interferon alfacon-1 | interféron alfacon-1 | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 77 | 118390-30-0 |
| intetumumab | intétumumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 101 | 725735-28-4 |
| intiquinate | intiquinate | 2933.49 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 99 | 445041-75-8 |
| iocanlidic acid | acide iocanlidique (123l) | 2844.40 | | 42.100 Ann. O (VI) | HSC/21 | 1998 | 77 | 74855-17-7 |
| iodine (124l) girentuximab | girentuximab iodé (124l) | 2844.40 | | NC1604B1b Ann. N/5 | HSC/46 | 2010 | 101 | 1011710-99-8 |
| iodofiltic acid (123l) | acide iodofiltique (123 l) | 2844.40 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 123748-56-1 |
| iodophthalein sodium | iodophtaléine sodique | 2918.90 | | 38.100 Ann. Q (No. 361) | HSC/11 | 1993 | 1 | 2217-44-9 |
| ioflubenzamide (131l) | ioflubenzamide (131l) | 2844.40 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 1214283-52-9 |
| ioflupane (123l) | ioflupane (123l) | 2844.40 | | 42.100 Ann. O (IV) | HSC/21 | 1998 | 75 | 155798-07-5 |
| iofolastat (123l) | iofolastat (123l) | 2844.40 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 949575-24-0 |
| ioforminol | ioforminol | 2924.29 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 1095110-48-7 |
| iolopride (123l) | iolopride (123l) | 2844.40 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 73 | 113716-48-6 |
| iometopane (123l) | iométopane (123l) | 2844.40 | | 42.100 Ann. O (V) | HSC/21 | 1998 | 76 | 136794-86-0 |
| iosimenol | iosiméno | 2924.29 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 181872-90-2 |
| ipafricept | ipafricept | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 109 | 1391727-24-4 |
| ipamorelin | ipamoréline | 2937.19 | | NC1649B3b Ann. R/10 | HSC/47 | 2011 | 78 | 170851-70-4 |
| ipatasertib | ipatasertib | 2933.59 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1001264-89-6 |
| ipazilide | ipazilide | 2933.19 | | 38.100 Ann. Q (No. 362) | HSC/11 | 1993 | 62 | 115436-73-2 |
| ipenoxazone | ipénoxazone | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 71 | 104454-71-9 |
| ipidacrine | ipidacrine | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 73 | 62732-44-9 |
| ipilimumab | ipilimumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 94 | 477202-00-9 |
| ipragliflozin | ipragliflozine | 2934.99 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 761423-87-4 |
| ipragratine | ipragratine | 2933.39 | | 38.100 Ann. Q (No. 363) | HSC/11 | 1993 | 35 | 22150-28-3 |
| ipratropium bromide | bromure d'ipratropium | 2939.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 31 | 22254-24-6 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|--------------------------|----------------------------|------------|------------|---|---------|--------------|--------------|--------------|
| ipravacaine | ipravacaine | 2933.39 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 166181-63-1 |
| iproxamine | iproxamine | 2922.19 | | 40.260 Ann. L/2 (No. 81) | HSC/17 | 1996 | 34 | 52403-19-7 |
| ipsapirone | ipsapirone | 2934.20 | | 38.760 Ann. D, par. 34 | HSC/13 | 1994 | 54 | 95847-70-4 |
| iralukast | iralukast | 2932.99 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 151581-24-7 |
| irampanel | irampanel | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 82 | 206260-33-5 |
| iratumumab | iratumumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 94 | 640735-09-7 |
| irbesartan | irbésartan | 2933.29 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 71 | 138402-11-6 |
| irbinitinib | irbinitinib | 2934.99 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 937263-43-9 |
| irdabisant | irdabisant | 2933.99 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 1005402-19-6 |
| irinotecan | irinotécan | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 64 | 97682-44-5 |
| irolfulven | irolfulvène | 2914.40 | | NC0430B2 Ann. Q/1 (I) | HSC/27 | 2001 | 82 | 158440-71-2 |
| irolpact | irolpact | 3002.10 | 3002.12 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 74 | 154248-96-1 |
| irosustat | irosustat | 2932.20 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 288628-05-7 |
| iroxanadine | iroxanadine | 2934.99 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 276690-58-5 |
| irtemazole | irtémazole | 2933.29 | | 38.100 Ann. Q (No. 366) | HSC/11 | 1993 | 60 | 115574-30-6 |
| isalmadol | isalmadol | 2922.50 | | NC1059B2b Ann. O/4 | HSC/37 | 2006 | 92 | 269079-62-1 |
| isamoltan | isamoltan | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 58 | 116861-00-8 |
| isatoribine | isatoribine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 83 | 122970-40-5 |
| isavuconazole | isavuconazole | 2934.10 | | NC1310B1b Ann. N/10 | HSC/41 | 2008 | 96 | 241479-67-4 |
| isavuconazonium chloride | chlorure d'isavuconazonium | 2934.10 | | NC1310B1b Ann. N/10 | HSC/41 | 2008 | 96 | 338990-84-4 |
| isbufylline | isbufylline | 2939.59 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 62 | 90162-60-0 |
| iseganan | iséganan | 2934.99 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 257277-05-7 |
| isepamicin | isépamicine | 2941.90 | | 38.100 Ann. Q (No. 369) | HSC/11 | 1993 | 54 | 58152-03-7 |
| ismomultin alfa | ismomultine alfa | 2934.99 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 457913-93-8 |
| isoetarine | isoétarine | 2922.50 | | 38.100 Ann. Q (No. 370) | HSC/11 | 1993 | 13 | 530-08-5 |
| isoflupredone | isofluprédone | 2937.22 | | 38.100 Ann. Q (No. 371) | HSC/11 | 1993 | 36 | 338-95-4 |
| isometamidium chloride | chlorure d'isoméтамidium | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 18 | 34301-55-8 |
| isomethadone | isométhadone | 2922.39 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 1 | 466-40-0 |
| isophane insulin | isophane insuline | 3003.31 | | 38.100 Ann. Q (No. 373) | HSC/11 | 1993 | 4 | 8052-74-2 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-----------------|-----------------|------------|------------|---|---------|--------------|--------------|--------------|
| isoprednidene | isoprednidène | 2937.29 | | 42.100 Ann. O (I) | HSC/21 | 1998 | 24 | 17332-61-5 |
| isoprenaline | isoprénaline | 2922.50 | | 38.100 Ann. Q (No. 374) | HSC/11 | 1993 | 1 | 7683-59-2 |
| isosorbide | isosorbide | 2932.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 61 | 652-67-5 |
| isosulpride | isosulpride | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 36 | 42792-26-7 |
| ispinesib | ispinesib | 2933.59 | | NC1059B2b Ann. O/4 | HSC/37 | 2006 | 92 | 336113-53-2 |
| ispronidine | ispronidine | 2933.39 | | NC1059B2b Ann. O/5 | HSC/37 | 2006 | 93 | 252870-53-4 |
| israpafant | israpafant | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 76 | 117279-73-9 |
| istaroxime | istaroxime | 2928.00 | | NC1059B2b Ann. O/5 | HSC/37 | 2006 | 93 | 203737-93-3 |
| itameline | itaméline | 2933.39 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 71 | 121750-57-0 |
| itolizumab | itolizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 103 | 1116433-11-4 |
| itriglumide | itriglumide | 2933.39 | | NC0430B2 Ann. Q/1 (I) | HSC/27 | 2001 | 82 | 201605-51-8 |
| itrocainide | itrocaïnide | 2933.49 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 54 | 90828-99-2 |
| iturelix | iturélix | 2933.39 | | NC0090B2 Ann. M/1 (II) | HSC/23 | 1999 | 79 | 112568-12-4 |
| ivabradine | ivabradine | 2933.79 | | 42.100 Ann. O (IV) | HSC/21 | 1998 | 75 | 155974-00-8 |
| ivacaftor | ivacaftor | 2933.49 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 873054-44-5 |
| ivermectin | ivermectine | 2932.20 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 43 | 70288-86-7 |
| ivoqualine | ivoqualine | 2933.49 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 52 | 72714-75-1 |
| ixabepilone | ixabépilone | 2941.90 | | NC1059B2b Ann. O/3 | HSC/37 | 2006 | 89 | 219989-84-1 |
| ixazomib | ixazomib | 2931.00 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 1072833-77-2 |
| ixekizumab | ixékizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 105 | 1143503-69-8 |
| izonsteride | izonstéride | 2934.20 | | NC0250B2 Ann. P/1 (II) | HSC/25 | 2000 | 81 | 176975-26-1 |
| josamycin | josamycine | 2941.90 | | 38.100 Ann. Q (No. 380) | HSC/11 | 1993 | 23 | 16846-24-5 |
| kalafungin | kalafungine | 2941.90 | | 38.100 Ann. Q (No. 381) | HSC/11 | 1993 | 20 | 11048-15-0 |
| kallidinogenase | kallidinogénase | 3507.90 | | 38.100 Ann. Q (No. 382) | HSC/11 | 1993 | 22 | 9001-01-8 |
| kanamycin | kanamycine | 2941.90 | | 38.100 Ann. Q (No. 383) | HSC/11 | 1993 | 10 | 59-01-8 |
| keliximab | kéliximab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 76 | 174722-30-6 |
| keracyanin | kéracyanine | 2938.90 | | 38.100 Ann. Q (No. 384) | HSC/11 | 1993 | 31 | 18719-76-1 |
| ketanserine | kétansérine | 2933.59 | | 38.100 Ann. Q (No. 385) | HSC/11 | 1993 | 46 | 74050-98-9 |
| ketazocine | kétazocine | 2933.39 | | 38.100 Ann. Q (No. 386) | HSC/11 | 1993 | 34 | 36292-69-0 |
| ketazolam | kétazolam | 2934.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 26 | 27223-35-4 |
| ketobemidone | cétobémidone | 2933.33 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 1 | 469-79-4 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|---------------|---------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| ketocaine | kétocaïne | 2922.19 | | 40.260 Ann. L/2 (No. 82) | HSC/17 | 1996 | 15 | 1092-46-2 |
| ketocainol | kétocaïnol | 2922.19 | | 40.260 Ann. L/2 (No. 83) | HSC/17 | 1996 | 32 | 7488-92-8 |
| ketorfanol | kétorfanol | 2933.49 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 49 | 79798-39-3 |
| ketotrexate | kétotrexate | 2933.59 | | 38.100 Ann. Q (No. 388) | HSC/11 | 1993 | 50 | 52196-22-2 |
| khelloside | khelloside | 2938.90 | | 38.100 Ann. Q (No. 389) | HSC/11 | 1993 | 8 | 17226-75-4 |
| kitasamycin | kitasamycine | 2941.90 | | 38.100 Ann. Q (No. 390) | HSC/11 | 1993 | 13 | 1392-21-8 |
| labetuzumab | labetuzumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 85 | 219649-07-7 |
| labradimil | labradimil | 2937.19 | | NC0730B2 Ann. M/4 | HSC/31 | 2003 | 83 | 159768-75-9 |
| lacosamide | lacosamide | 2924.29 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 90 | 175481-36-4 |
| lactalfate | lactalfate | 2940.00 | | 38.100 Ann. Q (No. 391) | HSC/11 | 1993 | 53 | 96427-12-2 |
| ladarixin | ladarixine | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 105 | 849776-05-2 |
| ladirubicin | ladirubicine | 2941.90 | | NC0430B2 Ann. Q/1 (II) | HSC/27 | 2001 | 83 | 171047-47-5 |
| laflunimus | laflunimus | 2926.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 147076-36-6 |
| lafutidine | lafutidine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 70 | 118288-08-7 |
| lagatide | lagatide | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 75 | 157476-77-2 |
| lagociclovir | lagociclovir | 2934.99 | | NC1649B3b Ann. R/12 | HSC/47 | 2011 | 101 | 92562-88-4 |
| laidlomycin | laidlomycine | 2941.90 | | 38.100 Ann. Q (No. 392) | HSC/11 | 1993 | 61 | 56283-74-0 |
| lambrolizumab | lambrolizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 109 | 1374853-91-4 |
| lamifiban | lamifiban | 2933.39 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 144412-49-7 |
| lampalizumab | lampalizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 107 | 1278466-20-8 |
| lamtidine | lamtidine | 2933.39 | | 38.100 Ann. Q (No. 393) | HSC/11 | 1993 | 48 | 73278-54-3 |
| lancovutide | lancovutide | 2934.99 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 1391-36-2 |
| landiolol | landiolol | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 75 | 133242-30-5 |
| lanepitant | lanépitant | 2933.39 | | 42.100 Ann. O (VI) | HSC/21 | 1998 | 77 | 170566-84-4 |
| langlenatide | langlénatide | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 109 | 1296200-77-5 |
| lanicemine | lanicémine | 2933.39 | | NC0430B2 Ann. Q/1 (I) | HSC/27 | 2001 | 82 | 153322-05-5 |
| lanimostim | lanimostim | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 91 | 117276-75-2 |
| laninamivir | laninamivir | 2932.99 | | NC1500B1b Ann. K/6 | HSC/44 | 2009 | 100 | 203120-17-6 |
| laniquidar | laniquidar | 2933.49 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 197509-46-9 |
| lanoteplase | lanotéplase | 3507.90 | | NC0090B2 Ann. M/1 (III) | HSC/23 | 1999 | 76 | 171870-23-8 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|----------------------|-----------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| lanperisone | lanpérisone | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 72 | 116287-14-0 |
| lanprostion | lanprostone | 2932.99 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 105674-77-9 |
| lapaquistat | lapaquistat | 2934.99 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 189059-71-0 |
| lapisteride | lapistéride | 2933.79 | | NC0730B2 Ann. M/4 (III) | HSC/31 | 2003 | 85 | 142139-60-4 |
| laprafylline | laprafylline | 2939.59 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 60 | 90749-32-9 |
| laquinimod | laquinimod | 2933.79 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 248281-84-7 |
| larazotide | larazotide | 2933.99 | | NC1553B1b Ann. O/4 | HSC/45 | 2010 | 99 | 258818-34-7 |
| laromustine | laromustine | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 98 | 173424-77-6 |
| laronidase | laronidase | 3507.90 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 210589-09-6 |
| laropiprant | laropiprant | 2933.99 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 571170-77-9 |
| larotaxel | larotaxel | 2932.99 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 156294-36-9 |
| lasalocid | lasalocide | 2941.90 | | 38.100 Ann. Q (No. 395) | HSC/11 | 1993 | 30 | 25999-31-9 |
| lasinavir | lasinavir | 2924.29 | | 42.100 Ann. O (V) | HSC/21 | 1998 | 76 | 175385-62-3 |
| lasmiditan | lasmiditan | 2933.39 | | NC1604B1b Ann. N/6 | HSC/46 | 2010 | 102 | 439239-90-4 |
| lasofoxifene | lasofoxifène | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 81 | 180916-16-9 |
| latamoxef | latamoxef | 2941.90 | | 38.100 Ann. Q (No. 396) | HSC/11 | 1993 | 46 | 64952-97-2 |
| latanoprostene bunod | latanoprostène bunod | 2937.50 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 860005-21-6 |
| latidectin | latidectine | 2941.90 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 371918-51-3 |
| latrepirdine | latrépirdine | 2933.39 | | NC1604B1b Ann. N/6 | HSC/46 | 2010 | 102 | 3613-73-8 |
| latromotide | latromotide | 3002.20 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 1049674-65-8 |
| laurcetium bromide | bromure de laurcétium | 2923.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 1794-75-8 |
| lauroguadine | lauroguadine | 2925.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 29 | 135-43-3 |
| lauromacrogol 400 | lauromacrogol 400 | 3402.13 | | 38.100 Ann. Q (No. 398) | HSC/11 | 1993 | 90 | 9002-92-0 |
| lavoltidine | lavoltidine | 2933.39 | | 38.100 Ann. Q (No. 399) | HSC/11 | 1993 | 61 | 76956-02-0 |
| lebrikizumab | lébrikizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 101 | 953400-68-5 |
| lecimibide | lécimibide | 2933.29 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 130804-35-2 |
| leconotide | léconotide | 2934.99 | | NC0730B2 Ann. M/6 | HSC/31 | 2003 | 86 | 247207-64-3 |
| lecozotan | lecozotan | 2934.99 | | NC1059B2b Ann. O/5 | HSC/37 | 2006 | 93 | 434283-16-6 |
| ledipasvir | ledipasvir | 2933.39 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 1256388-51-8 |
| ledismase | ledismase | 3507.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 149394-67-2 |
| ledoxantrone | ledoxantrone | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 76 | 113457-05-9 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-------------------|-------------------|------------|------------|---|---------|--------------|--------------|--------------|
| lefamulin | léfamuline | 2941.90 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1061337-51-6 |
| lefetamine | léfétamine | 2921.46 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 30 | 7262-75-1 |
| lefradafiban | léfradafiban | 2933.79 | | 42.100 Ann. O (IV) | HSC/21 | 1998 | 75 | 149503-79-7 |
| lemalesomab | lémalésomab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 84 | 250242-54-7 |
| lemborexant | lemborexant | 2933.59 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1369764-02-2 |
| lemidosul | lémidosul | 2930.90 | | 38.100 Ann. Q (No. 400) | HSC/11 | 1993 | 52 | 88041-40-1 |
| lemoxinol | lémoxinol | 3824.90 | 3824.99 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 70 | no mention |
| lemuteporfin | lémutéporfine | 2933.99 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 215808-49-4 |
| lenalidomide | lénalidomide | 2933.79 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 191732-72-6 |
| lenampicillin | lénampicilline | 2941.10 | | 38.100 Ann. Q (No. 401) | HSC/11 | 1993 | 50 | 86273-18-9 |
| lenapenem | lénapénem | 2941.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 73 | 149951-16-6 |
| lenercept | lénercept | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 72 | 156679-34-4 |
| lenomorelin | lénomoréline | 2937.19 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 258279-04-8 |
| lensiprazine | lensiprazine | 2934.99 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 327026-93-7 |
| lenvatinib | lenvatinib | 2933.49 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 417716-92-8 |
| lenzilumab | lenzilumab | 3002.10 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1229575-09-0 |
| lepirudin | lépirudine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 73 | 138068-37-8 |
| lerdelimumab | lerdelimumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 83 | 285985-06-0 |
| leridistim | leridistim | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 80 | 193700-51-5 |
| lerimazoline | lérimazoline | 2933.29 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 54765-26-3 |
| lersivirine | lersivirine | 2933.19 | | NC1604B1b Ann. N/5 | HSC/46 | 2010 | 101 | 473921-12-9 |
| lesinurad | lésinurad | 2933.99 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 878672-00-5 |
| lesogaberan | lésogabéran | 2931.00 | | NC1500B1b Ann. K/6 | HSC/44 | 2009 | 100 | 344413-67-8 |
| lestaurtinib | lestaurtinib | 2934.99 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 111358-88-4 |
| letaxaban | létaxaban | 2933.59 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 870262-90-1 |
| leteprinin | létéprinin | 2933.59 | | NC0090B2 Ann. M/5 | HSC/23 | 1999 | 80 | 138117-50-7 |
| letermovir | létermovir | 2933.59 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 917389-32-3 |
| letrozole | létrozole | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 70 | 112809-51-5 |
| leuprorelin | léuproréline | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 47 | 53714-56-0 |
| levacetylmethadol | lévacétylméthadol | 2922.19 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 27 | 34433-66-4 |
| levallorphan | lévallorphane | 2933.49 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 2 | 152-02-3 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|---------------------|---------------------|------------|------------|---|---------|--------------|--------------|--------------|
| levamfetamine | lévamdéfamine | 2921.46 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 12 | 156-34-3 |
| levamlodipine | lévamdodipine | 2933.39 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 103129-82-4 |
| levisoprenaline | lévisoprénaline | 2922.50 | | 38.100 Ann. Q (No. 404) | HSC/11 | 1993 | 10 | 51-31-0 |
| levmetamfetamine | levmétdmfétamine | 2921.49 | | NC0430B2 Ann. Q/1 (II) | HSC/27 | 2001 | 83 | 33817-09-3 |
| levobetaxolol | lévobétaxolol | 2922.19 | | 40.260 Ann. L/2 (No. 84) | HSC/17 | 1996 | 61 | 93221-48-8 |
| levobunolol | lévobunolol | 2922.19 | | 40.260 Ann. L/2 (No. 85) | HSC/17 | 1996 | 42 | 47141-42-4 |
| levobupivacaine | lévobupivacaine | 2933.39 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 27262-47-1 |
| levocetirizine | lévocétirizine | 2933.59 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 130018-77-8 |
| levodopa | lévodopa | 2922.50 | | 38.100 Ann. Q (No. 405) | HSC/11 | 1993 | 21 | 59-92-7 |
| levoglucose | lévoglucose | 1702.30 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 921-60-8 |
| levolansoprazole | lévolansoprazole | 2933.39 | | NC1059B2b Ann. O/5 | HSC/37 | 2006 | 93 | 138530-95-7 |
| levomefolic acid | acide lévoméfolique | 2936.29 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 31690-09-2 |
| levomequitazine | lévoméquitazine | 2934.30 | | NC1649B3b Ann. R/12 | HSC/47 | 2011 | 101 | 88598-74-7 |
| levomethorphan | lévométhorphane | 2933.49 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 1 | 125-70-2 |
| levomilnacipran | lévomilnaciprane | 2924.29 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 96847-55-1 |
| levomoprolol | lévomoprolol | 2922.19 | | 40.260 Ann. L/2 (No. 86) | HSC/17 | 1996 | 58 | 77164-20-6 |
| levomoramide | lévomoramide | 2934.99 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 6 | 5666-11-5 |
| levonadifloxacin | lévonadifloxacine | 2933.39 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 154357-42-3 |
| levonebivolol | lévonébivolol | 2932.99 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 118457-16-2 |
| levonorgestrel | lévonorgestrel | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 33 | 797-63-7 |
| levophenacymorphan | lévophénacymorphane | 2933.49 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 9 | 10061-32-2 |
| levopropoxyphene | lévopropoxyphène | 2922.19 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 7 | 2338-37-6 |
| levopropylhexedrine | lévopropylhexédrine | 2921.30 | | 38.100 Ann. Q (No. 409) | HSC/11 | 1993 | 37 | 6192-97-8 |
| levormeloxifene | lévorméloxifène | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 73 | 78994-23-7 |
| levorphanol | lévorphanol | 2933.41 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 4 | 77-07-6 |
| levosalbutamol | lévosalbutamol | 2922.50 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 34391-04-3 |
| levosemotiadil | lévosémotiadil | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 72 | 116476-16-5 |
| levosulpiride | lévosulpiride | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 63 | 23672-07-3 |
| levotofisopam | levotofisopam | 2933.99 | | NC1004B1b Ann. L/11 | HSC/36 | 2005 | 92 | 82059-51-6 |
| lexacalcitol | lexacalcitol | 2909.49 | | 42.100 Ann. O (VII) | HSC/21 | 1998 | 71 | 131875-08-6 |
| lexanopadol | lexanopadol | 2934.99 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 1357348-09-4 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|----------------------|-----------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| lexaptetid pegol | lexaptépid pégol | 3907.20 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1390631-57-8 |
| lexatumumab | lexatumumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 95 | 845816-02-6 |
| lexibulin | lexibuline | 2933.59 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 917111-44-5 |
| lexipafant | lexipafant | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 70 | 139133-26-9 |
| liafensine | liafensine | 2933.49 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 1198790-53-2 |
| liatermin | liatermine | 2934.90 | | NC0250B2 Ann. P/1 (II) | HSC/25 | 2000 | 81 | 188630-14-0 |
| liatermin | liatermine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 81 | 188630-14-0 |
| libenzapril | libenzapril | 2933.79 | | 38.100 Ann. Q (No. 412) | HSC/11 | 1993 | 58 | 97878-35-8 |
| libivirumab | libivirumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 91 | 569658-79-3 |
| licarbazepine | licarbazépine | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 81 | 29331-92-8 |
| licofelone | licofélonge | 2933.99 | | NC0730B2 Ann. M/6 | HSC/31 | 2003 | 86 | 156897-06-2 |
| licostinel | licostinel | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 77 | 153504-81-5 |
| lidadronic acid | acide lidadronique | 2931.00 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 63132-38-7 |
| lidamidine | lidamidine | 2925.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 41 | 66871-56-5 |
| lidorestat | lidorestat | 2934.20 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 245116-90-9 |
| lifastuzumab vedotin | lifastuzumab védotine | 3002.10 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1401812-88-1 |
| lifibrol | lifibrol | 2918.90 | | 38.100 Ann. Q (No. 414) | HSC/11 | 1993 | 62 | 96609-16-4 |
| lificiguat | lificiguat | 2934.99 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 170632-47-0 |
| lifitegrast | lifitegrast | 2934.99 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 1025967-78-5 |
| ligelizumab | ligelizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 107 | 1322627-61-1 |
| lilopristone | lilopristone | 2922.50 | | 38.100 Ann. Q (No. 415) | HSC/11 | 1993 | 54 | 97747-88-1 |
| limiglidole | limiglidole | 2933.99 | | NC1500B1b Ann. K/6 | HSC/44 | 2009 | 100 | 64644-54-8 |
| linaclotide | linaclotide | 3002.90 | | NC1443B1b Ann. P/2 | HSC/43 | 2009 | 96 | 851199-59-2 |
| linagliptin | linagliptine | 2933.59 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 668270-12-0 |
| linaprazan | linaprazan | 2933.99 | | NC1004B1b Ann. L/11 | HSC/36 | 2005 | 92 | 248919-64-4 |
| linetastine | linétastine | 2933.39 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 159776-68-8 |
| linezolid | linézolide | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 76 | 165800-03-3 |
| linifanib | linifanib | 2933.99 | | NC1604B1b Ann. N/6 | HSC/46 | 2010 | 102 | 796967-16-3 |
| linopristin | linopristine | 2941.90 | | NC1553B1b Ann. O/3 | HSC/45 | 2010 | 98 | 325965-23-9 |
| linsitinib | linsitinib | 2933.49 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 867160-71-2 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|---------------------|------------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| linitript | linitript | 2934.10 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 136381-85-6 |
| lintuzumab | lintuzumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 76 | 166089-32-3 |
| liothyronine | liothyronine | 2937.90 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 6 | 1823692 |
| lipegfilgrastim | lipegfilgrastim | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 105 | 1117844-87-7 |
| liraglutide | liraglutide | 2937.19 | | NC0845B2 Ann. M/1 (II) | HSC/33 | 2004 | 87 | 204656-20-2 |
| lirequinil | liréquinil | 2933.79 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 143943-73-1 |
| lirexapride | lirexapride | 2933.39 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 145414-12-6 |
| lirilumab | lirilumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 107 | 1000676-41-4 |
| lirimilast | lirimilast | 2932.99 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 329306-27-6 |
| lisadimate | lisadimate | 2922.49 | | 40.260 Ann. L/2 (No. 87) | HSC/17 | 1996 | 63 | 136-44-7 |
| lisdexamfetamine | lisdexamphétamine | 2924.29 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 608137-32-2 |
| lisofylline | lisofylline | 2939.59 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 72 | 100324-81-0 |
| lisuride | lisuride | 2939.69 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 25 | 18016-80-3 |
| litenimod | liténimod | 2934.99 | | NC1310B1b Ann. N/10 | HSC/41 | 2008 | 96 | 852313-25-8 |
| litomeglovir | litomégllovir | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 84 | 321915-31-5 |
| litronesib | litronésib | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 101 | 910634-41-2 |
| livaraparin calcium | livaraparin calcium | 3001.90 | | NC1553B1b Ann. O/5 | HSC/45 | 2010 | 85 | 0-00-0 |
| lividomycin | lividomycine | 2941.90 | | 38.100 Ann. Q (No. 419) | HSC/11 | 1993 | 32 | 36441-41-5 |
| lixazinone | lixazinone | 2933.59 | | 38.100 Ann. Q (No. 420) | HSC/11 | 1993 | 57 | 94192-59-3 |
| lixisenatide | lixisénatide | 2937.19 | | NC1760B1b Ann. N/3 | HSC/49 | 2012 | 99 | 320367-13-3 |
| lixivaptan | lixivaptan | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 83 | 168079-32-1 |
| lobeglitazone | lobéglitazone | 2934.10 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 607723-33-1 |
| lobeline | lobéline | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 4 | 90-69-7 |
| lobucavir | lobucavir | 2933.59 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 127759-89-1 |
| lodelcizumab | lodelcizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 108 | 1355338-54-3 |
| lodenafil carbonate | carbonate de lodenafil | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 94 | 398507-55-6 |
| lodenosine | lodénosine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 78 | 110143-10-7 |
| lodoxamide | lodoxamide | 2926.90 | | 38.100 Ann. Q (No. 422) | HSC/11 | 1993 | 38 | 53882-12-5 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-------------------------|-------------------------|------------|------------|--|---------|--------------|--------------|--------------|
| lometraline | lométraline | 2922.29 | | 38.100 Ann. Q (No. 423) | HSC/11 | 1993 | 28 | 39951-65-0 |
| lometrexol | lométrexol | 2933.59 | | 38.100 Ann. Q (No. 424) | HSC/11 | 1993 | 63 | 106400-81-1 |
| lomevactone | lomévactone | 2932.20 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 48 | 81478-25-3 |
| lomibuvir | lomibuvir | 2934.99 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 1026785-55-6 |
| lomifylline | lomifylline | 2939.59 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 37 | 10226-54-7 |
| lomitapide | lomitapide | 2933.39 | | NC1604B1b Ann. N/5 | HSC/46 | 2010 | 101 | 182431-12-5 |
| lonafarnib | lonafarnib | 2933.39 | | NC0730B2 Ann. M/6 | HSC/31 | 2003 | 86 | 193275-84-2 |
| lonapalene | lonapalène | 2915.39 | | 38.100 Ann. Q (No. 427) | HSC/11 | 1993 | 55 | 91431-42-4 |
| lonaprisan | lonaprisan | 2937.29 | | NC1377E1b Ann. G/17 | HSC/42 | 2008 | 97 | 211254-73-8 |
| lonococog alfa | lonococog alfa | 3002.10 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1388129-63-2 |
| lopinavir | lopinavir | 2933.59 | | NC0090B2 Ann. M/5 | HSC/23 | 1999 | 80 | 192725-17-0 |
| lopobutan | lopobutan | 2922.50 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 6582-30-5 |
| loprazolam | loprazolam | 2933.55 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 44 | 61197-73-7 |
| loprodiol | loprodiol | 2905.59 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 43 | 2209-86-1 |
| loracarbef | loracarbef | 2941.90 | | 38.100 Ann. Q (No. 429) | HSC/11 | 1993 | 60 | 76470-66-1 |
| lorajmine | lorajmine | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 34 | 47562-08-3 |
| lorazepam | lorazépam | 2933.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 23 | 846-49-1 |
| lorcaserin | lorcasérine | 2933.99 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 616202-92-7 |
| loreclézole | loréclézole | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 60 | 117857-45-1 |
| lorediplon | lorédiplon | 2934.99 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 917393-39-6 |
| lormetazepam | lormétazépam | 2933.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 38 | 848-75-9 |
| lorpiprazole | lorpiprazole | 2933.59 | | 38.100 Ann. Q (No. 432) | HSC/11 | 1993 | 60 | 108785-69-9 |
| lorvotuzumab mertansine | lorvotuzumab mertansine | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 103 | 1008106-64-6 |
| losigamone | losigamone | 2932.20 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 61 | 112856-44-7 |
| losmapimod | losmapimod | 2933.39 | | NC1604B1b Ann. N/5 | HSC/46 | 2010 | 101 | 585543-15-3 |
| losmiprofen | losmiprofène | 2918.90 | | 38.100 Ann. Q (No. 434) | HSC/11 | 1993 | 61 | 74168-08-4 |
| lotilaner | lotilaner | 2934.99 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1369852-71-0 |
| lotilibcin | lotilibcine | 2941.90 | | NC1553B1b Ann. O/7 | HSC/45 | 2010 | 100 | 169148-84-9 |
| lotrafiban | lotrafiban | 2933.39 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 171049-14-2 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-----------------|-----------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| loviride | loviride | 2924.29 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 147362-57-0 |
| loxoprofen | loxoprophène | 2918.30 | | 38.100 Ann. Q (No. 435) | HSC/11 | 1993 | 50 | 68767-14-6 |
| lozilurea | lozilurée | 2924.21 | | 38.100 Ann. Q (No. 436) | HSC/11 | 1993 | 44 | 71475-35-9 |
| lubabegron | lubabégron | 2934.99 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 391920-32-4 |
| lubazodone | lubazodone | 2934.99 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 161178-07-0 |
| lubeluzole | lubéluzole | 2934.20 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 144665-07-6 |
| lubiprostone | lubiprostone | 2937.50 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 333963-40-9 |
| lucatumumab | lucatumumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 98 | 903512-50-5 |
| lucerastat | lucérastat | 2933.39 | | NC1874B1b Ann. O/1 | HSC/51 | 2013 | 106 | 141206-42-0 |
| lucimycin | lucimycine | 2941.90 | | 38.100 Ann. Q (No. 437) | HSC/11 | 1993 | 13 | 13058-67-8 |
| lucitanib | lucitanib | 2933.49 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 1058137-23-7 |
| luliconazole | luliconazole | 2934.99 | | NC0730B2 Ann. M/6 | HSC/31 | 2003 | 86 | 187164-19-8 |
| lulizumab pegol | lulizumab pégol | 3002.10 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1421830-13-8 |
| lumacaftor | lumacaftor | 2934.99 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 936727-05-8 |
| lumefantrine | luméfantrine | 2922.19 | | 42.100 Ann. O (VI) | HSC/21 | 1998 | 77 | 82186-77-4 |
| lumiliximab | lumiliximab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 90 | 357613-86-6 |
| luminespib | luminespib | 2934.99 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 747412-49-3 |
| lumiracoxib | lumiracoxib | 2922.49 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 220991-20-8 |
| lumretuzumab | lumrétuzumab | 3002.10 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1448327-63-6 |
| lunacalcipol | lunacalcipol | 2930.90 | | NC1760B1b Ann. N/5 | HSC/49 | 2012 | 102 | 250384-82-8 |
| lupitidine | lupitidine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 53 | 83903-06-4 |
| lurasidone | lurasidone | 2934.20 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 367514-87-2 |
| lurbnectedin | lurbnectédine | 2934.99 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 497871-47-3 |
| lurtotecan | lurtotécan | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 74 | 149882-10-0 |
| lusaperidone | lusapéridone | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 82 | 214548-46-6 |
| luseogliflozin | luséogliflozine | 2934.99 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 898537-18-3 |
| luspatercept | luspatercept | 3002.10 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1373715-00-4 |
| lusupultide | lusupultide | 2933.29 | | NC0250B2 Ann. P/1 (I) | HSC/25 | 2000 | 80 | 200074-80-2 |
| lusutrombopag | lusutrombopag | 2934.10 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 1110766-97-6 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-----------------------|-------------------------|------------|------------|--|---------|--------------|--------------|--------------|
| lutrelin | lutréline | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 51 | 66866-63-5 |
| lutropin alfa | lutropine alfa | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 71 | 152923-57-4 |
| lymecycline | lymécycline | 2941.30 | | 38.100 Ann. Q (No. 440) | HSC/11 | 1993 | 14 | 992-21-2 |
| lynestrenol | lynestrénol | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 13 | 52-76-6 |
| lypressin | lypressine | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 13 | 50-57-7 |
| lysergide | lysergide | 2933.69 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 8 | 50-37-3 |
| macimorelin | macimoréline | 2937.90 | | NC1874B1b Ann. O/3 | HSC/51 | 2013 | 100 | 381231-18-1 |
| macitentan | macitentan | 2933.59 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 441798-33-0 |
| macrogol ester | ester de macrogol | 3402.13 | | NC0250B2 Ann. P/1 | HSC/25 | 2000 | 34 | no mention |
| macrosalb (131 I) | macrosalb (131 I) | 2844.40 | | 38.100 Ann. Q (No. 444) | HSC/11 | 1993 | 33 | 54182-63-7 |
| macrosalb (99m Tc) | macrosalb (99m Tc) | 2844.40 | | 38.100 Ann. Q (No. 445) | HSC/11 | 1993 | 33 | 54277-47-3 |
| maduramicin | maduramicine | 2941.90 | | 38.100 Ann. Q (No. 446) | HSC/11 | 1993 | 55 | 84878-61-5 |
| magaldrate | magaldrate | 2842.90 | | 38.100 Ann. Q (No. 447) | HSC/11 | 1993 | 49 | 74978-16-8 |
| magnesium clofibrate | clofibrate de magnésium | 2918.90 | | 38.100 Ann. Q (No. 448) | HSC/11 | 1993 | 31 | 14613-30-0 |
| maletamer | malétamère | 3911.90 | | 38.100 Ann. Q (No. 449) | HSC/11 | 1993 | 14 | 29535-27-1 |
| maleylsulfathiazole | maléylsulfathiazol | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 1 | 515-57-1 |
| malotilate | malotilate | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 44 | 59937-28-9 |
| managlinat dialanetil | managlinat dialanétil | 2934.10 | | NC1310B1b Ann. N/10 | HSC/41 | 2008 | 96 | 280782-97-0 |
| mangafodipir | mangafodipir | 2933.39 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 155319-91-8 |
| manifaxine | manifaxine | 2934.99 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 135306-39-7 |
| manitimus | manitimus | 2926.90 | | NC1059B2b Ann. O/5 | HSC/37 | 2006 | 93 | 202057-76-9 |
| mannitol hexanitate | hexanitate de mannitol | 2920.90 | | 38.100 Ann. Q (No. 452) | HSC/11 | 1993 | 1 | 15825-70-4 |
| mannosulfan | mannosulfan | 2905.49 | | 38.100 Ann. Q (No. 453) | HSC/11 | 1993 | 24 | 7518-35-6 |
| manozodil | manozodil | 2934.20 | | 38.100 Ann. Q (No. 454) | HSC/11 | 1993 | 47 | 77528-67-7 |
| mantabegron | mantabégron | 2922.19 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 36144-08-8 |
| mapatumumab | mapatumumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 93 | 658052-09-6 |
| mapinastine | mapinastine | 2933.59 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 140945-32-0 |
| mapracorat | mapracorat | 2934.99 | | NC1649B3b Ann. R/13 | HSC/47 | 2011 | 102 | 887375-26-0 |
| maraciclatide | maraciclatide | 2934.99 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 489427-17-0 |
| maraviroc | maraviroc | 2933.39 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 376348-65-1 |
| margetuximab | margetuximab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 109 | 1350624-75-7 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|----------------------|-----------------------|------------|------------|--|---------|--------------|--------------|--------------|
| maribavir | maribavir | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 80 | 176161-24-3 |
| maridomycin | maridomycine | 2941.90 | | 38.100 Ann. Q (No. 455) | HSC/11 | 1993 | 32 | 35775-82-7 |
| marimastat | marimastat | 2928.00 | | 42.100 Ann. O (IV) | HSC/21 | 1998 | 75 | 154039-60-8 |
| mariptiline | mariptiline | 2928.00 | | 38.100 Ann. Q (No. 456) | HSC/11 | 1993 | 44 | 60070-14-6 |
| marizomib | marizomib | 2934.99 | | NC1604B1b Ann. N/6 | HSC/46 | 2010 | 102 | 437742-34-2 |
| maropitant | maropitant | 2933.39 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 147116-67-4 |
| masilukast | masilukast | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 94 | 136564-68-6 |
| masitinib | masitinib | 2934.10 | | NC1310B1b Ann. N/10 | HSC/41 | 2008 | 96 | 790299-79-5 |
| matuzumab | matuzumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 88 | 339186-68-4 |
| mavacoxib | mavacoxib | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 94 | 170569-88-7 |
| mavatrep | mavatrep | 2933.99 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 956274-94-5 |
| mavoglurant | mavoglurant | 2933.99 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 543906-09-8 |
| mavrilimumab | mavrilimumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 102 | 1085337-57-0 |
| maxacalcitol | maxacalcitol | 2909.49 | | 42.100 Ann. O (IV) | HSC/21 | 1998 | 75 | 103909-75-7 |
| mazapertine | mazapertine | 2933.59 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 134208-17-6 |
| mazindol | mazindol | 2933.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 23 | 22232-71-9 |
| mazipredone | mazipredone | 2937.29 | | 38.100 Ann. Q (No. 457) | HSC/11 | 1993 | 32 | 13085-08-0 |
| mazokalim | mazokalim | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 75 | 164178-54-5 |
| mebeverine | mébévérine | 2922.50 | | 38.100 Ann. Q (No. 458) | HSC/11 | 1993 | 14 | 3625-06-7 |
| mebolazine | mébolazine | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 21 | 3625-07-8 |
| mebutamate | mébutamate | 2924.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 12 | 64-55-1 |
| mebutizide | mébutizide | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 15 | 3568-00-1 |
| mecamylamine | mécamylamine | 2921.30 | | 38.100 Ann. Q (No. 462) | HSC/11 | 1993 | 6 | 60-40-2 |
| mecasermin rinfabate | mecasermine rinfabate | 2933.29 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 478166-15-3 |
| mecillinam | mécillinam | 2941.90 | | 38.100 Ann. Q (No. 463) | HSC/11 | 1993 | 32 | 32887-01-7 |
| meclinertant | méclinertant | 2933.49 | | NC0730B2 Ann. M/4 (III) | HSC/31 | 2003 | 88 | 146362-70-1 |
| meclocycline | méclocycline | 2941.30 | | 38.100 Ann. Q (No. 464) | HSC/11 | 1993 | 14 | 2013-58-3 |
| mecloqualone | mécloqualone | 2933.55 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 12 | 340-57-8 |
| meclorisone | méclorisone | 2937.22 | | 38.100 Ann. Q (No. 467) | HSC/11 | 1993 | 40 | 4732-48-3 |
| mecobalamin | mécobalamine | 2936.26 | | 38.100 Ann. Q (No. 468) | HSC/11 | 1993 | 26 | 13422-55-4 |
| medazepam | médazépam | 2933.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 20 | 2898-12-6 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-----------------------|-----------------------|------------|------------|--|---------|--------------|--------------|-------------|
| medifoxamine | médifoxamine | 2922.50 | | 40.260 Ann. L/2 (No. 88) | HSC/17 | 1996 | 33 | 32359-34-5 |
| medorinone | médorinone | 2933.79 | | 38.100 Ann. Q (No. 470) | HSC/11 | 1993 | 54 | 88296-61-1 |
| medorubicin | médorubicine | 2941.90 | | 38.100 Ann. Q (No. 471) | HSC/11 | 1993 | 47 | 64314-52-9 |
| medrogestone | médrogestone | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 15 | 977-79-7 |
| medroxyprogesterone | médroxyprogestérone | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 10 | 520-85-4 |
| medrylamine | médrylamine | 2922.19 | | 40.260 Ann. L/2 (No. 89) | HSC/17 | 1996 | 1 | 524-99-2 |
| mefenorex | méfénorex | 2921.46 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 19 | 17243-57-1 |
| mefeserpine | méfésérpine | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 15 | 3735-85-1 |
| mefruside | méfruside | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 16 | 7195-27-9 |
| megalomicin | mégalomicine | 2941.90 | | 38.100 Ann. Q (No. 476) | HSC/11 | 1993 | 40 | 28022-11-9 |
| megestrol | mégestrol | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 13 | 3562-63-8 |
| meglucycline | méglucycline | 2941.30 | | 38.100 Ann. Q (No. 478) | HSC/11 | 1993 | 22 | 31770-79-3 |
| melagatran | mélagatran | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 74 | 159776-70-2 |
| meldonium | meldonium | 2928.00 | | NC0730B2 Ann. M/6 | HSC/31 | 2003 | 86 | 76144-81-5 |
| melengestrol | mélengestrol | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 13 | 5633-18-1 |
| melevodopa | mélévodopa | 2922.50 | | NC0430B2 Ann. Q/1 (II) | HSC/27 | 2001 | 83 | 7101-51-1 |
| melogliptin | mélogliptine | 2933.99 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 868771-57-7 |
| meloxicam | méloxicam | 2934.10 | | 38.100 Ann. Q (No. 480) | HSC/11 | 1993 | 52 | 71125-38-7 |
| melphalan flufenamide | melphalan flufénamide | 2924.29 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 380449-51-4 |
| melquinast | mélquinast | 2933.59 | | 38.100 Ann. Q (No. 481) | HSC/11 | 1993 | 62 | 87611-28-7 |
| meluadrine | méluadrine | 2922.50 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 134865-33-1 |
| menfegol | menfégol | 3402.13 | | 38.100 Ann. Q (No. 482) | HSC/11 | 1993 | 36 | 57821-32-6 |
| menogaril | ménogaril | 2941.90 | | 38.100 Ann. Q (No. 483) | HSC/11 | 1993 | 51 | 71628-96-1 |
| meobentine | méobentine | 2925.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 38 | 46464-11-3 |
| mephenytoin | méphénytoïne | 2933.21 | | 38.100 Ann. Q (No. 485) | HSC/11 | 1993 | 1 | 50-12-4 |
| mepitiostane | mépitiostane | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 34 | 21362-69-6 |
| mepolizumab | mépolizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 81 | 196078-29-2 |
| mepramidil | mépramidil | 2922.19 | | 40.260 Ann. L/2 (No. 90) | HSC/17 | 1996 | 27 | 23891-60-3 |
| meprobamate | méprobamate | 2924.11 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 6 | 57-53-4 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|---------------------|-----------------------|------------|------------|--|---------|--------------|--------------|--------------|
| meproscillarín | méproscillarine | 2938.90 | | 38.100 Ann. Q (No. 488) | HSC/11 | 1993 | 38 | 33396-37-1 |
| meprylcaine | méprylcaïne | 2922.19 | | 38.100 Ann. Q (No. 489) | HSC/11 | 1993 | 4 | 495-70-5 |
| meradimate | méradimate | 2922.49 | | NC0430B2 Ann. Q/1 (II) | HSC/27 | 2001 | 83 | 134-09-8 |
| meralein sodium | méraléine sodique | 2932.99 | | 42.100 Ann. O (I) | HSC/21 | 1998 | 13 | 4386-35-0 |
| meralluride | méralluride | 3003.40 | | 38.100 Ann. Q (No. 490) | HSC/11 | 1993 | 1 | 8069-64-5 |
| merbromin | merbromine | 2932.99 | | 42.100 Ann. O (I) | HSC/21 | 1998 | 1 | 129-16-8 |
| mercaptomerin | mercaptomérine | 2930.90 | | 42.100 Ann. O (I) | HSC/21 | 1998 | 1 | 20223-84-1 |
| mercumatilin sodium | mercumatiline sodique | 3003.40 | | 38.100 Ann. Q (No. 491) | HSC/11 | 1993 | 4 | 60135-06-0 |
| mercuphylline | mercuphylline | 3003.40 | | 38.100 Ann. Q (No. 492) | HSC/11 | 1993 | 1 | 8012-34-8 |
| mergocriptine | mergocriptine | 2939.69 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 54 | 81968-16-3 |
| meribendan | méribendan | 2933.19 | | 38.100 Ann. Q (No. 494) | HSC/11 | 1993 | 62 | 119322-27-9 |
| mericitabine | méricitabine | 2934.99 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 940908-79-2 |
| merimepodib | mérimépodib | 2934.99 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 198821-22-6 |
| merisoprol (197 Hg) | mérisoprol (197 Hg) | 2844.40 | | 38.100 Ann. Q (No. 495) | HSC/11 | 1993 | 24 | 5579-94-2 |
| meropenem | méropénem | 2941.90 | | 38.100 Ann. Q (No. 496) | HSC/11 | 1993 | 60 | 96036-03-2 |
| merotocin | mérotocine | 2937.19 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1190083-57-8 |
| mesabolone | mésabolone | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 29 | 7483-09-2 |
| mesocarb | mésocarb | 2934.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 34 | 34262-84-5 |
| mespiperone (11C) | mespipérone (11C) | 2844.40 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 94153-50-1 |
| mestanolone | mestanolone | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 10 | 521-11-9 |
| mesterolone | méstérolone | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 15 | 1424-00-6 |
| mestranol | mestranol | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 15 | 72-33-3 |
| mesulergine | mésulergine | 2939.69 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 47 | 64795-35-3 |
| mesulfamide | mésulfamide | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 41 | 122-89-4 |
| mesulfen | mésulfène | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 1 | 135-58-0 |
| mesuprine | mésuprine | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 21 | 7541-30-2 |
| mesuximide | mésuximide | 2925.19 | | 38.100 Ann. Q (No. 505) | HSC/11 | 1993 | 6 | 77-41-8 |
| metaglycodol | métaglycodol | 2906.29 | | 38.100 Ann. Q (No. 506) | HSC/11 | 1993 | 12 | 13980-94-4 |
| metahexamide | métahexamide | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 10 | 565-33-3 |
| metamfetamine | métamfétamine | 2939.91 | 2939.71 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 55 | 537-46-2 |
| metaraminol | métaraminol | 2939.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 1 | 54-49-9 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-----------------------------|--------------------------------|------------|------------|---|---------|--------------|--------------|--------------|
| metaterol | métatérol | 2922.50 | | 38.100 Ann. Q (No. 510) | HSC/11 | 1993 | 43 | 3571-71-9 |
| metazocine | métazocine | 2933.39 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 9 | 3734-52-9 |
| metelimumab | métélimumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 86 | 272780-74-2 |
| metenkefalin | métenkéfaline | 2930.90 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 58569-55-4 |
| metenolone | méténlone | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 12 | 153-00-4 |
| metergoline | méteergoline | 2939.69 | | 42.100 Ann. O (I) | HSC/21 | 1998 | 18 | 17692-51-2 |
| metergotamine | méteergotamine | 2939.69 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 29 | 22336-84-1 |
| metescufylline | métescufylline | 2939.59 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 15 | 15518-82-8 |
| metesculetol | métesculétol | 2932.20 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 41 | 52814-39-8 |
| metesind | métésind | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 76 | 138384-68-6 |
| metformin glycinate | glycinate de metformine | 2925.29 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 121369-64-0 |
| methadone | méthadone | 2922.31 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 1 | 76-99-3 |
| methandriol | méthandriol | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 1 | 521-10-8 |
| methaqualone | méthaaqualone | 2933.55 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 10 | 72-44-6 |
| metharbital | métharbital | 2933.54 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 1 | 50-11-3 |
| methazolamide | méthazolamide | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 10 | 554-57-4 |
| methdilazine | methdilazine | 2934.30 | | 38.100 Ann. Q (No. 519) | HSC/11 | 1993 | 90 | 1982-37-2 |
| methiodal sodium | méthiodal sodique | 2904.90 | 2904.99 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 1 | 126-31-8 |
| methoprene | méthoprène | 2918.90 | | 38.100 Ann. Q (No. 521) | HSC/11 | 1993 | 60 | 40596-69-8 |
| methyldesorphine | méthyl désorphine | 2939.19 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 5 | 16008-36-9 |
| methyl dihydromorphine | méthyl dihydromorphine | 2939.19 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 5 | 509-56-8 |
| methylergometrine | méthyl ergométrine | 2939.69 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 1 | 113-42-8 |
| methyl naltrexone bromide | bromure de méthyl naltrexone | 2939.19 | | NC1310B1b Ann. N/10 | HSC/41 | 2008 | 96 | 73232-52-7 |
| methylphenidate | méthylphénidate | 2933.33 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 6 | 113-45-1 |
| methylphenobarbital | méthylphénobarbital | 2933.53 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 1 | 115-38-8 |
| methylrosanilinium chloride | chlorure de méthylrosanilinium | 3204.13 | | 38.100 Ann. Q (No. 523) | HSC/11 | 1993 | 1 | 548-62-9 |
| methylsamidorphane chloride | méthylsamidorphane chloride | 2933.49 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 1118885-67-8 |
| methylthiouracil | méthylthiouracile | 2933.59 | | 38.100 Ann. Q (No. 524) | HSC/11 | 1993 | 1 | 56-04-2 |
| methypylon | méthypylone | 2933.72 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 6 | 125-64-4 |
| methysergide | méthysergide | 2939.69 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 11 | 361-37-5 |
| metipirox | métipirox | 2933.39 | | 38.100 Ann. Q (No. 526) | HSC/11 | 1993 | 26 | 29342-02-7 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|----------------------|-----------------------|------------|------------|---|---------|--------------|--------------|--------------|
| metipranolol | métipranolol | 2922.19 | | 40.260 Ann. L/2 (No. 91) | HSC/17 | 1996 | 38 | 22664-55-7 |
| metkefamide | metkéfamide | 2930.90 | | 38.100 Ann. Q (No. 527) | HSC/11 | 1993 | 44 | 66960-34-7 |
| metogest | métogest | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 33 | 52279-58-0 |
| metopon | métopon | 2939.19 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 1 | 143-52-2 |
| metoprolol | métoprolol | 2922.19 | | 40.260 Ann. L/2 (No. 92) | HSC/17 | 1996 | 30 | 37350-58-6 |
| metoquizine | métoquizine | 2933.19 | | 38.100 Ann. Q (No. 529) | HSC/11 | 1993 | 17 | 7125-67-9 |
| metralindole | métralindole | 2933.59 | | 40.260 Ann. L/2 (No. 28) | HSC/17 | 1996 | 42 | 54188-38-4 |
| metreleptin | métréleptine | 2937.19 | | NC0590B2 Ann. L/10 | HSC/29 | 2002 | 82 | 186018-45-1 |
| metribolone | métribolone | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 17 | 965-93-5 |
| metynodiol | métynodiol | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 27 | 23163-42-0 |
| mexafylline | mexafylline | 2939.59 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 48 | 80294-25-3 |
| mexrenoate potassium | mexrénoate potassique | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 33 | 43169-54-6 |
| mezacopride | mézacopride | 2933.39 | | 38.100 Ann. Q (No. 534) | HSC/11 | 1993 | 56 | 89613-77-4 |
| mezilamine | mézilamine | 2933.59 | | 38.100 Ann. Q (No. 535) | HSC/11 | 1993 | 36 | 50335-55-2 |
| mibampator | mibampator | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 103 | 375345-95-2 |
| mibefradil | mibéfradil | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 72 | 116644-53-2 |
| mibenratide | mibenratide | 2934.99 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1239011-83-6 |
| mibolerone | mibolérone | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 27 | 3704-09-4 |
| micafungin | micafungine | 2941.90 | | NC0730B2 Ann. M/4 | HSC/31 | 2003 | 84 | 235114-32-6 |
| midafotel | midafotel | 2933.59 | | NC0090B2 Ann. M/1 (II) | HSC/23 | 1999 | 79 | 117414-74-1 |
| midaglizole | midaglizole | 2933.39 | | 38.100 Ann. Q (No. 537) | HSC/11 | 1993 | 57 | 66529-17-7 |
| midaxifylline | midaxifylline | 2939.59 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 79 | 151159-23-8 |
| midazolam | midazolam | 2933.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 40 | 59467-70-8 |
| midostaurin | midostaurine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 79 | 120685-11-2 |
| mifamurtide | mifamurtide | 2932.99 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 83461-56-7 |
| mifepristone | mifépristone | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 54 | 84371-65-3 |
| migalastat | migalastat | 2933.39 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 108147-54-2 |
| miglustat | miglustat | 2933.39 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 72599-27-0 |
| milacainide | milacainide | 2933.39 | | 42.100 Ann. O (VI) | HSC/21 | 1998 | 77 | 141725-10-2 |
| milameline | milaméline | 2933.39 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 139886-32-1 |
| milataxel | milataxel | 2932.19 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 393101-41-2 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|---------------------|-----------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| milatuzumab | milatuzumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 98 | 899796-83-9 |
| milciclib | milciclib | 2933.59 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 802539-81-7 |
| milfasartan | milfasartan | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 76 | 148564-47-0 |
| milipertine | milipertine | 2933.59 | | 38.100 Ann. Q (No. 539) | HSC/11 | 1993 | 20 | 24360-55-2 |
| milodistim | milodistim | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 74 | 137463-76-4 |
| miltefosine | miltefosine | 2923.90 | | 38.100 Ann. Q (No. 540) | HSC/11 | 1993 | 61 | 58066-85-6 |
| milveterol | milvétérol | 2924.29 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 652990-07-3 |
| mimopezil | mimopézil | 2933.79 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 180694-97-7 |
| minalrestat | minalrestat | 2925.19 | | 42.100 Ann. O (V) | HSC/21 | 1998 | 76 | 129688-50-2 |
| mindodilol | mindodilol | 2933.39 | | 38.100 Ann. Q (No. 541) | HSC/11 | 1993 | 52 | 70260-53-6 |
| mindoperone | mindopérone | 2933.39 | | 38.100 Ann. Q (No. 542) | HSC/11 | 1993 | 38 | 52157-83-2 |
| minepentate | minépentate | 2922.19 | | 40.260 Ann. L/2 (No. 93) | HSC/17 | 1996 | 18 | 13877-99-1 |
| minocycline | minocycline | 2941.30 | | 38.100 Ann. Q (No. 543) | HSC/11 | 1993 | 14 | 10118-90-8 |
| minodronic acid | acide minodronique | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 78 | 127657-42-5 |
| minolteparin sodium | minoltéparine sodique | 3001.90 | | NC1553B1b Ann. O/5 | HSC/45 | 2010 | 73 | 0-00-0 |
| minopafant | minopafant | 2933.39 | | NC0090B2 Ann. M/5 | HSC/23 | 1999 | 80 | 128420-61-1 |
| minretumomab | minrétumomab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 80 | 195189-17-4 |
| mipitroban | mipitroban | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 73 | 136122-46-8 |
| mipomersen | mipomersen | 2934.99 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 1000120-98-8 |
| miproxifene | miproxifène | 2922.19 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 129612-87-9 |
| mipsagargin | mipsagargine | 2932.20 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1245732-48-2 |
| mirabegron | mirabégron | 2934.10 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 223673-61-8 |
| miravirsen | miravirsen | 2934.99 | | NC1604B1b Ann. N/5 | HSC/46 | 2010 | 101 | 1072874-90-8 |
| miriplatin | miriplatine | 2843.90 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 141977-79-9 |
| mirisetron | mirisétron | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 72 | 135905-89-4 |
| mirococept | mirococept | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 91 | 507453-82-9 |
| mirodenafil | mirodénafil | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 95 | 862189-95-5 |
| mirogabalin | mirogabaline | 2922.49 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 1138245-13-2 |
| mirostipen | mirostipen | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 85 | 244130-01-6 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-------------------------|----------------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| mirtazapine | mirtazapine | 2933.59 | | 38.100 Ann. Q (No. 544) | HSC/11 | 1993 | 61 | 61337-67-5 |
| mitemcinal | mitemcinal | 2932.20 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 86 | 154738-42-8 |
| mitiglinide | mitiglinide | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 78 | 145375-43-5 |
| mitomalcin | mitomalcine | 2941.90 | | 38.100 Ann. Q (No. 545) | HSC/11 | 1993 | 19 | 11043-99-5 |
| mitomycin | mitomycine | 2941.90 | | 38.100 Ann. Q (No. 546) | HSC/11 | 1993 | 26 | 50-07-7 |
| mitoquidone | mitoquidone | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 54 | 91753-07-0 |
| mitratapide | mitratapide | 2934.99 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 90 | 179602-65-4 |
| mitumomab | mitumomab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 82 | 216503-58-1 |
| mivobulin | mivobuline | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 77 | 122332-18-7 |
| mivotilate | mivotilate | 2934.10 | | NC0090B2 Ann. M/5 | HSC/23 | 1999 | 80 | 130112-42-4 |
| mobenakin | mobénakine | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 72 | 124146-64-1 |
| mocetinoestat | mocétinoestat | 2933.59 | | NC1604B1b Ann. N/5 | HSC/46 | 2010 | 101 | 726169-73-9 |
| mocimycin | mocimycine | 2941.90 | | 38.100 Ann. Q (No. 548) | HSC/11 | 1993 | 28 | 50935-71-2 |
| modaline | modaline | 2933.39 | | 38.100 Ann. Q (No. 549) | HSC/11 | 1993 | 15 | 2856-74-8 |
| modimelanotide | modimélanotide | 2937.19 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 926277-68-1 |
| modithromycin | modithromycine | 2941.90 | | NC1649B3b Ann. R/12 | HSC/47 | 2011 | 101 | 736992-12-4 |
| mofarotene | mofarotène | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 70 | 125533-88-2 |
| mofebutazone | mofébutazone | 2933.19 | | 38.100 Ann. Q (No. 550) | HSC/11 | 1993 | 15 | 2210-63-1 |
| mogamulizumab | mogamulizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 104 | 1159266-37-1 |
| molidustat | molidustat | 2934.99 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1154028-82-6 |
| momelotinib | momelotinib | 2934.99 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 1056634-68-4 |
| mometasone | mométasone | 2937.22 | | 38.100 Ann. Q (No. 551) | HSC/11 | 1993 | 56 | 105102-22-5 |
| monepantel | monépantel | 2930.90 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 887148-69-8 |
| mongersen | mongersen | 2934.99 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1443994-46-4 |
| monoethanolamine oleate | oléate de monoéthanolamine | 2922.11 | | 38.100 Ann. Q (No. 552) | HSC/11 | 1993 | 1 | 2272-11-9 |
| monophosphothiamine | monophosphothiamine | 2936.22 | | 38.100 Ann. Q (No. 553) | HSC/11 | 1993 | 8 | 532-40-1 |
| monteplase | montéplase | 3507.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 71 | 156616-23-8 |
| moprolol | moprolol | 2922.19 | | 40.260 Ann. L/2 (No. 94) | HSC/17 | 1996 | 36 | 5741-22-0 |
| moracizine | moracizine | 2934.30 | | 38.100 Ann. Q (No. 554) | HSC/11 | 1993 | 25 | 31883-05-3 |
| moroctocog alfa | moroctocog alfa | 3002.10 | 3002.12 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 72 | 0-00-0 |
| morolimumab | morolimumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 79 | 202833-07-6 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-----------------------|-----------------------------|------------|------------|---|---------|--------------|--------------|--------------|
| morpheridine | morphéridine | 2934.99 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 6 | 469-81-8 |
| morphine glucuronide | glucuroconjugué de morphine | 2939.19 | | NC1059B2b Ann. O/4 | HSC/37 | 2006 | 92 | 20290-10-2 |
| motavizumab | motavizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 95 | 677010-34-3 |
| motesanib | motésanib | 2933.39 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 453562-69-1 |
| motexafin | motéxafine | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 82 | 189752-49-6 |
| moxestrol | moxestrol | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 24 | 34816-55-2 |
| moxetumomab pasudotox | moxétumomab pasudotox | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 102 | 1020748-57-5 |
| moxidectin | moxidectine | 2932.20 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 64 | 113507-06-5 |
| moxifloxacin | moxifloxacine | 2933.49 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 78 | 151096-09-2 |
| moxilubant | moxilubant | 2925.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 78 | 146978-48-5 |
| moxisylyte | moxisylyte | 2922.19 | | 40.260 Ann. L/2 (No. 95) | HSC/17 | 1996 | 14 | 54-32-0 |
| mozavaptan | mozavaptan | 2933.99 | | NC0845B2 Ann. M/1 (II) | HSC/33 | 2004 | 87 | 137975-06-5 |
| mozenavir | mozénavir | 2933.99 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 174391-92-5 |
| mubritinib | mubritinib | 2934.99 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 366017-09-6 |
| muplestim | muplestim | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 72 | 148641-02-5 |
| murabutide | murabutide | 2932.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 49 | 74817-61-1 |
| muraglitazar | muraglitazar | 2934.99 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 331741-94-7 |
| mureletecan | murélétécan | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 85 | 246527-99-1 |
| murodermin | murodermine | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 63 | 54017-73-1 |
| mycophenolic acid | acide mycophénolique | 2941.90 | | 38.100 Ann. Q (No. 559) | HSC/11 | 1993 | 24 | 24280-93-1 |
| myrophine | myrophine | 2939.19 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 5 | 467-18-5 |
| nabilone | nabilone | 2932.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 49 | 51022-71-0 |
| nacartocin | nacartocine | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 51 | 77727-10-7 |
| nacolomab tafenatox | nacolomab tafénatox | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 71 | 150631-27-9 |
| nadolol | nadolol | 2922.19 | | 40.260 Ann. L/2 (No. 96) | HSC/17 | 1996 | 34 | 42200-33-9 |
| nadroparin calcium | nadroparine calcique | 3001.90 | | NC1553B1b Ann. O/5 | HSC/45 | 2010 | 65 | 0-00-0 |
| nafamostat | nafamostat | 2925.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 53 | 81525-10-2 |
| nafarelin | nafaréline | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 50 | 76932-56-4 |
| nafetolol | nafétolol | 2922.19 | | 40.260 Ann. L/2 (No. 97) | HSC/17 | 1996 | 39 | 42050-23-7 |
| naflocort | naflocort | 2937.22 | | 38.100 Ann. Q (No. 564) | HSC/11 | 1993 | 50 | 59497-39-1 |
| naftalofos | naftalofos | 2929.90 | | 38.760 Ann. D, par. 29 | HSC/13 | 1994 | 16 | 1491-41-4 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|------------------------|------------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| naftazone | naftazone | 2928.00 | | 38.100 Ann. Q (No. 566) | HSC/11 | 1993 | 16 | 15687-37-3 |
| nagrestipen | nagrestipen | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 76 | 166089-33-4 |
| nalbuphine | nalbuphine | 2939.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 21 | 20594-83-6 |
| naldemedine | naldémédine | 2939.19 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 916072-89-4 |
| nalfurafine | nalfurafine | 2939.19 | | NC0845B2 Ann. M/1 (II) | HSC/33 | 2004 | 87 | 152657-84-6 |
| nalmefene | nalméfène | 2939.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 49 | 55096-26-9 |
| nalmexone | nalmexone | 2939.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 19 | 16676-26-9 |
| nalorphine | nalorphine | 2939.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 1 | 62-67-9 |
| naloxegol | naloxécol | 2939.19 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 854601-70-0 |
| naloxone | naloxone | 2939.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 13 | 465-65-6 |
| naltalimide | naltalimide | 2934.99 | | NC1874B1b Ann. O/1 | HSC/51 | 2013 | 106 | 160359-68-2 |
| naluzotan | naluzotan | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 101 | 740873-06-7 |
| namilumab | namilumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 104 | 1206681-39-1 |
| naminidil | naminidil | 2926.90 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 220641-11-2 |
| namitecan | namitécan | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 100 | 372105-27-6 |
| namoxyrate | namoxyrate | 2922.19 | | 38.760 Ann. D, par. 29 | HSC/13 | 1994 | 15 | 1234-71-5 |
| nanterinone | nantérinone | 2933.79 | | 38.100 Ann. Q (No. 573) | HSC/11 | 1993 | 60 | 102791-47-9 |
| napabucasin | napabucasine | 2932.99 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 83280-65-3 |
| napitane | napitane | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 73 | 148152-63-0 |
| naproxcinod | naproxcinod | 2920.90 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 163133-43-5 |
| napsagatran | napsagatran | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 72 | 154397-77-0 |
| naptumomab estafenatox | naptumomab estafénatox | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 96 | 676258-98-3 |
| narlaprevir | narlaprévir | 2933.99 | | NC1760B1b Ann. N/4 | HSC/49 | 2012 | 102 | 865466-24-6 |
| narnatumab | narnatumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 105 | 1188275-92-4 |
| naronapride | naronapride | 2933.39 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 860174-12-5 |
| nasaruplase beta | nasaruplase beta | 3507.90 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 136653-69-5 |
| natalizumab | natalizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 79 | 189261-10-7 |
| nateglinide | natéglinide | 2924.29 | | 42.100 Ann. O (VI) | HSC/21 | 1998 | 77 | 105816-04-4 |
| nateplase | natéplase | 3507.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 73 | 159445-63-3 |
| navarixin | navarixine | 2932.19 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 473727-83-2 |
| naveglitazar | navéglitazar | 2918.90 | | NC1059B2b Ann. O/4 | HSC/37 | 2006 | 92 | 476436-68-7 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|---------------|---------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| navitoclax | navitoclax | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 103 | 923564-51-6 |
| navuridine | navuridine | 2934.99 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 84472-85-5 |
| naxifylline | naxifylline | 2939.59 | | NC0730B2 Ann. M/6 | HSC/31 | 2003 | 86 | 166374-49-8 |
| nebentan | nébentan | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 90 | 403604-85-3 |
| nebicapone | nébicapone | 2914.70 | 2914.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 93 | 274925-86-9 |
| neboglamine | néboglamine | 2924.29 | | NC0430B2 Ann. Q/1 (I) | HSC/27 | 2001 | 85 | 163000-63-3 |
| nebotermin | nébotermin | 2934.99 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 246539-15-1 |
| neceprevir | nécéprevir | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 107 | 1229626-28-1 |
| necitumumab | necitumumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 100 | 906805-06-9 |
| nelarabine | nélarabine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 80 | 121032-29-9 |
| nelezaprine | nélézaprine | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 59 | 69624-60-8 |
| nelfinavir | nelfinavir | 2933.49 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 76 | 159989-64-7 |
| nelivaptan | nélivaptan | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 98 | 439687-69-1 |
| nelociguat | nélociguat | 2933.59 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 625115-52-8 |
| nelotanserin | nélotansérine | 2933.19 | | NC1604B1b Ann. N/5 | HSC/46 | 2010 | 101 | 839713-36-9 |
| nemadectin | némadectine | 2941.90 | | 38.100 Ann. Q (No. 575) | HSC/11 | 1993 | 60 | 102130-84-7 |
| nemifitide | némifitide | 2933.99 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 173240-15-8 |
| nemonoxacin | némonoxacine | 2933.49 | | NC1310B1b Ann. N/10 | HSC/41 | 2008 | 96 | 378746-64-6 |
| nemorubicin | némorubicine | 2941.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 71 | 108852-90-0 |
| nepadutant | népadutant | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 78 | 183747-35-5 |
| nepafenac | népafénac | 2924.29 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 78281-72-8 |
| nepaprazole | népaprazole | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 74 | 156601-79-5 |
| nepicastat | népicastat | 2933.29 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 173997-05-2 |
| nepidermin | népidermine | 2934.99 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 62253-63-8 |
| neramexane | néramexane | 2921.30 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 219810-59-0 |
| neratinib | nératinib | 2933.49 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 698387-09-6 |
| nerelimomab | nérélimomab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 76 | 162774-06-3 |
| nerispiridine | nerispiridine | 2933.39 | | NC1059B2b Ann. O/5 | HSC/37 | 2006 | 93 | 119229-65-1 |
| nesbuvir | nesbuvir | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 98 | 691852-58-1 |
| nesiritide | nésiritide | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 80 | 124584-08-3 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|--------------------------|-----------------------------|------------|------------|---|---------|--------------|--------------|--------------|
| nesvacumab | nesvacumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 108 | 1296818-77-3 |
| netazepide | nétazépide | 2933.39 | | NC1649B3b Ann. R/12 | HSC/47 | 2011 | 106 | 155488-25-8 |
| netilmicin | nétilmicine | 2941.90 | | 38.100 Ann. Q (No. 576) | HSC/11 | 1993 | 36 | 56391-56-1 |
| netivudine | nétivudine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 72 | 84558-93-0 |
| netoglitazone | nétoglitazone | 2934.10 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 161600-01-7 |
| netupitant | nétupitant | 2933.59 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 290297-26-6 |
| neutamycin | neutamycine | 2941.90 | | 38.100 Ann. Q (No. 577) | HSC/11 | 1993 | 15 | 1404-08-6 |
| nexeridine | nexéridine | 2922.19 | | 38.100 Ann. Q (No. 578) | HSC/11 | 1993 | 34 | 53716-48-6 |
| nicanartine | nicanartine | 2933.39 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 150443-71-3 |
| nicocodine | nicocodine | 2939.19 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 12 | 3688-66-2 |
| nicocortonide | nicocortonide | 2937.29 | | 38.100 Ann. Q (No. 579) | HSC/11 | 1993 | 40 | 65415-41-0 |
| nicodicodine | nicodicodine | 2939.19 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 15 | 808-24-2 |
| nicomorphine | nicomorphine | 2939.11 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 7 | 639-48-5 |
| nicoracetam | nicoracétam | 2933.79 | | 38.100 Ann. Q (No. 580) | HSC/11 | 1993 | 63 | 128326-80-7 |
| nicotredole | nicotrédole | 2933.39 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 29876-14-0 |
| nifekalant | nifékalant | 2933.59 | | 42.100 Ann. O (IV) | HSC/21 | 1998 | 75 | 130636-43-0 |
| nifungin | nifungine | 2941.90 | | 38.100 Ann. Q (No. 581) | HSC/11 | 1993 | 24 | 11056-16-9 |
| nilotinib | nilotinib | 2933.59 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 641571-10-0 |
| nilutamide | nilutamide | 2933.21 | | 38.100 Ann. Q (No. 582) | HSC/11 | 1993 | 56 | 63612-50-0 |
| nimetazepam | nimétazépam | 2933.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 26 | 2011-67-8 |
| nimorazole | nimorazole | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 22 | 6506-37-2 |
| nimotuzumab | nimotuzumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 94 | 828933-51-3 |
| niperotidine | nipérotidine | 2932.19 | | 38.100 Ann. Q (No. 584) | HSC/11 | 1993 | 54 | 84845-75-0 |
| niprofazone | niprofazone | 2933.39 | | 38.100 Ann. Q (No. 585) | HSC/11 | 1993 | 29 | 15387-10-7 |
| niraparib | niraparib | 2933.39 | | NC1874B1b Ann. O/1 | HSC/51 | 2013 | 106 | 1038915-60-4 |
| niraxostat | niraxostat | 2933.19 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 99 | 206884-98-2 |
| nitisinone | nitisinone | 2914.70 | 2914.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 78 | 104206-65-7 |
| nitraquazone | nitraquazone | 2933.59 | | 38.100 Ann. Q (No. 586) | HSC/11 | 1993 | 53 | 56739-21-0 |
| nitrazepam | nitrazépam | 2933.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 16 | 146-22-5 |
| nitricholine perchlorate | perchlorate de nitricholine | 2923.90 | | 38.100 Ann. Q (No. 587) | HSC/11 | 1993 | 6 | 7009-91-8 |
| nivimedone | nivimédone | 2914.70 | 2914.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 37 | 49561-92-4 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-----------------------|--------------------------|------------|------------|---|---------|--------------|--------------|--------------|
| nivocasan | nivocasan | 2934.99 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 908253-63-4 |
| nivolumab | nivolumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 107 | 946414-94-4 |
| nobiprostolan | nobiprostolan | 2937.50 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 120373-67-3 |
| nofecainide | nofécaïnide | 2933.79 | | 38.100 Ann. Q (No. 589) | HSC/11 | 1993 | 44 | 50516-43-3 |
| nogalamycin | nogalamycine | 2941.90 | | 42.100 Ann. O (II) | HSC/21 | 1998 | 16 | 1404-15-5 |
| nolatrexed | nolatrexed | 2933.59 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 147149-76-6 |
| nolomirole | nolomirole | 2922.29 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 90060-42-7 |
| nolpitantium besilate | bésilate de nolpitantium | 2933.39 | | 42.100 Ann. O (IV) | HSC/21 | 1998 | 75 | 155418-06-7 |
| nonacog alfa | nonacog alfa | 3002.10 | 3002.12 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 77 | 113478-33-4 |
| nonacog beta pegol | nonacog bêta pegol | 3002.10 | 3002.12 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 103 | 1175512-71-6 |
| nonacog gamma | nonacog gamma | 3002.10 | 3002.12 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 108 | 181054-95-5 |
| nonathymulin | nonathymuline | 2933.79 | | 38.100 Ann. Q (No. 590) | HSC/11 | 1993 | 56 | 63958-90-7 |
| nonoxinol | nonoxinol | 3402.13 | | 38.100 Ann. Q (No. 591) | HSC/11 | 1993 | 34 | 9016-45-9 |
| noracymethadol | noracyméthadol | 2922.19 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 12 | 1477-39-0 |
| norclostebol | norclostébol | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 22 | 13583-21-6 |
| norcodeine | norcodéine | 2939.19 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 7 | 467-15-2 |
| nordazepam | nordazépam | 2933.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 39 | 1088-11-5 |
| nordinone | nordinone | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 32 | 33122-60-0 |
| norelgestromin | norelgestromine | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 83 | 53016-31-2 |
| norgesterone | norgestérone | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 14 | 13563-60-5 |
| norgestimate | norgestimate | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 35 | 35189-28-7 |
| norgestomet | norgestomet | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 32 | 25092-41-5 |
| norgestrienone | norgestriénone | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 18 | 848-21-5 |
| norletimol | norlétimol | 2925.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 38 | 886-08-8 |
| norleusactide | norleusactide | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 18 | 17692-62-5 |
| norlevorphanol | norlévorphanol | 2933.49 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 9 | 1531-12-0 |
| normethadone | norméthadone | 2922.31 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 5 | 467-85-6 |
| normorphine | normorphine | 2939.19 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 7 | 466-97-7 |
| norpipanone | norpipanone | 2933.39 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 14 | 561-48-8 |
| nortopixantrone | nortopixantrone | 2933.99 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 156090-17-4 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|------------------|---------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| norvinisterone | norvinist rone | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 10 | 6795-60-4 |
| nosantine | nosantine | 2933.59 | | 38.100 Ann. Q (No. 603) | HSC/11 | 1993 | 55 | 76600-30-1 |
| nupafant | nupafant | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 70 | 139133-27-0 |
| nuvenzepine | nuvenz pine | 2933.39 | | 38.100 Ann. Q (No. 604) | HSC/11 | 1993 | 59 | 96487-37-5 |
| obatoclax | obatoclax | 2933.99 | | NC1123B1b Ann. N/1 | HSC/38 | 2006 | 94 | 803712-67-6 |
| obenoxazine | obenoxazine | 2934.99 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 173352-21-1 |
| oberadilol | ob radilol | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 77 | 114856-44-9 |
| obeticholic acid | acide ob ticholique | 2937.29 | | NC1649B3b Ann. R/12 | HSC/47 | 2011 | 101 | 459789-99-2 |
| obinepitide | obin pitide | 2937.19 | | NC1310B1b Ann. N/10 | HSC/41 | 2008 | 96 | 348119-84-6 |
| oblimersen | oblimersen | 2934.99 | | NC0845B2 Ann. M/1 (II) | HSC/33 | 2004 | 87 | 190977-41-4 |
| ocaratumumab | ocaratumumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 107 | 1169956-08-4 |
| ocinaplon | ocinaplon | 2933.59 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 96604-21-6 |
| oclitinib | oclitinib | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 105 | 1208319-26-9 |
| ocrelizumab | ocrelizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 94 | 637334-45-3 |
| ocriplasmin | ocriplasmine | 3002.10 | 3002.12 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 101 | 1048016-09-6 |
| octinoxate | octinoxate | 2918.90 | | NC0430B2 Ann. Q/1 (II) | HSC/27 | 2001 | 84 | 5466-77-3 |
| octisalate | octisalate | 2918.23 | | NC0430B2 Ann. Q/1 (II) | HSC/27 | 2001 | 83 | 118-60-5 |
| octocog alfa | octocog alfa | 3002.10 | 3002.12 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 73 | 139076-62-3 |
| octopamine | octopamine | 2937.90 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 32 | 104-14-3 |
| octotiamine | octotiamine | 2936.90 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 13 | 137-86-0 |
| octoxinol | octoxinol | 3402.13 | | 38.100 Ann. Q (No. 607) | HSC/11 | 1993 | 34 | 9002-93-1 |
| odalasvir | odalasvir | 2933.99 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1415119-52-6 |
| odanacatib | odanacatib | 2930.90 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 603139-19-1 |
| odulimomab | odulimomab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 73 | 159445-64-4 |
| ofatumumab | ofatumumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 93 | 679818-59-8 |
| oftasceine | oftasc ine | 3204.90 | | 38.100 Ann. Q (No. 608) | HSC/11 | 1993 | 40 | 1461-15-0 |
| oglemilast | ogl milast | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 94 | 778576-62-8 |
| oglufanide | oglufanide | 2933.99 | | NC0730B2 Ann. M/6 | HSC/31 | 2003 | 86 | 38101-59-6 |
| olamufloxacin | olamufloxacin | 2933.49 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 79 | 167887-97-0 |
| olanexidine | olanexidine | 2925.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 81 | 146510-36-3 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|---------------------------|---------------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| olaparib | olaparib | 2933.59 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 763113-22-0 |
| olaptosed pegol | olaptéséd pégol | 3907.20 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1390628-22-4 |
| olaratumab | olaratumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 103 | 1024603-93-7 |
| olcegepant | olcégépant | 2933.59 | | NC0845B2 Ann. M/1 (I) | HSC/33 | 2004 | 86 | 204697-65-4 |
| olcorolimus | olcorolimus | 2941.90 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 186752-78-3 |
| olesoxime | olésoxime | 2928.00 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 22033-87-0 |
| oletimol | olétimol | 2925.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 38 | 5879-67-4 |
| olipudase alfa | olipudase alfa | 3507.90 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 927883-84-9 |
| olmesartan | olmésartan | 2933.29 | | NC1059B2b Ann. O/5 | HSC/37 | 2006 | 93 | 144689-24-7 |
| olodaterol | olodatérol | 2934.99 | | NC1649B3b Ann. R/12 | HSC/47 | 2011 | 101 | 868049-49-4 |
| olokizumab | olokizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 103 | 1007223-17-7 |
| olopatadine | olopatadine | 2932.99 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 113806-05-6 |
| olpadronic acid | acide olpadronique | 2931.00 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 71 | 63132-39-8 |
| olprinone | olprinone | 2933.79 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 106730-54-5 |
| olsalazine | olsalazine | 3204.12 | | 38.100 Ann. Q (No. 94) | HSC/11 | 1993 | 52 | 15722-48-2 |
| omacetaxine mepesuccinate | omacétaxine mépésuccinate | 2934.99 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 26833-87-4 |
| omaciclovir | omaciclovir | 2933.59 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 124265-89-0 |
| omadacycline | omadacycline | 2941.30 | | NC1649B3b Ann. R/13 | HSC/47 | 2011 | 102 | 389139-89-3 |
| omalizumab | omalizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 84 | 242138-07-4 |
| omapatrilat | omapatrilate | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 78 | 167305-00-2 |
| omarigliptin | omarigliptine | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 107 | 1226781-44-7 |
| ombitasvir | ombitasvir | 2933.99 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 1258226-87-7 |
| ombrabulin | ombrabuline | 2924.29 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 181816-48-8 |
| omecamtiv mecarbil | omécamtiv mécarbil | 2933.59 | | NC1649B3b Ann. R/13 | HSC/47 | 2011 | 102 | 873697-71-3 |
| omeprazole | oméprazole | 2933.39 | | 38.100 Ann. Q (No. 610) | HSC/11 | 1993 | 46 | 73590-58-6 |
| omigapil | omigapil | 2932.99 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 181296-84-4 |
| omiloxetine | omiloxétine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 76 | 176894-09-0 |
| omipalisib | omipalisib | 2935.00 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1086062-66-9 |
| omocianine | omocianine | 2933.99 | | NC1004B1b Ann. L/11 | HSC/36 | 2005 | 92 | 154082-13-0 |
| omoconazole | omoconazole | 2933.29 | | 38.100 Ann. Q (No. 611) | HSC/11 | 1993 | 58 | 74512-12-2 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|----------------------------|-------------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| ompinamer | ompinamère | 3911.90 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1359979-10-4 |
| omtriptolide | omtriptolide | 2932.20 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 95 | 195883-06-8 |
| onapristone | onapristone | 2922.50 | | 42.100 Ann. O (VII) | HSC/21 | 1998 | 58 | 96346-61-1 |
| onartuzumab | onartuzumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 104 | 1133766-06-9 |
| ondansetron | ondansétron | 2933.29 | | 38.100 Ann. Q (No. 612) | HSC/11 | 1993 | 59 | 116002-70-1 |
| ondelopropan | ondélopropan | 2934.99 | | NC1874B1b Ann. O/1 | HSC/51 | 2013 | 106 | 676501-25-0 |
| onercept | onercept | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 82 | 199685-57-9 |
| ontazolast | ontazolast | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 72 | 147432-77-7 |
| ontuxizumab | ontuxizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 109 | 946415-62-9 |
| opanixil | opanixil | 2933.59 | | 42.100 Ann. O (VI) | HSC/21 | 1998 | 77 | 152939-42-9 |
| opaviriline | opaviriline | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 83 | 178040-94-3 |
| opebacan | opébacan | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 83 | 206254-79-7 |
| opicapone | opicapone | 2934.99 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 923287-50-7 |
| oportuzumab monatox | oportuzumab monatox | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 100 | 945228-48-8 |
| opratonium iodide | iodure d'opratonium | 2924.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 76 | 210419-36-6 |
| oprelvekin | oprelvékine | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 76 | 145941-26-0 |
| oprozomib | oprozomib | 2934.10 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 935888-69-0 |
| orantinib | orantinib | 2933.79 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 252916-29-3 |
| orazipone | orazipone | 2930.90 | | 42.100 Ann. O (VI) | HSC/21 | 1998 | 77 | 137109-78-5 |
| orbofiban | orbofiban | 2933.79 | | 42.100 Ann. O (IV) | HSC/21 | 1998 | 75 | 163250-90-6 |
| orciprenaline | orciprénaline | 2922.50 | | 38.100 Ann. Q (No. 613) | HSC/11 | 1993 | 14 | 586-06-1 |
| ordopidine | ordopidine | 2933.39 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 871351-60-9 |
| oregovomab | orégovomab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 86 | 213327-37-8 |
| oreptacog alfa (activated) | oreptacog alfa (activé) | 3002.10 | 3002.12 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 109 | 1360054-92-7 |
| orgotein | orgotéine | 3507.90 | | 38.100 Ann. Q (No. 614) | HSC/11 | 1993 | 31 | 9016-01-7 |
| orientiparcin | orientiparcine | 2941.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 159445-62-2 |
| orilotimod | orilotimod | 2933.99 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 186087-26-3 |
| oritavancin | oritavancine | 2941.90 | | NC0430B2 Ann. Q/1 (II) | HSC/27 | 2001 | 83 | 171099-57-3 |
| orlistat | orlistat | 2932.20 | | NC1760B1b Ann. N/9 | HSC/49 | 2012 | 66 | 96829-58-2 |
| ornipressin | ornipressine | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 22 | 3397-23-7 |
| ortataxel | ortataxel | 2932.99 | | NC0845B2 Ann. M/1 (II) | HSC/33 | 2004 | 87 | 186348-23-2 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|---------------------|-----------------------|------------|------------|--|---------|--------------|--------------|--------------|
| orteronel | ortéronel | 2933.99 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 566939-85-3 |
| orticumab | orticumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 107 | 1314241-10-5 |
| orvepitant | orvépitant | 2933.79 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 579475-18-6 |
| osanetant | osanétant | 2933.39 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 160492-56-8 |
| oseltamivir | oséltamivir | 2924.29 | | NC0090B2 Ann. M/5 | HSC/23 | 1999 | 80 | 196618-13-0 |
| osemozotan | osémozotan | 2932.99 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 137275-81-1 |
| osilodrostat | osilodrostat | 2933.99 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 928134-65-0 |
| ospemifene | ospémifène | 2909.49 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 128607-22-7 |
| osutidine | osutidine | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 76 | 140695-21-2 |
| otamixaban | otamixaban | 2933.39 | | NC0730B2 Ann. M/6 | HSC/31 | 2003 | 86 | 193153-04-7 |
| otelixizumab | otélixizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 98 | 881191-44-2 |
| otenabant | otenabant | 2933.59 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 686344-29-6 |
| otenzepad | otenzépad | 2933.39 | | 38.100 Ann. Q (No. 616) | HSC/11 | 1993 | 63 | 100158-38-1 |
| oteracil | otéracil | 2933.69 | | NC0090B2 Ann. M/5 | HSC/23 | 1999 | 80 | 937-13-3 |
| otlertuzumab | otlertuzumab | 3002.10 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1372645-37-8 |
| ovemotide | ovemotide | 3002.20 | | NC1248E1b Ann. F/11 par. 8 | HSC/40 | 2007 | 94 | 181477-91-8 |
| oxabolone cipionate | cipionate d'oxabolone | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 14 | 1254-35-9 |
| oxabrexine | oxabrexine | 2922.29 | | 40.260 Ann. L/2 (No. 98) | HSC/17 | 1996 | 40 | 65415-42-1 |
| oxaliplatin | oxaliplatine | 2843.90 | | 38.100 Ann. Q (No. 618) | HSC/11 | 1993 | 56 | 61825-94-3 |
| oxandrolone | oxandrolone | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 12 | 53-39-4 |
| oxatomide | oxatomide | 2933.59 | | 38.100 Ann. Q (No. 620) | HSC/11 | 1993 | 38 | 60607-34-3 |
| oxazepam | oxazéпам | 2933.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 13 | 604-75-1 |
| oxazolam | oxazolam | 2934.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 25 | 24143-17-7 |
| oxeclosporin | oxéclosporine | 2933.79 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 135548-15-1 |
| oxeglitazar | oxéglitazar | 2932.99 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 280585-34-4 |
| oxeladin | oxéladine | 2922.19 | | 40.260 Ann. L/2 (No. 99) | HSC/17 | 1996 | 6 | 468-61-1 |
| oxelumab | oxélumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 103 | 89957-37-9 |
| oxetacillin | oxétacilline | 2941.10 | | 38.100 Ann. Q (No. 621) | HSC/11 | 1993 | 33 | 53861-02-2 |
| oxifentorex | oxifentorex | 2929.90 | | 40.260 Ann. L/2 (No. 13) | HSC/17 | 1996 | 20 | 4075-88-1 |
| oxilofrine | oxilofrine | 2939.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 62 | 365-26-4 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-----------------------|------------------------|------------|------------|---|---------|--------------|--------------|--------------|
| oximonam | oximonam | 2941.90 | | 38.100 Ann. Q (No. 622) | HSC/11 | 1993 | 54 | 90898-90-1 |
| oxiperomide | oxipéromide | 2933.39 | | 38.100 Ann. Q (No. 623) | HSC/11 | 1993 | 30 | 5322-53-2 |
| oxipurinol | oxipurinol | 2933.59 | | 38.100 Ann. Q (No. 624) | HSC/11 | 1993 | 18 | 2465-59-0 |
| oxitefonium bromide | bromure d'oxitéfonium | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 18 | 17692-63-6 |
| oxitropium bromide | bromure d'oxitropium | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 36 | 30286-75-0 |
| oxogestone | oxogestone | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 19 | 3643-00-3 |
| oxprenolol | oxprénolol | 2922.19 | | 40.260 Ann. L/2 (No. 100) | HSC/17 | 1996 | 20 | 6452-71-7 |
| oxybutynin | oxybutynine | 2922.19 | | 40.260 Ann. L/2 (No. 101) | HSC/17 | 1996 | 13 | 5633-20-5 |
| oxycodone | oxycodone | 2939.11 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 1 | 76-42-6 |
| oxymorphone | oxymorphone | 2939.11 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 5 | 76-41-5 |
| ozanezumab | ozanezumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 108 | 1310680-64-8 |
| ozarelix | ozarélix | 2937.19 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 295350-45-7 |
| ozenoxacin | ozénoxacine | 2933.49 | | NC1310B1b Ann. N/10 | HSC/41 | 2008 | 96 | 245765-41-7 |
| ozogamicin | ozogamicine | 2941.90 | | NC0430B2 Ann. Q/1 (II) | HSC/27 | 2001 | 83 | 400046-53-9 |
| ozoralizumab | ozoralizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 105 | 1167985-17-2 |
| paclitaxel | paclitaxel | 2932.99 | | NC1178E1c Ann. E par. 5 | HSC/39 | 2007 | 68 | 33069-62-4 |
| paclitaxel ceribate | Céribate de paclitaxel | 2932.99 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 186040-50-6 |
| paclitaxel poliglumex | paclitaxel poliglumex | 3908.90 | | NC1310B1b Ann. N/1 | HSC/41 | 2008 | 90 | 263351-82-2 |
| paclitaxel trevatide | paclitaxel trévatide | 2932.99 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 1075214-55-9 |
| pacrinolol | pacrinolol | 2926.90 | | 40.260 Ann. L/2 (No. 15) | HSC/17 | 1996 | 44 | 65655-59-6 |
| pacritinib | pacritinib | 2934.99 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 937272-79-2 |
| padeliporfin | padéliporfine | 2843.90 | | NC1310B1b Ann. N/10 | HSC/41 | 2008 | 96 | 759457-82-4 |
| padoporfin | padoporfine | 2843.90 | | NC1059B2b Ann. O/5 | HSC/37 | 2006 | 93 | 274679-00-4 |
| pafenolol | pafénolol | 2924.21 | | 42.100 Ann. O (II) | HSC/21 | 1998 | 46 | 75949-61-0 |
| pafuramidine | pafuramidine | 2932.19 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 186953-56-0 |
| pagibaximab | pagibaximab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 93 | 595566-61-3 |
| pagoclone | pagoclone | 2933.79 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 133737-32-3 |
| palbociclib | palbociclib | 2933.79 | | NC2116B1b Ann. R/3 | HSC/55 | 2015 | 109 | |
| palifermin | palifermine | 2933.29 | | NC0730B2 Ann. M/6 | HSC/31 | 2003 | 86 | 162394-19-6 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-------------------------|----------------------------|------------|------------|---------------------------|---------|--------------|--------------|--------------|
| paliflutine | paliflutine | 2933.59 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 845614-11-1 |
| palifosfamide | palifosfamide | 2929.90 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 31645-39-3 |
| palinavir | palinavir | 2933.49 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 74 | 154612-39-2 |
| paliperidone | palipéridone | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 83 | 144598-75-4 |
| paliroden | palirodène | 2933.39 | | NC1059B2b Ann. O/5 | HSC/37 | 2006 | 93 | 188396-77-2 |
| palivizumab | palivizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 79 | 188039-54-5 |
| palonosetron | palonosétron | 2933.79 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 135729-56-5 |
| palosuran | palosuran | 2933.49 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 540769-28-6 |
| palovarotene | palovarotène | 2933.19 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 410528-02-8 |
| pamapimod | pamapimod | 2933.79 | | NC1310B1b Ann. N/10 | HSC/41 | 2008 | 96 | 449811-01-2 |
| pamaqueside | pamaquéside | 2938.90 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 150332-35-7 |
| pamicogrel | pamicogrel | 2934.10 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 101001-34-7 |
| pamiteplase | pamitéplase | 3507.90 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 151912-42-4 |
| panamesine | panamésine | 2934.10 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 73 | 139225-22-2 |
| pancopride | pancopride | 2933.39 | | 38.100 Ann. Q (No. 628) | HSC/11 | 1993 | 62 | 121650-80-4 |
| panitumumab | panitumumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 91 | 339177-26-3 |
| panobacumab | panobacumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 100 | 885053-97-4 |
| panobinostat | panobinostat | 2933.99 | | NC1310B1b Ann. N/10 | HSC/41 | 2008 | 96 | 404950-80-7 |
| panomifene | panomifène | 2922.19 | | 40.260 Ann. L/2 (No. 102) | HSC/17 | 1996 | 58 | 77599-17-8 |
| panthenol | panthénol | 2936.24 | | 38.100 Ann. Q (No. 629) | HSC/11 | 1993 | 14 | 16485-10-2 |
| panulisib | panulisib | 2933.39 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 1356033-60-7 |
| paquinimod | paquinimod | 2933.79 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 248282-01-1 |
| pararosaniline embonate | embonate de pararosaniline | 3204.13 | | 42.100 Ann. O (II) | HSC/21 | 1998 | 15 | 7232-51-1 |
| parathyroid hormone | hormone parathyroïdienne | 2937.19 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 345663-45-8 |
| pardoprunox | pardoprunox | 2934.99 | | NC1310B1b Ann. N/10 | HSC/41 | 2008 | 96 | 269718-84-5 |
| parecoxib | parécoxib | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 80 | 198470-84-7 |
| parethoxycaine | paréthoxycaine | 2922.19 | | 40.260 Ann. L/2 (No. 103) | HSC/17 | 1996 | 1 | 94-23-5 |
| pargeverine | pargévérine | 2922.19 | | 40.260 Ann. L/2 (No. 104) | HSC/17 | 1996 | 38 | 13479-13-5 |
| pargolol | pargolol | 2922.19 | | 40.260 Ann. L/2 (No. 105) | HSC/17 | 1996 | 36 | 47082-97-3 |
| paricalcitol | paricalcitol | 2906.19 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 131918-61-1 |
| parnaparin sodium | parnaparine sodique | 3001.90 | | NC1553B1b Ann. O/5 | HSC/45 | 2010 | 64 | 0-00-0 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-----------------------|-----------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| parogrelil | parogrénil | 2933.39 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 139145-27-0 |
| parsatuzumab | parsatuzumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 107 | 1312797-14-0 |
| pascolizumab | pascolizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 87 | 331243-22-2 |
| pasireotide | pasiréotide | 2933.99 | | NC1059B2b Ann. O/3 | HSC/37 | 2006 | 90 | 396091-73-9 |
| pasotuxizumab | pasotuxizumab | 3002.10 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1442657-12-6 |
| pateclizumab | patéclizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 105 | 1202526-59-7 |
| patiromer calcium | patiromère calcique | 3906.90 | | NC1874B1b Ann. O/1 | HSC/51 | 2013 | 106 | 1208912-84-8 |
| patisiran | patisiran | 2934.99 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 1420706-45-1 |
| patritumab | patritumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 106 | 1262787-83-6 |
| patupilone | patupilone | 2941.90 | | NC1059B2b Ann. O/3 | HSC/37 | 2006 | 89 | 152044-54-7 |
| paulomycin | paulomycine | 2941.90 | | 38.100 Ann. Q (No. 630) | HSC/11 | 1993 | 47 | 59794-18-2 |
| paxamate | paxamate | 2924.29 | | 38.100 Ann. Q (No. 631) | HSC/11 | 1993 | 13 | 5579-05-5 |
| pazinaclone | pazinaclone | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 70 | 103255-66-9 |
| pazopanib | pazopanib | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 94 | 444731-52-6 |
| pazufloxacin | pazufloxacin | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 71 | 127045-41-4 |
| pefcalcitol | pefcalcitol | 2924.29 | | NC2004B1b Ann. O/2 | HSC/53 | 2014 | 107 | |
| peficitinib | péficitinib | 2933.99 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 944118-01-8 |
| peforelin | peforeline | 2937.19 | | NC1059B2b Ann. O/5 | HSC/37 | 2006 | 93 | 147859-97-0 |
| pegacaristim | pégacaristim | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 80 | 187139-68-0 |
| pegamotecan | pégamotécan | 2939.99 | | NC1059B2b Ann. O/3 | HSC/37 | 2006 | 91 | 203066-49-3 |
| pegaptanib | pégaptanib | 3907.20 | | NC0845B2 Ann. M/1 (II) | HSC/33 | 2004 | 87 | 0-00-0 |
| pegargiminase | pégargiminase | 3507.90 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1394129-74-8 |
| pegbovigrastim | pegbovigrastim | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 109 | 1363409-60-2 |
| pegdinetanib | pegdinétanib | 3002.10 | 3002.12 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 103 | 906450-24-6 |
| pegfilgrastim | pegfilgrastim | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 85 | 208265-92-3 |
| peginesatide | péginésatide | 3907.20 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 108 | 1350810-60-4 |
| peginterferon alfa-2a | péginterféron alfa-2a | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 84 | 198153-51-4 |
| peginterferon alfa-2b | péginterféron alfa-2b | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 84 | 215647-85-1 |
| peginterferon beta-1a | péginterféron bêta-1a | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 108 | 1211327-92-2 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-------------------------|-------------------------|------------|------------|--|---------|--------------|--------------|--------------|
| peginterferon lambda-1a | peginterféron lambda-1a | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 105 | 914617-98-4 |
| pegloticase | pégloticase | 3507.90 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 885051-90-1 |
| pegmusirudin | pegmusirudine | 3907.20 | | 42.100 Ann. O (VI) | HSC/21 | 1998 | 77 | 186638-10-8 |
| pegnartograstim | pegnartograstim | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 80 | 204565-76-4 |
| pegnivacogin | pégnivacogin | 3907.20 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 959716-28-0 |
| pegorgotein | pégorgotéine | 3507.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 155773-57-2 |
| pegrisantaspase | pegrisantaspase | 3507.90 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1448590-54-2 |
| pegsiticase | pegsiticase | 3507.90 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 1040753-26-1 |
| pegsunercept | pegsunercept | 3907.20 | | NC0845B2 Ann. M/1 (II) | HSC/33 | 2004 | 87 | 330988-75-5 |
| pegteograstim | pegtéograstim | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 109 | 1329602-23-4 |
| pegvaliase | pegvaliase | 3507.90 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1585984-95-7 |
| pegvisomant | pegvisomant | 2937.19 | | NC0590B2 Ann. L/10 | HSC/29 | 2002 | 82 | 218620-50-9 |
| peldesine | peldésine | 2933.59 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 133432-71-0 |
| peliglitazar | péliglitazar | 2934.99 | | NC1059B2b Ann. O/4 | HSC/37 | 2006 | 92 | 331744-64-0 |
| pelitinib | pélatinib | 2933.49 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 257933-82-7 |
| pelitrexol | pélitrexol | 2934.99 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 446022-33-9 |
| pelubiprofen | pélubiprofène | 2918.30 | | 42.100 Ann. O (V) | HSC/21 | 1998 | 76 | 69956-77-0 |
| pemaglitazar | pémaglitazar | 2930.90 | | NC1004B1b Ann. L/11 | HSC/36 | 2005 | 92 | 496050-39-6 |
| pemetrexed | pémétrexed | 2933.59 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 137281-23-3 |
| pemoline | pémoline | 2934.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 12 | 2152-34-3 |
| penbutolol | penbutolol | 2922.19 | | 40.260 Ann. L/2 (No. 106) | HSC/17 | 1996 | 25 | 38363-40-5 |
| penciclovir | penciclovir | 2933.59 | | 38.100 Ann. Q (No. 632) | HSC/11 | 1993 | 61 | 39809-25-1 |
| pentamorphone | pentamorphone | 2939.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 60 | 68616-83-1 |
| pentazocine | pentazocine | 2933.33 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 14 | 359-83-1 |
| pentobarbital | pentobarbital | 2933.53 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 1 | 76-74-4 |
| pentoxifylline | pentoxifylline | 2939.59 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 29 | 6493-05-6 |
| pentoxyverine | pentoxyvérine | 2922.19 | | 40.260 Ann. L/2 (No. 107) | HSC/17 | 1996 | 6 | 77-23-6 |
| peplomycin | péplomycine | 2941.90 | | 39.600 Ann. D/1, par. 15 | HSC/16 | 1995 | 44 | 68247-85-8 |
| perakizumab | pérakizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 107 | 89957-37-9 |
| peramivir | péramivir | 2925.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 86 | 229614-55-5 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|----------------------------|---------------------------|------------|------------|---|---------|--------------|--------------|--------------|
| perampanel | pérampanel | 2933.79 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 380917-97-5 |
| peretinoin | péretoïne | 2916.19 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 81485-25-8 |
| perflenapent | perflénapent | 2903.30 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 678-26-2 |
| perflexane | perflexane | 2903.30 | | NC0430B2 Ann. Q/1 (I) | HSC/27 | 2001 | 82 | 355-42-0 |
| perflisobutane | perflisobutane | 2903.30 | | NC1004B1b Ann. L/11 | HSC/36 | 2005 | 92 | 354-92-7 |
| perflisopent | perflisopent | 2903.30 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 594-91-2 |
| perflubrodec | perflubrodec | 2903.47 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 307-43-7 |
| perflubutane | perflubutane | 2903.30 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 355-25-9 |
| perflutren | perflutrène | 2903.30 | | NC0430B2 Ann. Q/1 (I) | HSC/27 | 2001 | 82 | 76-19-7 |
| perifosine | pérfosine | 2933.39 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 157716-52-4 |
| perospirone | pérospirone | 2934.20 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 71 | 150915-41-6 |
| perzinfotel | perzinfotel | 2933.99 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 144912-63-0 |
| pethidine | péthidine | 2933.33 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 4 | 57-42-1 |
| petrichloral | pétrichloral | 2911.00 | | 42.100 Ann. O (I) | HSC/21 | 1998 | 6 | 78-12-6 |
| pevonedistat | pévonédistat | 2933.59 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 905579-51-3 |
| pexacerfont | pexacerfont | 2933.39 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 459856-18-9 |
| pexastimogene devacirepvec | pexastimogène devacirévec | 3002.90 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1058624-46-6 |
| pexelizumab | pexelizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 85 | 219685-93-5 |
| pexiganan | pexiganan | 2924.29 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 172820-23-4 |
| pexmetinib | pexmétinib | 2933.19 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 945614-12-0 |
| phenadoxone | phénadoxone | 2934.99 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 1 | 467-84-5 |
| phenampromide | phénampromide | 2933.39 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 10 | 129-83-9 |
| phenazocine | phénazocine | 2933.39 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 9 | 127-35-5 |
| phencyclidine | phencyclidine | 2933.33 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 11 | 77-10-1 |
| phendimetrazine | phendimétrazine | 2934.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 11 | 634-03-7 |
| phenmetrazine | phenmétrazine | 2934.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 6 | 134-49-6 |
| phenobarbital | phénobarbital | 2933.53 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 4 | 50-06-6 |
| phenobarbital sodium | phénobarbital sodique | 2933.53 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 4 | 57-30-7 |
| phenomorphan | phénomorphane | 2933.49 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 5 | 468-07-5 |
| phenoperidine | phénopéridine | 2933.33 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 11 | 562-26-5 |
| phentermine | phentermine | 2921.46 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 11 | 122-09-8 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|---------------------|----------------------|------------|------------|---|---------|--------------|--------------|--------------|
| phenethylone | phénythilone | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 6 | 115-55-9 |
| pholcodine | pholcodine | 2939.11 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 1 | 509-67-1 |
| piboserod | pibosérod | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 79 | 152811-62-6 |
| pibrozelesin | pibrozélésine | 2933.59 | | NC0250B2 Ann. P/1 (II) | HSC/25 | 2000 | 81 | 154889-68-6 |
| pibutidine | pibutidine | 2933.39 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 103922-33-4 |
| piclamilast | piclamilast | 2933.39 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 73 | 144035-83-6 |
| piclozotan | piclozotan | 2934.99 | | NC1059B2b Ann. O/4 | HSC/37 | 2006 | 92 | 182415-09-4 |
| picoplatin | picoplatine | 2843.90 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 181630-15-9 |
| pictrelisib | pictrélisib | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 105 | 957054-30-7 |
| pidilizumab | pidilizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 108 | 1036730-42-3 |
| pifonakin | pifonakine | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 77 | 112721-39-8 |
| pilaralisib | pilaralisib | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 108 | 934526-89-3 |
| pimasertib | pimasertib | 2933.39 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 1236699-92-5 |
| pimavanserin | pimavansérine | 2933.39 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 706779-91-1 |
| pimecrolimus | pimécrolimus | 2934.99 | | NC1874B1b Ann. O/5 | HSC/51 | 2013 | 81 | 137071-32-0 |
| pimilprost | pimilprost | 2918.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 71 | 139403-31-9 |
| piminodine | piminodine | 2933.39 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 9 | 13495-09-5 |
| pinatuzumab vedotin | pinatuzumab védotine | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 108 | 1313706-14-7 |
| pinazepam | pinazépam | 2933.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 32 | 52463-83-9 |
| pinokalant | pinokalant | 2933.49 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 82 | 149759-26-2 |
| pipendoxifene | pipendoxifène | 2933.39 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 198480-55-6 |
| piragliatin | piragliatine | 2933.99 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 625114-41-2 |
| pirarubicin | pirarubicine | 2941.90 | | 38.100 Ann. Q (No. 636) | HSC/11 | 1993 | 59 | 72496-41-4 |
| pirazmonam | pirazmonam | 2941.90 | | 38.100 Ann. Q (No. 637) | HSC/11 | 1993 | 58 | 108319-07-9 |
| piridoxilate | piridoxilate | 2933.39 | | 38.100 Ann. Q (No. 638) | HSC/11 | 1993 | 26 | 24340-35-0 |
| piritramide | piritramide | 2933.33 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 15 | 302-41-0 |
| piromelatine | piromélatine | 2937.90 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 946846-83-9 |
| pitavastatin | pitavastatin | 2933.49 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 83 | 147511-69-1 |
| pitolisant | pitolisant | 2933.39 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 100 | 362665-56-3 |
| pitracinra | pitracinra | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 84 | 0-00-0 |
| pivmecillinam | pivmécillinam | 2941.90 | | 42.100 Ann. O (II) | HSC/21 | 1998 | 32 | 32886-97-8 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-----------------------|--------------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| placulumab | placulumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 107 | 945781-29-3 |
| plazomicin | plazomicine | 2941.90 | | NC1874B1b Ann. O/1 | HSC/51 | 2013 | 106 | 1154757-24-0 |
| plecanatide | plécanatide | 2937.19 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 467426-54-6 |
| pleconaril | pléconaril | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 77 | 153168-05-9 |
| plerixafor | plerixafor | 2933.99 | | NC1059B2b Ann. O/5 | HSC/37 | 2006 | 93 | 110078-46-1 |
| pleuromulin | pleuromuline | 2941.90 | | 42.100 Ann. O (I) | HSC/21 | 1998 | 35 | 125-65-5 |
| plevitrexed | plévitrexed | 2933.59 | | NC0845B2 Ann. M/1 (II) | HSC/33 | 2004 | 87 | 153537-73-6 |
| plinabulin | plinabuline | 2933.79 | | NC1649B3b Ann. R/13 | HSC/47 | 2011 | 102 | 714272-27-2 |
| plitidepsin | plitidepsine | 2934.99 | | NC1059B2b Ann. O/5 | HSC/37 | 2006 | 93 | 137219-37-5 |
| plusonermin | plusonermine | 3003.39 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 73 | 0-00-0 |
| pobilukast | pobilukast | 2930.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 107023-41-6 |
| pocapavir | pocapavir | 2909.30 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 146949-21-5 |
| podiflen | podifène | 2934.10 | | 38.100 Ann. Q (No. 639) | HSC/11 | 1993 | 22 | 13409-53-5 |
| polaprezinc | polaprézinc | 3824.90 | 3824.99 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 66 | 107667-60-7 |
| polatuzumab vedotin | polatuzumab védotine | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 108 | 1313206-42-6 |
| policapram | policapram | 3908.10 | | 38.100 Ann. Q (No. 640) | HSC/11 | 1993 | 31 | 25038-54-4 |
| policresulen | policrésulène | 3909.40 | | 38.100 Ann. Q (No. 641) | HSC/11 | 1993 | 55 | 101418-00-2 |
| polidexide sulfate | sulfate de polidexide | 3914.00 | | 38.100 Ann. Q (No. 642) | HSC/11 | 1993 | 38 | 56227-39-5 |
| poligeenan | poligeenane | 3913.90 | | 38.100 Ann. Q (No. 643) | HSC/11 | 1993 | 22 | 53973-98-1 |
| poliglecaprone | poliglécaprone | 3907.99 | | 39.600 Ann. D/1, par. 15 | HSC/16 | 1995 | 66 | 41706-81-4 |
| polixetonium chloride | chlorure de polixétonium | 3911.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 31512-74-0 |
| polmacoxib | polmacoxib | 2935.00 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 301692-76-2 |
| poloxalene | poloxalène | 3402.13 | | 40.600 Ann. D par. 6 | HSC/18 | 1996 | 17 | 9003-11-6 |
| polysorbate 20 | polysorbate 20 | 3402.13 | | 42.100 Ann. O (VII) | HSC/21 | 1998 | 33 | 9005-64-5 |
| polysorbate 21 | polysorbate 21 | 3402.13 | | 42.100 Ann. O (VII) | HSC/21 | 1998 | 33 | 9005-64-5 |
| polysorbate 40 | polysorbate 40 | 3402.13 | | 42.100 Ann. O (VII) | HSC/21 | 1998 | 33 | 9005-66-7 |
| polysorbate 60 | polysorbate 60 | 3402.13 | | 42.100 Ann. O (VII) | HSC/21 | 1998 | 33 | 9005-67-8 |
| polysorbate 61 | polysorbate 61 | 3402.13 | | 42.100 Ann. O (VII) | HSC/21 | 1998 | 33 | 9005-67-8 |
| polysorbate 65 | polysorbate 65 | 3907.20 | | 42.100 Ann. O (VII) | HSC/21 | 1998 | 33 | 9005-71-4 |
| polysorbate 80 | polysorbate 80 | 3402.13 | | 42.100 Ann. O (VII) | HSC/21 | 1998 | 33 | 9005-65-6 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|------------------------|------------------------|------------|------------|----------------------------|---------|--------------|--------------|--------------|
| polysorbate 81 | polysorbate 81 | 3402.13 | | 42.100 Ann. O (VII) | HSC/21 | 1998 | 33 | 9005-65-6 |
| polysorbate 85 | polysorbate 85 | 3402.13 | | 42.100 Ann. O (VII) | HSC/21 | 1998 | 33 | 9005-70-3 |
| pomaglumetad methionil | pomaglumétad méthionil | 2934.99 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 635318-55-7 |
| pomalidomide | pomalidomide | 2925.19 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 19171-19-8 |
| pomisartan | pomisartan | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 73 | 144702-17-0 |
| ponatinib | ponatinib | 2933.59 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 943319-70-8 |
| ponazuril | ponazuril | 2933.69 | | NC0090B2 Ann. M/5 | HSC/23 | 1999 | 80 | 69004-04-2 |
| ponesimod | ponésimod | 2934.10 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 854107-55-4 |
| ponezumab | ponezumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 104 | 1178862-65-1 |
| posaconazole | posaconazole | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 82 | 171228-49-2 |
| posaraprost | posaraprost | 2937.50 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 172740-14-6 |
| posatirelin | posatiréline | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 60 | 78664-73-0 |
| posizolid | posizolid | 2934.99 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 252260-02-9 |
| poskine | poskine | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 8 | 585-14-8 |
| pozanicline | pozanicline | 2933.39 | | NC1553B1b Ann. O/7 | HSC/45 | 2010 | 100 | 161417-03-4 |
| poziotinib | poziotinib | 2933.59 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1092364-38-9 |
| pracinostat | pracinostat | 2933.99 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 929016-96-6 |
| pradefovir | pradefovir | 2934.99 | | NC1123E1b Ann. G/10 par. 3 | HSC/38 | 2006 | 93 | 625095-60-5 |
| pradigastat | pradigastat | 2933.39 | | NC1874B1b Ann. O/1 | HSC/51 | 2013 | 106 | 956136-95-1 |
| pradimotide | pradimotide | 3002.20 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 908587-83-7 |
| pradofloxacin | pradofloxacin | 2933.49 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 195532-12-8 |
| pralatrexate | pralatrexate | 2933.59 | | NC1059B2b Ann. O/4 | HSC/37 | 2006 | 92 | 146464-95-1 |
| pralmorelin | pralmoreline | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 77 | 158861-67-7 |
| pralnacasan | pralnacasan | 2934.99 | | NC0730B2 Ann. M/4 (III) | HSC/31 | 2003 | 85 | 192755-52-5 |
| pramiconazole | pramiconazole | 2934.99 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 219923-85-0 |
| pramipexole | pramipexole | 2934.20 | | 38.100 Ann. Q (No. 646) | HSC/11 | 1993 | 58 | 104632-26-0 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-----------------|-----------------|------------|------------|---|---------|--------------|--------------|--------------|
| pramiracetam | pramiracétam | 2933.79 | | 38.100 Ann. Q (No. 647) | HSC/11 | 1993 | 46 | 68497-62-1 |
| pramlintide | pramlintide | 2937.19 | | NC1760B1b Ann. N/3 | HSC/49 | 2012 | 74 | 151126-32-8 |
| pranazepide | pranazépide | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 75 | 150408-73-4 |
| prasugrel | prasugrel | 2934.99 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 150322-43-3 |
| prazosartan | pratosartan | 2933.99 | | NC0730B2 Ann. M/4 (III) | HSC/31 | 2003 | 85 | 153804-05-8 |
| pravastatin | pravastatine | 2918.19 | | 38.100 Ann. Q (No. 648) | HSC/11 | 1993 | 57 | 81093-37-0 |
| prazarelix | prazarélix | 2933.39 | | NC0250B2 Ann. P/1 (II) | HSC/25 | 2000 | 81 | 134457-28-6 |
| prazepam | prazépam | 2933.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 14 | 2955-38-6 |
| prednazoline | prednazoline | 2937.29 | | 38.100 Ann. Q (No. 649) | HSC/11 | 1993 | 22 | 6693-90-9 |
| prednimustine | prednimustine | 2937.29 | | 38.100 Ann. Q (No. 650) | HSC/11 | 1993 | 31 | 29069-24-7 |
| pregabalin | pregabaline | 2922.49 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 148553-50-8 |
| preladenant | préladénant | 2934.99 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 377727-87-2 |
| premafloxacin | prémafloxacin | 2933.49 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 72 | 143383-65-7 |
| prenalterol | prénaltérol | 2922.19 | | 40.260 Ann. L/2 (No. 108) | HSC/17 | 1996 | 38 | 57526-81-5 |
| prenoxidiazine | prénoxidiazine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 54 | 47543-65-7 |
| presatovir | présatovir | 2935.00 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1353625-73-6 |
| pretiadil | prétiadil | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 27 | 30840-27-8 |
| pretomanid | prétomanid | 2934.99 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 187235-37-6 |
| pridopidine | pridopidine | 2933.39 | | NC1604B1b Ann. N/6 | HSC/46 | 2010 | 102 | 346688-38-8 |
| priliximab | priliximab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 72 | 147191-91-1 |
| prinaberel | prinabérel | 2934.99 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 524684-52-4 |
| prinomastat | prinomastat | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 82 | 192329-42-3 |
| pritelivir | pritélivir | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 106 | 348086-71-5 |
| pritoxaximab | pritoxaximab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 108 | 1351470-16-0 |
| procinlol | procinlol | 2922.19 | | 40.260 Ann. L/2 (No. 109) | HSC/17 | 1996 | 25 | 27325-36-6 |
| proheptazine | proheptazine | 2933.99 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 5 | 77-14-5 |
| promegestone | promégestone | 2937.23 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 38 | 34184-77-5 |
| propafenone | propafénone | 2922.19 | | 40.260 Ann. L/2 (No. 110) | HSC/17 | 1996 | 29 | 54063-53-5 |
| propentofylline | propentofylline | 2939.59 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 46 | 55242-55-2 |
| properidine | propéridine | 2933.39 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 5 | 561-76-2 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|---------------------|-------------------------|------------|------------|---|---------|--------------|--------------|--------------|
| propetandrol | propétandrol | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 13 | 3638-82-2 |
| propikacin | propikacine | 2941.90 | | 42.100 Ann. O (II) | HSC/21 | 1998 | 43 | 66887-96-5 |
| propiram | propiram | 2933.33 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 16 | 15686-91-6 |
| propisergide | propisergide | 2939.69 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 35 | 5793-04-4 |
| propoxycaine | propoxycaine | 2922.50 | | 38.100 Ann. Q (No. 656) | HSC/11 | 1993 | 4 | 86-43-1 |
| propranolol | propranolol | 2922.19 | | 40.260 Ann. L/2 (No. 111) | HSC/17 | 1996 | 15 | 525-66-6 |
| propyl docetrizoate | docétrizoate de propyle | 2924.29 | | 38.100 Ann. Q (No. 657) | HSC/11 | 1993 | 10 | 5579-08-8 |
| prrenoate potassium | prorénoate potassique | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 32 | 49847-97-4 |
| prosultiamine | prosultiamine | 2936.22 | | 38.100 Ann. Q (No. 97) | HSC/11 | 1993 | 13 | 59-58-5 |
| proterguride | proterguride | 2939.69 | | 42.100 Ann. O (I) | HSC/21 | 1998 | 50 | 77650-95-4 |
| prucalopride | prucalopride | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 78 | 179474-81-8 |
| prulifloxacin | prulifloxacin | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 72 | 123447-62-1 |
| pruvanserine | pruvansérine | 2933.59 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 443144-26-1 |
| pseudoephedrine | pseudoéphédrine | 2939.42 | | E.N. Chap. 29 - List I-III (Precursors) | HSC/21 | 1998 | 11 | 90-82-4 |
| psilocybine | psilocybine | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 12 | 520-52-5 |
| pumafentrine | pumafentrine | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 82 | 207993-12-2 |
| pumaprazole | pumaprazole | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 76 | 158364-59-1 |
| pumosetrag | pumosétrag | 2934.99 | | NC0730B2 Ann. M/7 | HSC/31 | 2003 | 87 | 153062-94-3 |
| pyridoxine | pyridoxine | 2936.25 | | 38.100 Ann. Q (No. 659) | HSC/11 | 1993 | 1 | 65-23-6 |
| pyrithyldione | pyrithyldione | 2933.79 | | 38.100 Ann. Q (No. 660) | HSC/11 | 1993 | 45 | 77-04-3 |
| pyronaridine | pyronaridine | 2933.99 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 74847-35-1 |
| pyrovalerone | pyrovalérone | 2933.91 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 14 | 3563-49-3 |
| quadazocine | quadazocine | 2933.39 | | 38.100 Ann. Q (No. 661) | HSC/11 | 1993 | 55 | 71276-43-2 |
| quarfloxin | quarfloxine | 2934.99 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 865311-47-3 |
| quetiapine | quétiapine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 74 | 111974-69-7 |
| quifenadine | quifénadine | 2933.39 | | 38.100 Ann. Q (No. 662) | HSC/11 | 1993 | 42 | 10447-39-9 |
| quiflapon | quiflapon | 2933.49 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 72 | 136668-42-3 |
| quilizumab | quilizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 106 | 1228538-47-3 |
| quilstigmine | quilstigmine | 2933.49 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 76 | 139314-01-5 |
| quinagolide | quinagolide | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 62 | 87056-78-8 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|----------------|-----------------|------------|------------|---|---------|--------------|--------------|--------------|
| quinazosin | quinazosine | 2933.59 | | 38.100 Ann. Q (No. 664) | HSC/11 | 1993 | 17 | 15793-38-1 |
| quinbolone | quinbolone | 2937.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 14 | 2487-63-0 |
| quinelorane | quinélorane | 2933.59 | | 38.100 Ann. Q (No. 665) | HSC/11 | 1993 | 60 | 97466-90-5 |
| quinezamide | quinézamide | 2933.59 | | 38.100 Ann. Q (No. 666) | HSC/11 | 1993 | 54 | 77197-48-9 |
| quisinostat | quisinostat | 2933.59 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 875320-29-9 |
| quisultazine | quisultazine | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 51 | 64099-44-1 |
| quizartinib | quizartinib | 2934.99 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 950769-58-1 |
| rabacfosadine | rabacfosadine | 2933.59 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 859209-74-8 |
| rabeximod | rabeximod | 2933.99 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 872178-65-9 |
| rabusertib | rabusertib | 2934.99 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 911222-45-2 |
| racecadotril | racécadotril | 2930.90 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 73 | 81110-73-8 |
| racemethorphan | racéméthorphane | 2933.49 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 1 | 510-53-2 |
| racemoramide | racémoramide | 2934.99 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 6 | 545-59-5 |
| racemorphan | racémorphane | 2933.49 | | E.N. Chap. 29 - List I-I (Narcotic drugs) | HSC/25 | 2000 | 1 | 297-90-5 |
| racotumomab | racotumomab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 100 | 946832-34-4 |
| ractopamine | ractopamine | 2922.50 | | 38.100 Ann. Q (No. 668) | HSC/11 | 1993 | 54 | 97825-25-7 |
| radafaxine | radafaxine | 2934.99 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 192374-14-4 |
| radavirsen | radavirsen | 2934.99 | | NC1874B1b Ann. O/1 | HSC/51 | 2013 | 106 | 1228284-45-4 |
| radequinil | radéquinil | 2934.99 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 93 | 219846-31-8 |
| radezolid | radézolid | 2934.99 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 869884-78-6 |
| radiprodil | radiprodil | 2934.99 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 496054-87-6 |
| radotermin | radotermin | 2934.99 | | NC1059B2b Ann. O/4 | HSC/37 | 2006 | 92 | 575458-75-2 |
| radotinib | radotinib | 2933.59 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 926037-48-1 |
| radretumab | radrétumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 104 | 1253180812 |
| rafabegron | rafabégron | 2933.99 | | NC0845B2 Ann. M/2 | HSC/33 | 2004 | 88 | 244081-42-3 |
| rafigrelide | rafigrélide | 2933.59 | | NC1874B1b Ann. O/1 | HSC/51 | 2013 | 106 | 1029711-88-3 |
| rafivirumab | rafivirumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 99 | 944548-37-2 |
| ragaglitazar | ragaglitazar | 2934.99 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 85 | 222834-30-2 |
| ralimetinib | ralimétinib | 2933.29 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 862505-00-8 |
| ralpancizumab | ralpancizumab | 3002.10 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1407495-04-8 |
| raltegravir | raltégravir | 2934.99 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 518048-05-0 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|----------------------|-------------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| raltitrexed | raltitrexed | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 74 | 112887-68-0 |
| ramatercept | ramatercept | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 108 | 1169766-01-1 |
| ramatroban | ramatroban | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 73 | 116649-85-5 |
| ramciclane | ramciclane | 2922.19 | | 38.100 Ann. Q (No. 669) | HSC/11 | 1993 | 54 | 96743-96-3 |
| ramelteon | ramelteon | 2932.99 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 196597-26-9 |
| ramixotidine | ramixotidine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 55 | 84071-15-8 |
| ramosetron | ramosétron | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 70 | 132036-88-5 |
| ramucirumab | ramucirumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 100 | 947687-13-0 |
| ranelic acid | acide ranélique | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 74 | 135459-90-4 |
| ranibizumab | ranibizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 90 | 347396-82-1 |
| ranirestat | ranirestat | 2933.59 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 147254-64-6 |
| ranpirnase | ranpirnase | 3507.90 | | NC0250B2 Ann. P/1 (II) | HSC/25 | 2000 | 81 | 196488-72-9 |
| rapacuronium bromide | bromure de rapacuronium | 2933.39 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 156137-99-4 |
| rapastinel | rapastinel | 2933.99 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 117928-94-6 |
| rasagiline | rasagiline | 2921.49 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 70 | 136236-51-6 |
| rasburicase | rasburicase | 3507.90 | | NC0250B2 Ann. P/1 (II) | HSC/25 | 2000 | 81 | 134774-45-1 |
| raseglurant | raséglurant | 2933.39 | | NC1604B1b Ann. N/6 | HSC/46 | 2010 | 102 | 757950-09-7 |
| rathyronine | rathyronine | 2937.90 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 28 | 3130-96-9 |
| ravatrelin | ravatréline | 2937.90 | | NC1760B1b Ann. N/7 | HSC/49 | 2012 | 104 | 204386-76-5 |
| ravuconazole | ravuconazole | 2934.10 | | NC0430B2 Ann. Q/1 (II) | HSC/27 | 2001 | 83 | 182760-06-1 |
| raxibacumab | raxibacumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 92 | 565451-13-0 |
| razaxaban | razaxaban | 2934.99 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 218298-21-6 |
| razupenem | razupénel | 2941.90 | | NC1649B3b Ann. R/12 | HSC/47 | 2011 | 101 | 426253-04-5 |
| rebamipide | rébamipide | 2933.79 | | 38.100 Ann. Q (No. 672) | HSC/11 | 1993 | 61 | 111911-87-6 |
| rebastinib | rébastinib | 2933.49 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 1020172-07-9 |
| recaïnam | récaïnam | 2924.21 | | 38.100 Ann. Q (No. 673) | HSC/11 | 1993 | 54 | 74738-24-2 |
| recilisib | récilisib | 2930.90 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 334969-03-8 |
| recoflavone | récoflavone | 2932.99 | | NC1760B1b Ann. N/8 | HSC/49 | 2012 | 105 | 203191-10-0 |
| refametinib | réfamétinib | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 106 | 923032-37-5 |
| regadenoson | régadénoson | 2934.99 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 313348-27-5 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-------------------------|-----------------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| regavirumab | régavirumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 71 | 153101-26-9 |
| reglitazar | régлитазар | 2934.99 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 170861-63-9 |
| regorafenib | régorafénib | 2933.39 | | NC1553B1b Ann. O/7 | HSC/45 | 2010 | 100 | 755037-03-7 |
| regrelor | régrélor | 2934.99 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 787548-03-2 |
| relacatib | relacatib | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 94 | 362505-84-8 |
| relcovaptan | relcovaptan | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 82 | 150375-75-0 |
| relenopride | rélénopride | 2933.39 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1221416-43-8 |
| relugolix | rélugolix | 2934.99 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 737789-87-6 |
| remacemide | rémacémide | 2924.29 | | 38.100 Ann. Q (No. 674) | HSC/11 | 1993 | 63 | 128298-28-2 |
| remeglurant | réméglurant | 2933.59 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 1309783-00-3 |
| remimazolam | rémimazolam | 2933.39 | | NC1604B1b Ann. N/6 | HSC/46 | 2010 | 102 | 308242-62-8 |
| remogliflozin etabonate | étabonate de rémogliflozine | 2940.00 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 442201-24-3 |
| renytoline | rénytoline | 2925.29 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 13 | 1729-61-9 |
| renzapride | renzapride | 2933.39 | | 38.100 Ann. Q (No. 676) | HSC/11 | 1993 | 60 | 112727-80-7 |
| reparixin | réparixine | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 91 | 266359-83-5 |
| repifermin | repifermine | 2933.29 | | NC0430B2 Ann. Q/1 (I) | HSC/27 | 2001 | 82 | 219527-63-6 |
| repinotan | répinotan | 2934.20 | | NC0090B2 Ann. M/1 (II) | HSC/23 | 1999 | 79 | 144980-29-0 |
| resatorvid | résatorvid | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 96 | 243984-11-4 |
| rescimetol | rescimétol | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 44 | 73573-42-9 |
| resiquimod | resiquimod | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 82 | 144875-48-9 |
| reslizumab | reslizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 85 | 241473-69-8 |
| resminostat | resminostat | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 102 | 864814-88-0 |
| resocortol | résocortol | 2937.29 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 76675-97-3 |
| retapamulin | rétapamuline | 2941.90 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 224452-66-8 |
| retaspimycin | rétaspimycine | 2941.90 | | NC1443B1b Ann. P/6 | HSC/43 | 2009 | 99 | 857402-23-4 |
| retelliptine | rételliptine | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 57 | 72238-02-9 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|---------------------------|---------------------------|------------|------------|--------------------------|---------|--------------|--------------|--------------|
| reteplase | réteplase | 3507.90 | | 39.600 Ann. D/1, par. 15 | HSC/16 | 1995 | 69 | 133652-38-7 |
| retigabine | rétigabine | 2924.29 | | 42.100 Ann. O (V) | HSC/21 | 1998 | 76 | 150812-12-7 |
| retosiban | rétosiban | 2934.99 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 820957-38-8 |
| revamilast | révamilast | 2934.99 | | NC1604B1b Ann. N/6 | HSC/46 | 2010 | 102 | 893555-90-3 |
| revaprazan | révaprazan | 2933.59 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 199463-33-7 |
| revatropate | révatropate | 2933.39 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 149926-91-0 |
| reveglucosidase alfa | révéglucosidase alfa | 3507.90 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1446198-96-4 |
| revexepride | révexépride | 2934.99 | | NC2004B1b Ann. O/4 | HSC/53 | 2014 | 108 | 219984-49-3 |
| reviparin sodium | réviparine sodique | 3001.90 | | NC1553B1b Ann. O/5 | HSC/45 | 2010 | 64 | 0-00-0 |
| revusiran | révusiran | 2934.99 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1438322-82-7 |
| rezatomidine | rézatomidine | 2933.29 | | NC1649B3b Ann. R/14 | HSC/47 | 2011 | 103 | 847829-38-3 |
| ribaminol | ribaminol | 2933.59 | | 38.100 Ann. Q (No. 677) | HSC/11 | 1993 | 18 | 8063-28-3 |
| ribociclib | ribociclib | 2933.59 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1211441-98-3 |
| ribuvaptan | ribuvaptan | 2933.99 | | NC2116B1b Ann. R/4 | HSC/55 | 2015 | 110 | 1245620-47-6 |
| ricasetron | ricasétron | 2939.99 | 2939.79 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 70 | 117086-68-7 |
| ricolinostat | ricolinostat | 2933.59 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 1316214-52-4 |
| ridaforolimus | ridaforolimus | 2934.99 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 108 | 572924-54-0 |
| rifabutin | rifabutine | 2941.90 | | 42.100 Ann. O (I) | HSC/21 | 1998 | 52 | 72559-06-9 |
| rifalazil | rifalazil | 2941.90 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 129791-92-0 |
| rifaximin | rifaximine | 2941.90 | | 38.100 Ann. Q (No. 102) | HSC/11 | 1993 | 49 | 80621-81-4 |
| riferminogene pecaplasmid | riferminogène pécaplasmid | 2934.99 | | NC1553B1b Ann. O/7 | HSC/45 | 2010 | 100 | 1001859-46-6 |
| rigosertib | rigosertib | 2930.90 | | NC1874B1b Ann. O/1 | HSC/51 | 2013 | 106 | 592542-59-1 |
| rilapladib | rilapladib | 2933.49 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 412950-08-4 |
| rilimogene galvacirepvec | rilimogène galvacirépvec | 3002.90 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 1225283-43-1 |
| rilimogene glafolivec | rilimogène glafolivec | 3002.90 | | NC1874B1b Ann. O/2 | HSC/51 | 2013 | 107 | 1225283-43-0 |
| rilonacept | rilonacept | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 95 | 501081-76-1 |
| rilotumumab | rilotumumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 101 | 872514-65-3 |
| rilpivirine | rilpivirine | 2933.59 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 500287-72-9 |
| rimacalib | rimacalib | 2934.99 | | NC1059B2b Ann. O/5 | HSC/37 | 2006 | 93 | 215174-50-8 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|---------------|---------------|------------|------------|---------------------------|---------|--------------|--------------|--------------|
| rimegepant | rimégépant | 2933.39 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 1289023-67-1 |
| rimeporide | riméporide | 2930.90 | | NC1059B2b Ann. O/4 | HSC/37 | 2006 | 92 | 187870-78-6 |
| rimexolone | rimexolone | 2937.29 | | 38.100 Ann. Q (No. 678) | HSC/11 | 1993 | 38 | 49697-38-3 |
| rimiducid | rimiducid | 2933.39 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 195514-63-7 |
| rimonabant | rimonabant | 2933.39 | | NC0430B2 Ann. Q/1 (II) | HSC/27 | 2001 | 83 | 168273-06-1 |
| rintatolimod | rintatolimod | 2934.99 | | NC1649B3b Ann. R/13 | HSC/47 | 2011 | 102 | 38640-92-5 |
| riociguat | riociguat | 2933.59 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 625115-55-1 |
| ripasudil | ripasudil | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 109 | 223645-67-8 |
| ripisartan | ripisartan | 2933.59 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 73 | 148504-51-2 |
| risarestat | risarestat | 2934.10 | | NC0430B2 Ann. Q/1 (I) | HSC/27 | 2001 | 82 | 79714-31-1 |
| rismorelin | rismoréline | 2937.19 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 74 | 146706-68-5 |
| ritobegron | ritobégron | 2922.50 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 255734-04-4 |
| ritonavir | ritonavir | 2934.10 | | 42.100 Ann. O (III) | HSC/21 | 1998 | 74 | 155213-67-5 |
| ritosulfan | ritosulfan | 2922.19 | | 38.100 Ann. Q (No. 679) | HSC/11 | 1993 | 33 | 4148-16-7 |
| rituximab | rituximab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 77 | 174722-31-7 |
| rivanicline | rivanicline | 2933.39 | | NC1059B2b Ann. O/5 | HSC/37 | 2006 | 93 | 15585-43-0 |
| rivaroxaban | rivaroxaban | 2934.99 | | NC0938B2b Ann. O/3 (I) | HSC/35 | 2005 | 90 | 366789-02-8 |
| rivastigmine | rivastigmine | 2924.29 | | 42.100 Ann. O (VI) | HSC/21 | 1998 | 77 | 123441-03-2 |
| rivenprost | rivenprost | 2937.50 | | NC1059B2b Ann. O/5 | HSC/37 | 2006 | 93 | 256382-08-8 |
| riviciclib | riviciclib | 2934.99 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 920113-02-6 |
| rivipansel | rivipansel | 2940.00 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 927881-99-0 |
| rivoglitazone | rivoglitazone | 2934.10 | | NC0590B2 Ann. L/15 | HSC/29 | 2002 | 84 | 185428-18-6 |
| rizatriptan | rizatriptan | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 75 | 144034-80-0 |
| robalzotan | robalzotan | 2932.99 | | 42.750 Ann. O | HSC/22 | 1998 | 90 | 169758-66-1 |
| robatumumab | robatumumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 100 | 934235-44-6 |
| robenacoxib | robénacoxib | 2922.49 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 220991-32-2 |
| rocefpafant | rocéfpafant | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 71 | 132418-36-1 |
| rociletinib | rociléтинib | 2933.59 | | NC2116B1b Ann. R/5 | HSC/55 | 2015 | 111 | 1374640-70-6 |
| rociverine | rocivérine | 2922.19 | | 40.260 Ann. L/2 (No. 112) | HSC/17 | 1996 | 33 | 53716-44-2 |

| Product (En) | Produit (Fr) | Class 2012 | Class 2017 | HSC Report / CSH Rapport | Session | Year / Année | List / Liste | CAS No |
|-------------------------|-------------------------|------------|------------|--|---------|--------------|--------------|--------------|
| rodorubicin | rodorubicine | 2941.90 | | 38.100 Ann. Q (No. 680) | HSC/11 | 1993 | 54 | 96497-67-5 |
| rofecoxib | rofécoxib | 2932.20 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 80 | 162011-90-7 |
| rofleponide | rofléponide | 2937.29 | | 40.600 Ann. D, par. 6 | HSC/18 | 1996 | 72 | 144459-70-1 |
| roflumilast | roflumilast | 2933.39 | | 42.100 Ann. O (VI) | HSC/21 | 1998 | 77 | 162401-32-3 |
| rolapitant | rolapitant | 2933.79 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 552292-08-7 |
| roledumab | rolédumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 103 | 1174008-79-7 |
| rolicyclidine | rolicyclidine | 2933.99 | | E.N. Chap. 29 - List I-II (Psychotropic) | HSC/25 | 2000 | 44 | 2201-39-0 |
| rolicyprine | rolicyprine | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 14 | 2829-19-8 |
| rolipoltide | rolipoltide | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 94 | 698389-00-3 |
| rolofylline | rolofylline | 2939.59 | | NC1443B1b Ann. P/5 | HSC/43 | 2009 | 98 | 136199-02-5 |
| rolziracetam | rolzirécetam | 2933.79 | | 38.100 Ann. Q (No. 681) | HSC/11 | 1993 | 54 | 18356-28-0 |
| romidepsin | romidepsine | 2934.99 | | NC1178B1c Ann. O/3 | HSC/39 | 2007 | 94 | 128517-07-7 |
| romiplostim | romiplostim | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 97 | 267639-76-9 |
| romosozumab | romosozumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 106 | 909395-70-6 |
| ronacaleret | ronacaleret | 2922.19 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 753449-67-1 |
| roniciclib | roniciclib | 2933.59 | | NC2004B1b Ann. O/5 | HSC/53 | 2014 | 109 | 1223498-69-8 |
| rontalizumab | rontalizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 101 | 948570-30-7 |
| ropeginterferon alfa-2b | ropéginterféron alfa-2b | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 109 | 1335098-50-4 |
| ropidoxuridine | ropidoxuridine | 2934.99 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 93265-81-7 |
| ropinirole | ropinirole | 2933.79 | | 38.100 Ann. Q (No. 682) | HSC/11 | 1993 | 61 | 91374-21-9 |
| rosabulin | rosabuline | 2934.10 | | NC1178B1c Ann. O/5 | HSC/39 | 2007 | 95 | 501948-05-6 |
| rosiglitazone | rosiglitazone | 2934.10 | | 42.750 Ann. O | HSC/22 | 1998 | 78 | 122320-73-4 |
| rosonabant | rosonabant | 2933.39 | | NC1310B1b Ann. N/4 | HSC/41 | 2008 | 97 | 861151-12-4 |
| rostafuroxin | rostafuroxine | 2932.19 | | NC0938B2b Ann. O/3 (II) | HSC/35 | 2005 | 91 | 156722-18-8 |
| rostaporfin | rostaporfine | 2933.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 83 | 284041-10-7 |
| rosuvastatin | rosuvastatine | 2935.00 | 2935.90 | NC2116B1b Ann. S/1 | HSC/55 | 2015 | 83 | 287714-41-4 |
| rotamicillin | rotamicilline | 2941.10 | | 38.100 Ann. Q (No. 683) | HSC/11 | 1993 | 35 | 55530-41-1 |
| rotigaptide | rotigaptide | 2933.99 | | NC1123B1b Ann. N/1 | HSC/38 | 2006 | 94 | 355151-12-1 |
| rotigotine | rotigotine | 2934.99 | | NC2004B1b Ann. O/6 | HSC/53 | 2014 | 83 | 99755-59-6 |
| rovelizumab | rovélizumab | 3002.10 | 3002.13 | NC2116B1b Ann. S/2 | HSC/55 | 2015 | 81 | 197099-66-4 |